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This thesis discusses the role of coagulation proteins in the aetiology of cardiovascular 
disease, especially myocardial infarction and ischaemic stroke. The underlying question 
in each chapter is not only the effect of the protein under study, but also whether this 
effect differs for these two cardiovascular diseases. Ultimately, this thesis will discuss the 
implications of the findings for future research and treatment of myocardial infarction 
and ischaemic stroke. As an introduction to this thesis, this chapter provides background 
information on myocardial infarction and ischaemic stroke, the coagulation system, the 
RATIO study and an overview of the following chapters. 
Myocardial infarction 
Mechanism Myocardial infarction occurs when the flow of oxygen-rich blood to the 
downstream tissue is restricted and the oxygen demands can no longer be met, leading 
to tissue death. A reduced blood flow can be caused by stenosis due to an 
atherosclerotic lesion or a  ‘plaque’ . This can cause angina but often the blood supply is 
sufficient to sustain the downstream myocardium when oxygen demands are low. 
However, these atherosclerotic plaques may erode or rupture exposing the content of 
the lesion directly to the blood. This content is highly thrombogenic and activates blood 
coagulation, thrombus formation and thereby suddenly reduces or even completely 
blocks blood flow, resulting in infarction of the myocardium. 
Epidemiology The average age-adjusted incidence of myocardial infarction in the 
Netherlands is 2.3 per 1000 person-years (2.9  per 1000 person-years for men and 1.7 
per 1000 person-years for women.
1
 With age as the largest determinant of the incidence, 
these incidences strongly differ per age category. For example, myocardial infarction 
occurs 0.4 times per 1000 person- years in young white men aged 30-39 and up to 13.7 
per 1000 person-years for men aged 70-79. For women these two figures are 0.1 and 6.9 
per 1000 person-years. This sex disparity is also present in the average age of onset for 
myocardial infarction in data from the United States of America which is 64.5 years for 
men and 70.3 for women.
2
 Data from the United Kingdom and the United States of 
America paint a similar picture, although the incidences may be more pronounced than 
in the Netherlands.
1,3
 The case fatality rate of patients suffering from myocardial 
infarction is approximately 15% within one year after the event.
2
 Classical cardiovascular 
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risk factors include, but are not limited to, age, sex, hypertension, smoking, unhealthy 




Mechanism Stroke is a cardiovascular disease of the brain in which a rapid decline of 
brain function occurs and of which the aetiology can be roughly divided in cerebral 
bleeding and cerebral ischaemia. In the United States of America, 10% of all strokes 
constitute an intracerebral haemorrhage, 3% a subarachnoid bleeding and 87% an 
ischaemic stroke.
2
 Ischaemic stroke, like myocardial infarction, occurs when blood flow is 
markedly reduced with ischaemia as a result. The location of the infarcted cerebral tissue 
is dependent on the artery with reduced blood flow, resulting in a plethora of 
phenotypes. Several systems have been proposed to classify ischaemic strokes, such as 
the  Oxford Community Stroke Project classification and the TOAST criteria.
4,5
 The latter, 
proposed in 1993, has become widely used in both the clinic and research and classifies 
ischaemic strokes into five categories based on clinical presentation and further 
investigation. The five categories are defined by the location or presumed cause of the 
ischaemic stroke: large-artery atherosclerosis, cardio-embolism, small-vessel occlusion, 
stroke of other determined aetiology and stroke of undetermined aetiology. Such a 
classification is helpful in public health planning, diagnosis, subsequent treatment 
choices, but also in research by reducing the heterogeneity of the studied disease and its 
underlying causes. 
Epidemiology The average age-adjusted incidence of stroke in the Netherlands is 1.9 per 
1000 person-years.
6
 As with myocardial infarction the incidence of ischaemic stroke rises 
sharply with age, although there is no clear sex disparity.
2,3,6
 The 30 days case fatality of 
ischaemic stroke  ranges between 8% and 12% and increases with age.
3
 Functional 
recovery after stroke occurs in 50-70% of stroke survivors, whilst it leaves 15-30% 
permanently disabled. Major risk factors for ischaemic stroke are for example, in 




Traditionally, the biological system involved in haemostasis is divided in two parts, the 
primary haemostatic system focused around blood platelets and the secondary 
haemostatic system focused around the formation of fibrin.
7
 This latter system 
comprises a series of activation steps leading to clot formation. Each of these activation 
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steps involved a zymogen (inactive enzyme precursor) being activated by a serine 
protease. Once activated, this protein can activate the next zymogen ultimately leading 
to the conversion of fibrinogen to fibrin by thrombin. This ‘waterfall’ or ‘cascade’ model 
was simultaneously proposed by Davie and Ratnoff in the journal Science and McFarlane 
in the journal Nature (see figure 1).
8,9
 Both showed coagulation factor XII as the starting 
point of their cascade, but the mechanism was not clear. MacFarlane noted that 
‘contact’ of FXII to ‘foreign surfaces’ activates this protein and hypothesised that the 
unfolding of the protein was the underlying mechanism. Later, when the complexity of 
the secondary coagulation system became more apparent a distinction was made 
between the intrinsic, extrinsic and common pathway.
7
 The intrinsic coagulation 
pathway, also known as the contact activation pathway, was long considered of lesser 
importance in thrombosis and haemostasis, since persons who are deficient in the 
proteins of this part of the coagulation cascade have a mild or absent bleeding 
phenotype.
10
 However, recent evidence suggests that these proteins are actively 
involved in the amplification of the thrombotic response and even pathologic thrombus 
formation.
11
 Part of this knowledge is summarised in the so-called flywheel model (figure 
1, panel C): small amounts of thrombin are formed by activated coagulation factor X with 
coagulation factor V as a cofactor. Factor X can be activated by two routes, i.e. after 
tissue damage driven tissue factor release or factor XI activation. This small amount of 
thrombin can then activate more factor XI, amplifying the thrombotic response which 
leads to the formation of fibrin monomers which are crosslinked by coagulation factor 
XIII to result in a stabilised haemostatic plug.
12–16
 Additionally, it has become clear that 
the coagulation system is not an isolated system and has several links to other biological 
processes such as primary haemostasis, fibrinolysis, atherosclerosis, and inflammation. 
10,17–22
 
The RATIO study 
Motivation To investigate the role of thrombotic factors in the aetiology of both 
myocardial infarction and ischaemic stroke the studies presented in this thesis are 
embedded within the RATIO (Risk of Arterial Thrombosis In relation to Oral 
contraceptives) study.
23–25
 There are several reasons why the RATIO study provides a 
good opportunity to answer our research questions. First of all, the RATIO study only 
included women under 50 years. The implication of this choice is that the prevalence of 
comorbidities such as hypertension, hypercholesterolaemia, and diabetes, is kept to a 
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minimum. Therefore, the effects of prothrombotic risk factor are easier to identify in the 
young than in the elderly where the abundance of comorbidities could obscure these 
effects.  There is a drawback to the use of this age category; the incidence of myocardial 
infarction and ischaemic stroke is low rendering well-powered prospective cohort study 
unfeasible. However, the RATIO study uses a population-based case-control study design 
which allows the calculation of odds ratios as estimates of rate ratios with sufficient 
power.
26
 Secondly, because the RATIO study was initially designed with a focus on the 
risk of myocardial infarction and ischaemic stroke in relation to oral contraceptive use, 
detailed information on oral contraceptive use is available. Previous studies have shown 
that oral contraceptives use changes the expression and activity of certain coagulation 
factors and can synergistically increase the risk conferred by other prothrombotic risk 
factors.
27–29
 Therefore, oral contraceptive use might be an important player in the risk of 
myocardial infarction and ischaemic stroke in young women and the RATIO study 
provides a unique opportunity to investigate this topic. Thirdly, the RATIO study allows us 
to investigate two acute forms of arterial thrombosis, i.e. myocardial infarction and 
ischaemic stroke, within one study. This means that the results regarding these two 
diseases can be compared more easily than when they are derived from different studies 
with different designs and limitations. The incidences of myocardial infarction and 
ischaemic stroke are not only low, but also similar: approximately 0.14 per 1000 women 
under the age of 50 per year experience a myocardial infarction, whereas the incidence 
of ischaemic stroke is 0.12 or 0.14 per 1000 person-years, depending on the ICD codes 
used
1,6
 This implies that the estimates obtained in the RATIO study can be compared 
directly without scaling effects. 
 
Study design Eligible patients were women aged 18–50 years who were admitted for a 
first myocardial infarction or ischaemic stroke to one of the 16 participating centres 
(eight academic centres and eight large, non-academic hospitals) between 1990 and 
1995. Myocardial infarction was confirmed by symptoms, elevated concentrations of 
cardiac enzymes, and changes seen on electrocardiography; ischaemic stroke without an 
overt cardioembolic source was confirmed by medical history, physical examination, and 
CT or MRI scans, which were assessed by experienced neurologists at the participating 
centres. Exclusion criteria were transient ischaemic attack that lasted less than 24 hours, 
haemorrhagic stroke, cerebral sinus venous thrombosis, carotid artery dissection, 
 GENERAL INTRODUCTION 
 
7 
aphasia or cognitive impairment that prevented completion of the study questionnaire, 
or not speaking Dutch. It is important to note that women with an overt cardioembolic 
source were excluded, although it cannot be ruled out that a small percentage of the 
participants indeed suffered from a cardiac embolic stroke. 
 
Figure 1. Graphic representations of the coagulation system 
A B
C 
Panel A (Davie and Ratnoff, Science 1964) and panel B (MacFarlane, Nature 1964) picture the 
waterfall or cascade model of coagulation which has long been the basis of thrombosis and 
haemostasis research. New insights lead to several additions and revisions. For example, Bouma 
and Meijers proposed a fly wheel model (Current opinions in haematology, 2000) which includes 
the important role of coagulation factor XI in both amplification of the thrombin formation and 
the downregulation of fibrinolysis (Panel C).
8,9,13
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Control subjects were recruited by random-digit dialling, a technique based on the 
generation of a random set of telephone numbers that does not use existing telephone 
number databases. Each number was dialled at least seven times or until contact was 
made. Individuals were included as controls when they were women, aged 18–50 years, 
free of coronary, cerebral or peripheral arterial disease and did not meet the same 
exclusion criteria that were used for patient recruitment. Controls were frequency-
matched to patients for age, residence area, and index date of the event (defined as mid-
year of the same year as the event). Since control subjects were sampled from a dynamic 
population and matched on person-time, the distribution of exposure in the control 
group can be regarded as the distribution of person-time in the source population and 
the odds ratios calculated in the RATIO study can therefore be interpreted as measures 
of rate ratios.
26
 The matching procedure was chosen to ensure an optimal number of 
controls in each of the stratification categories given the number of cases. In this first 
phase of the RATIO study, women were asked to complete an extensive, structured and 
standardised questionnaire which was focussed on classic cardiovascular risk factors, 
family history and oral contraceptive use. The questions referred to the period before 
the index date (the date of myocardial infarction or ischaemic stroke for patients and 
mid-year of the same year for controls). A total of 248 women with myocardial infarction 
and 203 women with ischaemic stroke and 925 control subjects participated in this first 
phase of the RATIO study. 
In the second phase of the RATIO study all participating women were requested to 
donate either blood or a buccal swab for analyses. Not all women participated in this 
second phase. From the initial 248 women with myocardial infarction 30 refused to 
participate, leaving 218 cases. From the initial 203 women with ischaemic stroke, six had 
died, 10 refused to participate, 44 could not be traced and blood sampling failed in three, 
leaving 140 cases. From the initial 925 controls 128 refused to participate and 30 could 
not be traced, leaving 767 controls (see figure 2). To counteract this loss of statistical 
power in the ischaemic stroke group, an additional 50 women who presented with an 
ischaemic stroke at the University Medical Center Utrecht were additionally recruited 
between 1996 and 2001 using the same in- and exclusion criteria. 




Figure 2. Flowchart of RATIO study participants 
 
Blood samples were taken by venipuncture into tubes containing 0.106 M tri-sodium 
citrate for coagulation assays. Plasma was obtained by centrifugation of whole 
anticoagulated blood at 2000 G for 10 min and stored at –80°C. EDTA-anticoagulated 
blood was used for DNA extraction. If participants were adverse to venepuncture, a 
buccal swab was offered as an alternative for DNA extraction. In total, blood samples 
were available from 205 cases with myocardial infarction, 175 cases with ischaemic 
stroke and 638 control subjects. Blood was collected after a median of 69 months (range 
38 - 117) for myocardial infarction and 95 months for ischaemic stroke cases (range 23-
146) thereby ensuring blood was sampled after the acute phase to minimise the risk of 
revere causation, but increasing the likelihood of changes over time resulting in 
attenuation bias. 
With these numbers, the RATIO study has an approximate statistical power of 82% in the 
myocardial infarction analyses to detect an odds ratio of 1.65 with an exposure 
prevalence of 25% in controls under an alpha of 5%. The statistical power, with the same 
parameters, in the ischaemic stroke analyses is lower, i.e. 78%, given the lower number 
of ischaemic stroke cases. Similarly, a doubling in risk, given a 10% exposure prevalence 
in controls under an alpha of 5%, can be detected with 82% power in the ischaemic 
stroke analyses and 86% power in the myocardial infarction analyses. These figures, 
however, are approximations of the true power of the RATIO study due to the frequency-
















Blood samples Buccal swab
50 additional cases
Control group Myocardial infarction Ischaemic stroke
䙆ʒ
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matching procedure needs to be taken into account in the logistic regression analyses by 
including the matching variables (i.e. age, area of residence and index year) as covariates. 
In logistic regression analyses, this generally leads to a loss of precision, especially when 
the covariates are weak predictors of the outcome.
30,31
 
Outline of this thesis 
The research presented in this thesis is focused on the role of thrombotic factors in the 
aetiology of myocardial infarction and ischaemic stroke and whether this role differs 
between these two diseases.  
As a first exploration of a difference between these two cardiovascular diseases, the 
relation between a positive family history of either myocardial infarction, stroke (of all 
types) or a combination thereof and the risk of myocardial infarction and ischaemic 
stroke is investigated in chapter 2.  
The intrinsic coagulation proteins are dealt with subsequently: the relation between 
activation of these proteins and myocardial infarction and ischaemic stroke is studied in 
chapter 3, followed by the relationship of the antigen levels of these proteins and the 
diseases of interest in chapters 4 and 5. The role of the non-enzymatic protein of the 
intrinsic coagulation cascade, i.e. high-molecular weight kininogen, is interrogated in 
chapter 6. This co-factor is important in the binding of the intrinsic coagulation proteins 
to negatively charged surfaces, and therefore promotes the activation of the intrinsic 
coagulation proteins. 
The following section uses a genetic approach to determine whether proteins from the 
common pathway for coagulation are involved in myocardial infarction and ischaemic 
stroke. First, Chapter 7 discusses a particular form of instrumental variable analysis also 
known as Mendelian Randomisation, which uses genetic variation as a proxy for 
phenotypic changes that might lead to disease. Although this technique is not formally 
used in the following chapters, its line of reasoning is used in Chapter 8. This chapter 
presents results on the causal role of fibrinogen levels in the aetiology of myocardial 
infarction and ischaemic stroke based on the associations between genetic variation on 
one hand and disease and fibrinogen levels on the other. Chapter 9 focuses on the 
question whether the risk of myocardial infarction is affected by genetic variation in the 
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gene coding for coagulation XIII of which previous RATIO investigators showed there was 
an increase in risk of ischaemic stroke. 
Besides an increase in coagulation propensity a decreased fibrinolytic propensity might 
also increase the risk of myocardial infarction and ischaemic stroke. Chapter 10 
addresses the results of our analyses on fibrinolysis capacity as a risk factor for 
myocardial infarction and ischaemic stroke as measured by clot lysis time. Other 
thrombotic conditions are the topic of the two following chapters. Chapter 11 
investigates the role of Von Willibrand Factor and its natural counterpart ADAMTS13. 
Chapter 12 investigates the markers of the anti-phospholipid syndrome and their effect 
on the risk of myocardial infarction and ischaemic stroke.  
Finally, chapter 13 summarises the findings of the study presented in this thesis and 
discusses their similarities, differences and implications for our understanding of the 
etiologic mechanisms, for future research and for treatment of myocardial infarction and 
ischaemic stroke.  
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Introduction The phrases ‘cardiovascular disease’ and ‘arterial thrombosis’ might suggest 
that myocardial infarction (MI) and ischaemic stroke (IS) share a common aetiology and 
risk factors. This would imply that the family history of one disease would be predictive of 
occurrence of the other. A positive family history may help in risk stratification, especially 
in the young. This study assesses the specific predictive value of a positive family history of 
MI and stroke (of all types) for specific outcomes. 
Methods The RATIO study is a population-based case-control study including women with 
MI (N=248), IS (N=203) and 925 healthy controls, frequency-matched on age, year of event 
and area of residence. Odds ratios (OR) and 95% confidence intervals (CI) were calculated 
as measures of rate ratios for a positive family history of MI or stroke (affected first-degree 
relative <60 years) with logistic regression analyses.  
Results The risk of MI was almost fourfold increased in women with a family history 
positive for myocardial infarction (OR 3.70, 95%CI 2.68-5.10), whereas the risk of IS was, if 
anything, only slightly elevated (1.25, 0.83-1.87). A family history of stroke was associated 
with a twofold increased MI risk (2.00, 1.29-3.12), whereas the IS risk was again not clearly 
associated (1.37, 0.79-2.40).  
Discussion In young women, a positive family history of cardiovascular disease is a 
predictor for MI but not for IS. The differences between the associations of family history 
of myocardial infarction and stroke might be caused by the heterogeneous nature of 
stroke. These findings support the notion that MI and IS have different risk factor profiles 
and therefore different aetiologies.  




The term ‘arterial thrombosis’ is used to denote disorders resulting from obstructive 
arterial thrombi. The reduction in blood flow can result in acute ischaemia and may 
present clinically as myocardial infarction or ischaemic stroke. The more common term 
‘cardiovascular disease’ is used even more broadly and can include, but is not restricted to, 
myocardial infarction, angina, stroke, peripheral arterial disease but also venous 
thrombosis and even hypertension and diabetes .
1–4
 The use of one term for all forms of 
cardiovascular disease is common, but can be misleading in aetiologic studies since these 
diseases could have, despite several common risk factors, different causal mechanisms.
4–6
 
Risk stratification is used to identify those at high risk of developing a disease, and 
consequently to consider preventive measures. Family history can be used as such a tool: it 
can determine whether disease clusters in families and acts as a proxy for both genetic and 
environmental risk factors. The advantages of such an aggregate measure in a clinical 
setting is that family history is obtained easily and likely to be reported accurately.
7,8
 
However, the predictive value of a positive family history as a risk factor for cardiovascular 
diseases may differ per disease and patient group. 
Previous research in different patient populations has shown that a positive family history 
of myocardial infarction is associated with an approximate doubling of the risk of 
myocardial infarction.
4,8
 The risk of ischaemic stroke associated with a positive family of 
ischaemic stroke has also been studied extensively; a systematic review of 53 
heterogeneous studies indicated that a positive family history of stroke is associated with a 
small increase in stroke risk whereas these associations are likely to differ for the several 
subtypes of stroke.
9–13
 The addition of family history to a predictive model improved the 
prognostic value of some models, but not all.
14–16
 This is not surprising since improvements 
of prediction models can only be achieved by including variables with a strong 
association.
17
 One of the factors that could determine the value of family history is the age 
of the patient group. Since the incidence of cardiovascular disease rises sharply with 
increasing age, mainly due to the accumulation of traditional risk factors and a shift in the 
distribution of ischaemic stroke subtypes, an association between a positive family history 
and MI or IS is therefore likely to be stronger when studies are focused on early onset of 
disease and potentially more useful in risk stratification in these age categories.
15
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As both environmental and genetic risk factors for MI and IS might differ in their effects, 
the versus one of IS may differ too. Such differences would have direct consequences for 
the use of family history in risk stratification. In this study we first aim to determine the 
association of a family history of arterial thrombosis defined as a history of myocardial 
infarction or stroke (of all types) and the risk of MI and IS. Additionally, we impact of a 
family history of MI will also determine whether a positive family history of one of these 
diseases is equally prevalent in patients suffering from the other disease.  
 




* in the year prior to event (cases) or index year(controls).  








Age (mean, SD) 42.9  (6.1) 39.4 (8.4) 38.1 (8.3) 
Caucasian ethnicity 234 (94%) 188 (93%) 864 (93%) 
History of *       
 Hypertension 59 (24%) 48  (24%) 55 (6%) 
 Diabetes  
 
15  (6%) 11 (5%) 13  (1%) 
  Hypercholesterolaemia 28  (11%) 10  (5%) 24  (3%) 
Oral contraceptives use * 99  (40%) 100 (49%) 340  (37%) 
Smoking *  208 (84%) 126  (62%) 395  (43%) 
    
Family members affected by myocardial infarction 
before the age of 60 years 
 Father 73 (29%) 40 (20%) 138 (15%) 
 Mother  39 (16%) 9 (4%) 40 (4%) 
 Brother 38 (15%) 12 (6%) 41 (4%) 
 Sister 16 (6%) 5 (2%) 12 (1%) 
       
Family members affected by stroke  
before the age of 60 years 
 Father 14 (6%) 14 (7%) 36 (4%) 
 Mother  18 (7%) 10 (5%) 37 (4%) 
 Brother 7 (3%) 2 (1%) 10 (1%) 
 Sister 9 (4%) 4 (2%) 7 (1%) 
쵆 ߾ʯ 




Study design & participants The RATIO (Risk of Arterial thrombosis in relation to oral 
contraceptives) study is a nationwide multicenter case-control study designed to search for 
risk factors for myocardial infarction , ischaemic stroke and peripheral arterial disease in 
young women as has been described earlier.
18–20
 The current study focuses on the two 
acute forms, myocardial infarction and ischaemic stroke. In short, women between the 
ages 18 and 50 who were diagnosed with a form of arterial thrombosis in the 16 
participating hospitals were asked to participate. Diagnosis of myocardial infarction was 
based on the presence of symptoms, elevated cardiac-enzyme levels, and 
electrocardiographic changes (N=248), whereas ischaemic stroke was diagnosed on the 
basis of medical history, neurological examination, and CT or MRI scan by experienced 
neurologists in the participating centres. (N=203) The control group comprised women not 
suffering from myocardial infarction, ischaemic stroke or peripheral arterial disease who 
agreed to participate after they were approached by random digit dialling (N=925). The 
control group was frequency-matched with the case groups on age (in five year categories), 
year of event and area of residence. Al participants were asked to fill in a standardised 
questionnaire on several topics such as demographic characteristics, medical history 
among which family history and oral contraceptive use in index year. The study protocol 
was approved by the ethics committees of all participating hospitals and oral informed 
consent was obtained from all participants. 
Definitions A positive first degree relative family history of arterial thrombosis was defined 
as having a first degree relative (parent, sibling) with either a ‘myocardial infarction’ or a 
‘stroke’ before the age of 60.  We use the more generic term ‘stroke’ instead of ischaemic 
stroke deliberately because we cannot distinguish haemorrhagic from ischaemic stroke 
with the questions used in the questionnaire. For clarity and emphasis, we will not use 
abbreviations to refer to the family history. We also determined the risks associated with a 
family history positive for myocardial infarction or stroke separately. Additionally, a 
positive parental history was defined in a similar manner, but restricted to affected 
parents. To account for a variation in the number of siblings and to investigate a graded 
dose-dependent association we defined the percentage of affected first degree relative 
and categorised these as 0% (no affected sibling) >0-20%, 20-40% and 40% and up. Graded 
associations in parental family history were determined by investigating the number of 
affected parents. 
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Statistical analyses We calculated odds ratios and corresponding 95% confidence intervals 
(OR, 95%CI) from logistic models as measures of rate ratios. All models included age, index 
year and area of residence to account for the matching strategy.  
Results 
Traditional risk factors were more present in both case groups than in the control group 
(see table 1). Data on family history were missing in some participants resulting in 884 
control women, 228 MI cases and 181 IS cases available for the analyses. Data from missing 
individuals (20 MI cases, 22 IS cases and 41 controls) were considered as missing at 
random.  
Family history of arterial thrombosis  A positive history of arterial thrombosis in a first 
degree relative was more prevalent in patients with MI and to a lesser extent in IS patients 
than in controls (table 2). The risk of MI was increased in women with a positive family 
history of arterial thrombosis (OR 3.45, 95%CI 2.51 - 4.75), whereas the risk of IS was not 
substantially affected (OR 1.35, 95%CI 0.91 - 1.99). A similar pattern was observed when 
the analyses were restricted to parental history of arterial thrombosis. 
Family history of myocardial infarction A positive family history of myocardial infarction 
increased the risk of MI almost 4-fold (OR 3.70, 95%CI 2.68 - 5.10), whereas the risk of IS 
remained unchanged (OR 1.25, 95%CI 0.83 -1.87) (table 3). The risk of IS was only increased 
when >40% of first degree relatives had been affected with myocardial infarction. A similar 
pattern was observed for the analyses restricted to parental history of myocardial 
infarction: the risk of MI increased 3-fold (OR 3.00, 95%CI 2.17 - 4.15), and the risk of IS 
remained unaffected (OR 1.21, 95%CI 0.80 - 1.85).  
Family history of stroke A positive family history of stroke (both ischaemic and 
haemorrhagic) was associated with a doubling of MI risk (OR 2.00, 95%CI 1.29 - 3.12), 
whereas the risk of IS was only marginally increased (OR 1.37, 95% CI 0.79 - 2.40) (table 3).  
With more than 40% of their first degree relatives affected by stroke the risks were highest 
(MI OR 8.44, 95%CI 1.74 - 41; IS OR 6.78, 95%CI 1.15 - 40).  
Discussion 
A positive family history of arterial thrombosis is associated with an increased risk of MI 
and not clearly associated with IS risk. Furthermore, we found that a positive family history 
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of myocardial infarction was more frequent in cases who suffered from MI than in IS cases. 
A positive family history of stroke was associated with a moderate increase in risk of both 
MI and IS and the difference between MI and IS was less clear in these analyses. This was 
especially so in the analyses of parental family history, where most associations were less 
pronounced. So, our results show that a family history of neither myocardial infarction nor 
stroke are strong predictors of IS, whereas both are associated with MI indicating that the 
use of a combined family history as a predictor of disease is limited. 
 Our results are in line with a recent study on family clustering of coronary and cerebral 
events; myocardial infarction tends to cluster more in families compared with ischaemic 
stroke.
21
 This is perhaps a demonstration of the heterogeneous nature of ischaemic stroke, 
as is hypothesised by the auhors: myocardial infarction may be primarily caused by 
atherosclerotic plaque instability and subsequent rupture, where thromboembolisms and 
small vessel disease also determines ischaemic stroke risk. The OXVASC study also 
investigated the relation between the two diseases and showed there was sex-specific 
familial clustering across different vascular beds.
22
 The RATIO study only included women 
and therefore lacks the data to confirm this sex-differential heritability.  
Our study has some limitations. The information on family history was self-reported and 
was not validated. However, previous studies indicated that questionnaires are highly 
accurate on family history, especially among women and the young.
7
 Women who had 
missing data regarding their family history were excluded from our analyses. Upon closer 
examination of these data (not shown) the women with incomplete data were slightly 
more likely to rapport classical risk factors, although groups were too small to perform 
formal statistics. This means that, if anything, our point estimates are an underestimation 
of the true effects. Our questionnaire can also be a source of misclassification bias: the 
questions did not differentiate between ischaemic or haemorrhagic stroke. This could have 
affected our results if only a family history of ischaemic stroke affects risk in family 
members. However, ischaemic stroke makes up the bulk of all strokes, especially in stroke 
under 60 years of age, minimising the effect of this non-differential misclassification.
4
  
Myocardial infarction is thought to manifest at an earlier age than ischaemic stroke.
4,23
 This 
could mean that the affected parents of an ischaemic stroke patient are older than parents 
of a patient suffering from a myocardial infarction which could result in a differential 
chance of being ‘exposed’ for the two case groups introducing bias. However, since our 
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study is an age-matched case-control study with subjects under 50 years of age, and a 
positive family history defined as a event before the age of 60, this effect is minimised. 
Nonetheless, our restriction to young patients results in a lower prevalence of a positive 
family history resulting in a lower power for our analyses.  
Conclusion Our results indicate that a family history of the cardiovascular diseases 
myocardial infarction and stroke is a predictor of MI but not for IS, limiting the potential 
use of a these family histories for risk stratification. Additionally the difference in 
associations of these aggregate measures between the MI and IS analyses raises the 
question whether these two diseases are different diseases and should preferably be 
treated as such in aetiologic research.
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Introduction Classically, intrinsic coagulation proteins are thought to have a minor role in 
haemostasis. Recently, these proteins, especially FXII, were implicated as possible key 
players in the aetiology of thrombosis. This study aims to determine the risks of myocardial 
infarction and ischaemic stroke conferred by increased activation of intrinsic coagulation 
proteins in young women and the effect of oral contraceptive use on this association. 
Methods To do so, intrinsic coagulation protein activation was determined in the RATIO 
study, a population based case control study including young women (18-50 years) with 
myocardial infarction (MI; N=205), ischaemic stroke (IS; N=175) and 638 healthy controls. 
Activated protein-inhibitor complexes were determined as measures of protein activation. 
These complexes consist of activated proteins bound to C1-esterase inhibitor (FXIIa:C1-inh, 
FXIa:C1-inh, Kallikrein-C1-inh) or antitrypsin inhibitor (FXIa:AT-inh). Odds Ratios (OR) and 
corresponding confidence intervals (95%CI) were calculated with logistic regression. 
Results High levels of protein activation (>90th percentile of controls) showed an increased 
risk of IS: FXIIa:C1-inh (OR 2.1; 95%CI 1.3-3.5), FXIa:C1-inh (2.8; 1.6-4.7), FXIa:AT-inh (2.3; 
1.4-4.0) Kallikrein:C1-inh (4.3; 2.6-7.2). If anything, MI risk was only increased by 
Kallikrein:C1-inh (1.5; 0.9-2.5). Oral contraceptive use further increased the risks. 
Discussion High levels of activated proteins of the intrinsic coagulation system are 
associated with IS, but not with MI. This contradicts similar analyses among men in the 
Northwick Park Heart Study. Together with the finding that oral contraceptive use further 
increases the risks, the question whether the role of intrinsic coagulation proteins in the 





Arterial thrombosis occurs when an artery is occluded by a thrombus. Classical risk factors 
are diabetes, hypercholesterolemia, hypertension, smoking, obesity and oral contraceptive 
use. The most common manifestations are peripheral arterial disease, myocardial 
infarction and ischaemic stroke. Arterial thrombosis is common among the elderly and the 
most common cause of death in high income countries.
1
 
A thrombus is formed upon activation of the coagulation system. Historically, this system 
has been characterised by two separate activating pathways, i.e. the extrinsic and intrinsic. 
The intrinsic coagulation pathway consists of the serine proteases coagulation factor XII 
(FXII), coagulation factor XI (FXI) and prekallikrein (PK). It further includes one non-
enzymatic protein, i.e. High Molecular Weight Kininogen (HMWK).
2
 
FXII has the capacity of autoactivation upon binding on negatively charged surfaces.
3,4
 After 
activation, activated FXII (FXIIa) activates both FXI into activated factor XI (FXIa) and PK into 
its active form kallikrein (KAL). HMWK acts as a co-factor in both steps, during which the 
potent vasodilator bradykinin is released. FXIa further activates coagulation factor IX which 
forms together with cofactor VIIIa, Ca
2+
 ions and phospholipids the tenase complex, 
thereby activating the common pathway of the coagulation cascade.
5
 A subform of FXIIa 
(also known as βFXIIa) is also known to activate coagulation factor VII, initiating the 
common pathway by priming the extrinsic pathway.
6
 The intrinsic coagulation proteins are 
also involved in other biologic processes such as fibrinolysis (activation of plasminogen by 
FXIIa, FXIa, and KAL), vasoconstriction, inflammation and blood pressure control (KAL and 
bradykinin). Upon activation, the serine proteases of the intrinsic coagulation pathway are 
quickly bound by an inhibitor such as the C1-esterase inhibitory forming a protein-inhibitor 
complex which lacks the serine protease function.
7,8
 An excess of these inhibitors is readily 
available in plasma, so the availability of activated intrinsic coagulation proteins forms the 
limiting step in the formation of these protein-inhibitor complexes. This makes these 
protein-inhibitor complexes a good measure of the level of activated proteins. 
FXI deficiency causes mild bleeding in patients, whereas FXII, KAL and HMWK deficiencies 
do not.
2
 These observations led to the traditional view that the intrinsic coagulation 
proteins do not play a major role in haemostasis, and  are not likely to be a risk factor for 
thrombosis. However, recent evidence, both laboratory and clinical, indicates that these 




mice show that initiation of clot forming is not FXII dependent, but that propagation of clot 
formation is. 
9,10
 FXI deficient patients showed apart from their mild bleeding diathesis also 
a decreased risk of ischaemic stroke and venouos thrombosis, but this decrease is not 
observed for myocardial infarction.
11–13
 In middle aged men, high levels of FXI and low 
levels of FXII increased the risk of MI.
14
 An Austrian record-linkage study suggested that 
low FXII levels were associated with reduced overall death rates.
15
 In the Northwick Park 
Heart Study, which included middle-aged men, low levels of activation from selected 
intrinsic coagulation proteins caused an increase in risk for both myocardial infarction and 
ischaemic stroke.
16
 Since estrogens could have an impact on transcription levels of 
coagulation proteins, especially FXII due to an oestrogen receptive element in the 
promoter of the F12 gene, the relation between (intrinsic) coagulation proteins and the risk 
of arterial thrombosis is potentially different in females.
4,17
  
It is unknown to what extent intrinsic coagulation proteins are involved in the 
pathophysiologic processes that lead to the different forms of arterial thrombosis, 
especially in young women. This patient group is of particular interest because of their use 
of oestrogen containing medication (i.e. oral contraceptives).  We therefore set out to 
determine whether high levels of activation of the intrinsic coagulation system are 
associated with myocardial infarction or ischaemic stroke in young women and whether 
oral contraceptive use further increases this risk. 
Methods 
Study design & participants The Risk of Arterial Thrombosis In relation to Oral 
contraceptives (RATIO) study is a multicenter population-based case-control study. The 
study consists of three substudies, including patients with confirmed myocardial infarction, 
ischaemic stroke or peripheral arterial disease. One control group was frequency-matched 
to all three case groups. The study was initiated to evaluate the risk of arterial thrombosis 
due to the changing composition of oral contraceptive pills (1990 – 1995).
18–20
  Blood and 
DNA were collected during the second phase of the study (1998 – 2002). Informed consent 
was obtained from all participants and the study was approved by the medical ethics 
committees of the participating hospitals. For the current study we report data from the 
myocardial infarction and ischaemic stroke substudies. 
Patient selection has been described in detail previously.
18,19,21
 In short, all women aged 18 




stroke to one of the sixteen participating hospitals in the Netherlands between 1990 and 
1995 were eligible and approached for study participation. A standardised questionnaire 
on patient characteristics and possible cardiovascular risk factors such as (familial) medical 
history, use of oral contraceptives and smoking habits was filled in by both cases and 
controls. Some of these questions were targeted to the year prior of diagnosis (cases) or 
the matched index year (controls). All participants were reapproached to donate blood or 
buccal swab for DNA analyses during the second phase of the study. 
Measurements We determined protein-inhibitor complexes of the serine proteases of the 
intrinsic coagulation system as a measure of enzyme activation in citrated plasma. The 
inhibitor could either be a C1-esterase inhibitor for FXIIa, FXIa of kallikrein (FXIIa:C1-inh, 
FXIa:C1-inh, KAL:C1-inh) or antitrypsin inhibitor (FXIa:AT-inh). These complexes were 
measured by an ELISA, as described earlier.16 In short, for the FXIIa:C1-inh ELISA we used 
mAB KOK 12 which is specific for complexed C1-esterase inhibitor as antigen and mAb F3 
which recognises FXII as well as α-FXIIa and β-FXIIa subsequently as conjugate. The KAL:C1-
inh assay uses the same antigen, but uses mAb K15 which is directed against prekallikrein 
and kallikrein as conjugate.22,23 The FXIa protein-inhibitor assays both use the XI-5 mAB  
Table 1. Characteristics of the RATIO participants 
* in the year prior to event/index year, 
# 
levels are expressed as a proportion of fully activated 
normal pooled plasma. AT-inh, alpha 1-antitrypsin inhibitor; C1-inh, C1-esterase inhibitor; FXII, 











Age  (mean) 43 39 39 
Caucasian ethnicity 195 (95%) 167 (97%) 602 (94%) 
 History of *    
 Hypertension 53 (26%) 50 (29%) 40 (6%) 
 Diabetes  
 
10 (5%) 7 (4%) 
 
10 (2%) 
Hypercholesterolaemia 21 (10%) 14 (8%) 19 (3%) 
Oral contraceptives use * 81 (40%) 92 (53%) 213 (33%) 
Smoking *  169 (82%) 101 (58%) 270 (42%) 
    
FXIIa:C1-inh, median (Q1-Q3) 
 
0.23 (0.13-0.33) 0.28 (0.15-0.45) 0.24 (0.12-0.33) 
FXIa:C1-inh, median (Q1-Q3) 0.23 (0.14-0.60) 0.37 (0.18-0.76) 0.23 (0.15-0.52) 
FXIa:AT-inh, median (Q1-Q3) 0.24 (0.20-0.29) 0.29 (0.22-0.42) 0.25 (0.21-0.31) 





as antigen, which recognises both the native and activated FXI form of FXI.24 R11 mAB 
which binds to native, complexed and inactive C1-inhibitor, was used as conjugate for the 
FXIa:C1-inh assay; mAb AT-15, which is directed against complexed AT, was used as 
conjugate in the FXIa:AT-inh assay.25,26 All conjugates where biotinylated with EZLink N-
hydroxysuccinimide ester-biotin according to instructions from the manufacturer (Pierce, 
Rockford, IL, USA). Absorbance was read at 450 nm on an EL 808 Ultra microplate reader 
(Bio-tek Instruments Inc.,Winooski, VT, USA). 
Results were expressed as a proportion of fully activated normal pooled plasma; activation 
was performed by adding an equal volume of 0.2 mg mL
–1
 dextran sulphate (Mr 500 000; 
Sigma Chemical Co., St Louis, MO, USA) in the FXIIa:C1-inh and KAL:C1-inh assay. Normal 
pooled plasma for the FXIa protein-inhibitor assays was fully activated by adding kaolin 
(final concentration 5 mg mL
–1
). Activation was stopped by adding three volumes of 
phosphate-buffered saline (PBS) containing 0.1 mg mL–1 soybean trypsin inhibitor (Sigma 
Chemical Co.) and 0.05% (w/v) polybrene (Sigma Chemical Co.). Kaolin was removed by 
centrifuging the reaction mixture for 5 min at 13 000 x g. No signal was detected in FXII-, 
FXI- or kallikrein-deficient plasmas as a control for the specific ELISA.  
Statistical analyses With the 90
th
 percentile of the controls as a predefined cut-off point, 
we applied a logistic regression model to obtain odds ratios as measures for rate ratios 
associated with high levels of activation of the intrinsic coagulation factors. All odds ratios 
were adjusted for the frequency matching factors area of residence, year of event and age. 
Further adjustments were made for  potential confounders (diabetes, hypertension and 
hypercholesterolemia and smoking) in a fully adjusted model. To assess the intrinsic 
coagulation protein system as a whole, a dummy variable was created which counted the 
number of proteins with high activation levels. Interaction of all intrinsic coagulation 
proteins with OC use in the year prior to the event was assessed by comparing the risk in 
those with either or both exposures with those with no exposures.  
Results 
Table 1 displays the baseline characteristics of the study participants. As expected, cases 
had more cardiovascular risk factors such as smoking, hypercholesterolemia, diabetes and 
hypertension than controls. The median levels of activated protein-inhibitor complexes of 
the intrinsic coagulation proteins are displayed in table 1. Figure 1 shows the distribution of 





Figure 1. Levels of activated intrinsic coagulation proteins 
 
Individual levels of protein activation are expressed as a proportion of fully activated normal 
pooled plasma. Medians are displayed with horizontal bars. Patients with Myocardial infarction 
are depicted with open squares (), ischaemic stroke patients with triangles () and controls 
with circles (●). 
AT-inh, alpha 1-antitrypsin inhibitor; AU, arbitrary units; C1-inh, C1-esterase inhibitor; FXII, 
coagulation factor XII; FXI, coagulation factor XI; KAL, kallikrein; MI, myocardial infarction; IS, 










The relative risks for both myocardial infarction and ischaemic stroke conferred by high 
levels of activated intrinsic coagulation protein levels, as well as the corresponding cut-offs, 
are displayed in table 2. By our definition, 10% of controls have high levels of protein-
inhibitor complexes. No association between myocardial infarction and FXIIa:C1-inh was 
found (10% of cases exposed, Odds Ratio 0.82; 95% Confidence Interval 0.46-1.47). Also 
FXIa:C1-inh (9%, OR 0.96; 95% CI 0.54-1.71) and FXIa:AT-inh (9%, OR 0.94; 95% CI 0.53-
1.68) were not associated with myocardial infarction. KAL:C1-inh slightly increased the risk 
of myocardial infarction (15%, OR 1.50; 95% CI 0.91-2.47).  In ischaemic stroke patients, 
high levels of FXIIa:C1-inh were more frequent than in controls (23% exposed, OR 2.10; 
95% CI 1.27-3.48). Also high levels of FXIa:C1-inh (21%, OR 2.77; 95% CI 1.63-4.73) and 
FXIa:AT-inh (20%, OR 2.33; 95% CI 1.37-3.96) were more frequent. KAL:C1-inh conferred a 
fourfold increase in ischaemic stroke (28%, OR 4.34; 95% CI 2.62-7.18). Further 
adjustments for hypertension, diabetes, hypercholesterolemia and smoking did not change 
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Odds ratios are obtained from logistic regression and are adjusted for the stratification factors 
age, area of residence and year of event. Odds ratios depicted as ‘fully adjusted’ are additionally 
adjusted for diabetes, hypertension and hypercholesterolaemia and smoking. 
AT-inh, alpha 1-antitrypsin inhibitor; C1-inh, C1-esterase inhibitor; FXII, coagulation factor XII; 




The use of an oral contraceptive in the year prior to the event roughly doubled the risk of 
both myocardial infarction (OR 2.3; 95% CI 1.6-3.4) and ischaemic stroke (OR 2.8; 95% CI 
1.8-4.2).
16, 17
 The risk of ischaemic stroke conferred by a combination of high levels of 
intrinsic coagulation protein activation (i.e. >p90) and prior oral contraceptive use was 
higher than could be expected by the separate effects as can be seen in table 3.  The risk of 
myocardial infarction was not further increased by the combination of high levels of 
intrinsic coagulation protein activation and oral contraceptives, except for KAL:C1-inh. The 
combination of high levels of KAL:C1-inh and oral contraceptives use when compared with 
women who had neither risk factor increased the risk of myocardial infarction six fold (OR 
6.1; 95% CI  2.5- 15). This combined effect was also present in the ischaemic stroke 
analysis: women with both high levels of KAL:C1-inh and oral contraceptive use had a 17-
fold increase in ischaemic stroke risk (OR 17; 95% CI 7.4 – 41). Further adjustments for 
potential confounders (hypertension, diabetes, hypercholesterolemia and smoking) did not 
change the overall pattern, as is displayed in table 3 (‘fully adjusted’ odds ratios). 
Table 4 shows the odds ratios per number of proteins with high levels of activation. For 
each additional high level of protein-inhibitor complexes the risk of ischaemic stroke is 
increased 2-fold (OR 2.11; 95%CI 1.31-3.38) whereas the risk for myocardial infarction was 
not affected (OR 1.14; 95%CI 0.75-1.73). When compared to those without a high level of 
intrinsic coagulation protein activation, people with two or more high levels had a fourfold 
increase in risk for ischaemic stroke (OR 4.39; 95%CI 2.44-7.90), but no such association 
was found between multiple high levels and myocardial infarction (OR 1.30; 95% CI 0.66-
2.57). 
In total, 19 myocardial infarction and 21 ischaemic stroke patients were on anticoagulants. 
The results of the analyses when restricted to those patients who did not take oral 
anticoagulant therapy at the time of blood drawing did not change. Therefore, oral 
anticoagulant therapy does not change our results. The associations of FXIa:C1-inh, 
FXIa:AT-inh and KAL:C1-inh persist in ischaemic stroke patients whose blood was sampled 
years after the event (data not shown). The association of FXIIa:C1-inh appeared to 
attenuate with increasing time between event and blood drawing.  However, absence of 






Table 3. Risk of arterial thrombosis due to high levels of activated intrinsic coagulation 








































OR (95% CI) 










OR (95% CI) 
ORfully adjusted 
(95% CI) 
- - 376 107 1 [ref] 1 [ref]  62 1 [ref] 1 [ref] 
- + 192 75 2.4 (1.6-3.5) 2.0 (1.3-3.2)  68 2.8 (1.8-4.5) 2.7 (1.6-4.5) 











+ + 16 5 2.4 (0.7 - 1.8 (0.5-7.2)  21 8.7 (3.7-21) 8.1 (3.1-21) 
           
- - 382 111 1 [ref] 1 [ref]  60 1 [ref] 1 [ref] 
- + 186 73 2.5 (1.7 - 2.2 (1.4-3.5)  73 3.2 (2.0-5.1) 3.4 (2.0-5.7) 
+ - 40 12 1.1 (0.5 - 1.5 (0.7-3.2)  20 3.8 (1.9-7.7) 4.7 (2.1-10) 











          
- - 383 112 1 [ref] 1 [ref]  65 1 [ref] 1 [ref] 
- + 185 73 2.5 (1.6 - 2.2 (1.4-3.5)  69 3.1 (1.9-4.9) 3.1 (1.9-5.3) 










+ + 24 7 1.9 (0.7 - 1.3 (0.4-3.8)  19 4.8 (2.1-11) 4.1 (1.7-9.8) 
           
- - 377 106 1 [ref] 1 [ref]  62 1 [ref] 1 [ref] 
- + 193 68 2.2 (1.5- 3.3) 1.9 (1.2-3.0)  61 2.7 (1.7-4.4) 2.6 (1.5-4.5) 










+ + 17 13 6.1 (2.5 - 15) 6.8(2.5-18)  28 17 (7.4-41) 23 (9.2-59) 
           
 
 
Relative risks are stratified to oral contraceptive use prior to the event or index year (-/+), high 
levels of protein activation (+/-) or both (+/+) with the -/- category as reference. Odds ratios are 
obtained from logistic regression and are adjusted for the stratification factors age, area of 
residence and year of event. ‘Fully adjusted’ odds ratios are additionally adjusted for diabetes, 
hypertension and hypercholesterolemia and smoking. 
AT-inh, alpha 1-antitrypsin inhibitor; C1-inh, C1-esterase inhibitor; FXII, coagulation factor XII; 
FXI, coagulation factor XI; KAL, kallikrein; OC, oral contraceptive; OR, odds ratio; CI, confidence 





Our study shows that high levels of activated 
proteins of the intrinsic coagulation system 
are associated with ischaemic stroke, and not 
or to a lesser extent with myocardial 
infarction, in young women. In general, high 
levels increased the risk of ischaemic stroke 
2.5 fold whereas the risk of myocardial 
infarction was hardly affected. The increased 
risk of ischaemic stroke was further increased 
by oral contraceptive use. When the intrinsic 
coagulation proteins were assessed jointly, 
high levels were more frequent in cases with 
ischaemic stroke than in myocardial infarction 
cases. 
The rate-limiting step in the formation of the 
protein-inhibitor complexes is the availability 
of activated coagulation proteins, since the 
inhibitors are present in excess in plasma. The 
cause of the elevated complexes is not clear. It 
could either be a relative increase in which the 
absolute levels of zymogens remain stable 
with an increased activation rate or it could be 
an absolute increase of zymogens with a 
stable activation rate. Our study has some 
limitations; because of the case-control study 
design blood was collected after the event in 
the case groups. This might have led to 
reverse causation, a process in which a 
consequence of an event is mistaken for the 
cause of the event. Because blood sampling in 






































































































































































































































































































































































































































































































































































































































































































































event, we can safely rule out the possibility that our findings directly reflect the transient 
effects of the acute phase which lasts days to weeks. However, slow subsiding effects 
which are induced by ischaemic stroke could explain some of the relation between 
FXIIa:C1-inh and ischaemic stroke. Non-transient effects ( chronic effects) can still be the 
cause of reverse causation in our study and can only be ruled out in a prospective study. 
Furthermore, the necessity of a blood sample after the event implies that our results are 
only valid for non-fatal arterial thrombosis. Although our study can be considered to be of 
reasonable size, or even  large due to the rare nature of cardiovascular disease in young 
women, the RATIO study lacks power to detect small effects. Lack of precision, which is 
reflected in the wide confidence intervals,  hampers definite interpretation of some of our 
results. This is most clear when the intrinsic coagulation system is assessed as a whole; only 
few patients and controls were positive on three or all four assays, making it difficult to 
interpret the odds ratios for these strata. However, the pattern is clear: the risk increase 
found for ischaemic stroke was higher for each additionally elevated activated protein-
inhibitor complex, whereas this pattern was absent for myocardial infarction. This 
observation suggests that the pathogenic role of the intrinsic coagulation proteins is not 
similar for all manifestations of arterial thrombosis. 
Our results indicated that the risks conferred by high levels of intrinsic coagulation proteins 
were further increased by oral contraceptive use. This raises the question whether women 
who want to start with oral contraceptive use should be screened. The highest risk, after 
adjustment for potential confounders, was found in women who both had high levels of 
activated prekallikrein (>p90 of controls) and used oral contraceptives: a 23 fold increase in 
risk compared with women with neither risk factor (fully adjusted model). Even with this 
relative risk a total of ~15 000 women have to be screened for their kallikrein activation 
levels before the start of oral contraceptives to prevent one event. If the 10% of these 
women with the highest kallikrein activation levels do not start to use oral contraceptives, 
one ischaemic stroke case will be prevented per year. Although a formal cost-benefit 
analyses is likely to show a slightly different number, these calculations readily 
demonstrate  that screening is  not desirable, mainly due to the low incidence of ischaemic 
stroke in this population. This is even more clear when one considers the beneficial effects 
of oral contraceptive use in this population, such as a reduction of pregnancy-associated 




A case control study nested in the second Northwick Park Heart Study (NPHS II) also 
assessed the relationship between the protein-inhibitor complexes of intrinsic coagulation 
proteins and the risk of coronary heart disease (CHD, N=231) and stroke (N=56 of which 12 
haemorrhagic). CHD was defined as definite MI (fatal and nonfatal), possible MI (fatal), 
angina or coronary angiographic findings requiring intervention and ECG changes at 5 years 
of follow up. Strokes were diagnosed and categorised on the basis of clinical presentation, 
computed tomography, lumbar puncture, and autopsy findings. CHD risk was decreased in 
the second tertile of FXIIa:C1-inh; if anything, the third tertile also showed a decrease in 
risk, but to a lesser extent,  resulting in a U-shaped relation. Other protein-inhibitor 
complexes (FXI-C1-inh, FXI-AT-inh, KAL:C1-inh) did not  alter CHD risk. A similar U-shaped 
pattern was observed for the relation between KAL:C1-inh complexes and stroke. These 
results are essentially similar after reanalysis with the 90
th
 percentile as a cut-off (analyses 
done in collaboration with the NPHS II investigators; results not shown here). There are 
several possible explanations for the discrepant findings in the RATIO and the NPHS II 
analyses. First, the differences might be due to chance. Second, the NPHS II is a nested case 
control study, so blood draw was before the event. Although reverse causation in the 
RATIO study is not a likely explanation for our results, due to the timing of blood draw and 
the different effects for myocardial infarction and ischaemic stroke, it cannot be ruled out. 
Third, the case definitions in the RATIO study were more stringent than those in the NPHS. 
In the NPHS ischaemic and hemorrhagic strokes were combined and CHD also included 
possible MI and angina. Fourth, the largest difference between the studies is found in the 
sex and age of the participants: NPHS included only middle-aged men, whereas the RATIO 
study included only relatively young women. This difference is of particular interest 
because FXII transcription is oestrogen sensitive, due to an oestrogen responsive element 
in the promoter region of the F12 gene.
3
 Furthermore, a recent murine study suggests that 




The mechanisms by which these proteins are involved in the pathogenesis of ischaemic 
stroke in young women still have to be established. Perhaps such an increased activity of 
these proteins results in an imbalance of several systems in which the intrinsic coagulation 
proteins are involved (e.g. coagulation, fibrinolysis and inflammation). Ultimately, this 
imbalance then leads to a hypercoagulable state which  increases the risk of ischaemic 




blood flow, acts as a trigger of the start of coagulation. The extent of the following 
thrombus formation is dependent on the tendency to clot: patients suffering from a 
hypercoaguable state are more likely to form an occlusive thrombus with clinical effects 
than those without such a predisposition. This mechanism predicts that a dose-dependent 
effect should be observed: the greater the imbalance, the larger the tendency to coagulate, 
the greater the risk of ischaemic stroke. Not all forms of arterial thrombosis need to be 
subject to this hypothesised mechanism. Possibly, exposure of the highly thrombogenic 
surface after rupture of a coronary plaque inevitably will start clot formation, whether the 
patient is more prone to coagulation or not.  Although the formation of a thrombus in itself 
is involved in the aetiology of both myocardial infarction and ischaemic stroke, we 
postulate that the tendency to start a clot is an important risk factor for ischaemic stroke 
but not for myocardial infarction.  
Conclusion These results indicate that increased levels of activated intrinsic coagulation 
proteins are associated with ischaemic stroke, but not myocardial infarction, in young 
women. These risks are further increased by oral contraceptive use. These results differ 
from an earlier study in middle aged men (NPHS II). This raises two questions: why are the 
effects of intrinsic coagulation proteins different for young myocardial infarction and 
ischaemic stroke, and are these effects sex specific? Answers to these questions could 
come from both basic and epidemiologic research. Basic research is needed to further 
unravel the function of activated intrinsic coagulation proteins, and perhaps identify 
different mechanisms for different forms of arterial thrombosis. Epidemiologic research 
could also provide more insight in the potentially different mechanisms for MI and IS, for 
example by specifying the associations per stroke subtype. Furthermore, epidemiologic 
research could provide more insight on the sex-specific effects, by including both men and 
women. A prospective study design could also diminish the risk of reverse causation, but 
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Introduction FXI activation is associated with an increase in risk of ischaemic stroke. 
However, it is not known whether this is caused by an increase in the inactive precursor or 
a higher rate of protein activation. Therefore we set out to determine whether FXI antigen 
levels alter the risk of myocardial infarction and ischaemic stroke in young women. 
Additionally, we investigated to what extent measures of FXI presence, activation and 
activity are related. 
Methods The RATIO study is a nationwide case-control study including young women with 
myocardial infarction (N=205), ischaemic stroke (N=175), and healthy matched controls 
(N=638). FXI:ag levels were measured with a commercially available ELISA based assay and 
expressed as percentage of pooled normal plasma. Odds Ratios (OR) and corresponding 
95% confidence interval (CI) were calculated as measures of rate ratios and adjusted for 
potential confounders.  In the control group, we calculated correlation coefficients (r) 
between the several measurements of FXI to examine relationship between FXI antigen 
and activity assays and activation state. 
Results High levels of FXI:ag were marginally associated with an increase in risk of 
myocardial infarction (OR 1.55, 95%CI 0.89 – 2.69), whereas the risk of ischaemic stroke 
was substantially increased (OR 2.65, 1.51 – 4.88). Oral contraceptive use further increased 
this risk. Levels of FXI:ag did not correlate with the measures of FXI activation (FXIa:C1-inh: 
r -0.05, p=0.22 and  FXIa:AT-inh: r -0.07, p=0.08). 
Conclusion Higher antigen levels of FXI increase the risk of ischaemic stroke, whereas the 
risk of myocardial infarction is only affected marginally. These effects do not depend on FXI 
activation. Therefore, new antithrombotic drugs could target FXI through protein synthesis 





Cardiovascular disease is a major cause of morbidity and mortality in high income 
countries.
1
 Antithrombotic treatments (e.g. antiplatelet therapies, or inhibitors of 
coagulation such as heparin, vitamin K antagonist or direct factor inhibitors) can be used as 
secondary prevention measure to lower the thrombotic potential of a patient. However, 
this also increases the risk of severe bleeding. Therefore, treatment strategies should 
target groups with the best benefit-risk ratio and new treatments could focus on either 
increasing the efficacy or reducing the impact of side effects: new anticoagulants could 
therefore be targeted at reducing the bleeding risk. Animal studies suggest that 




FXI deficiency (i.e. FXI activity <15%) is  uncommon in the general population, except 
among Ashkenazi Jews. Patients experience a mild bleeding disorder and have a reduced 
risk of deep venous thrombosis, ischaemic stroke, but not myocardial infarction.
4–6
 
Increased levels of FXI are associated with increased risks of deep venous thrombosis.
7
 The 




The protein structure of FXI shows strong homology with kallikrein; both serine proteases 
have apple domains which play an important role in the binding of these proteins to other 
proteins.
9
 FXI is a dimer with two identical subunits.
10
 Each subunit comprises a catalytic 
domain and four apple domains. A disulfide bond links the fourth apple domain of the two 
subunits. Activation of FXI is a stepwise process in which each catalytic domain is activated 
separately; a conformational change is induced by the activation of the catalytic domain, 
thereby exposing several exosites on the apple domains that can bind other proteins such 
as platelets, thrombin, FIX, heparin and glycoprotein Ib.
11
 FXI is activated by FXIIa, but 
perhaps also by thrombin resulting in a positive feedback loop (or flywheel model) in the 
coagulation system.
12,13
 High molecular weight kininogen (HMWK) is a co-factor in the 
activation of FXI by FXII, but other co-factors have been identified: activated coagulation 
factor V and platelet derived polyphosphates act as cofactors in the activation of FXI by 
thrombin. 
14,15
 After activation of FXI, FXIa is quickly inhibited by its inhibitors such as the 
antitrypsin inhibitor and C1-inhibitor which are present in the bloodstream in large 




protein-inhibitor complexes FXIa:AT-inh and FXIa:C1-inh.
16
 The level of these protein-
inhibitor complexes can be regarded to reflect the activation state of the protein of 
interest; this activation state can be thought of the ‘background activation of FXI’ and is 
therefore not directly linked to the amount of FXIa that is generated during the acute 
activation of the coagulation system and the subsequent formation of a blood clot. High 
levels of these complexes might therefore be more indicative of a procoagulant state 
rather than direct evidence of the causal role of FXIa. 
Different key properties of FXI can be measured from citrated plasma with different assays 
which, due to their nature, do not necessarily have to correlate. FXI presence can be 
determined and quantified by a simple ELISA based assay, in which FXI proteins are 
captured and detected by antigens targeted towards FXI. The results of FXI antigen levels 
(FXI:ag) are normally expressed as percentage of a reference sample. FXI coagulant activity 
(FXI:C) is normally measured by a clotting assay in which a patients plasma is 1:1 mixed 
with reference plasma after which the clotting potential of this mixture is determined and 
expressed as percentage of clotting potential of the reference plasma. FXI activation can 
be determined by measuring the FXIa protein-inhibitor complexes by an ELISA based assay. 
The results of the measurement of these FXIa protein-inhibitor assays (e.g. FXIa:AT-inh) are 
expressed as percentage of a fully activated reference plasma.
17
 Presence, as measured by 
an antigen assay, and coagulant activity, as measured by an activity assay, are closely 
related: in a complete deficiency both are zero, and activity increases linearly with 
increasing antigen levels. However, when the protein is produced but not functioning 
properly, there may be discrepancies, which may be extreme (e.g. no activity and normal 
antigen levels when the protein is fully defect). 
FXI:C has previously been studied in the myocardial infarction subset of the RATIO study, a 
nationwide population-based case-control study on myocardial infarction, ischaemic stroke 
and peripheral arterial disease  in young Dutch women. FXI:C was not strongly associated 
with myocardial infarction in a quartile analysis, with odds ratios of 1.1 for the second 
quartile, 1.0 for the third, and only marginally increased in the highest quartile (OR 1.6, 
95% confidence interval 0.8-3.2), all relative to the lowest quartile of FXI:C level.
18
 In the 
same study, levels of FXIa:C1-inh and FXIa:AT-inh were not related to myocardial 
infarction.
19
 However, ischaemic stroke risk was 2- to 3-fold increased in those with high 
levels of FXI activation (i.e. >90
th
 percentile of controls). These results raised the question 




activation of FXI, or whether they reflect an increase in the presence of the inactive 
precursor, or zymogen, form of FXI, as measured by FXI:ag. Therefore, we set out to 
determine FXI:ag levels and the associated risks of myocardial infarction and ischaemic 
stroke. Additionally, we compared the different measures of FXI to see whether these truly 
reflect different properties of FXI. 
Methods  
Study design & participants The RATIO study is a population-based case-control study set 
up to investigate the association between the use of oral contraceptives and arterial 
thrombosis (i.e. myocardial infarction, ischaemic stroke and peripheral arterial disease), as 
has been described previously.
20–22
 Briefly, young women (aged 18-50) who where 
diagnosed with myocardial infarction, ischaemic stroke or peripheral arterial disease in one 
of the 16 participating centres were eligible to participate. Healthy controls were 
approached via random digit dialling and frequency-matched on age category, area of 
residence and index date. This analysis focuses on myocardial infarction and ischaemic 
stroke. In total, 248 cases with myocardial infarction, 203 cases with ischaemic stroke and 
925 frequency-matched controls were included in the first phase of the RATIO study. All 
participants were subsequently requested to provide either a blood sample or buccal  
Table 1. Characteristics of RATIO participants 
 
SD = standard deviation,  Q1 = 1
st
 quartile, Q3 = 3
rd
 quartile 
* in year prior to event 









Mean age 43 (6.1) 39 (7.9) 39 (7.9) 
Caucasian ethnicity 195 (95%) 168 (95%) 602 (94%) 
History of *       
    Hypertension (N, %) 53 (26%) 50 (29%) 40 (6%) 
    Diabetes (N, %) 
 
10 (5%) 7 (4%) 10 (2%) 
    Hypercholesterolaemia (N, %) 21 (10%) 14 (8%) 19 (3%) 
Oral contraceptives use (N, %) * 81 (40%) 92 (53%) 213 (33%) 
Smoking (N, %) * 169 (82%) 105 (60%) 270 (42%) 
    FXI:ag† Mean (SD) 126 (44) 132 (29) 115 (26) 





swabs for DNA extraction. During this phase 168 women refused to participate (30 MI 
cases, 10 IS cases and 128 control women) and 83 women were untraceable, died or had 
blood samples of low quality (53 IS cases and 30 control women). To counteract the loss of 
participants in the ischaemic stroke case group, an additional 50 cases were recruited 
yielding blood samples from 203 myocardial infarction cases, 175 ischaemic stroke cases 
and 638 healthy controls available for measurement of FXI:ag. 
Measurements FXI:ag levels were measured with a sandwich ELISA based assay. This 
commercially available kit (CEDARLANE inc., Burlington, Ontario, Canada) uses polyclonal 
purified coating IgG antibodies targeted against FXI (CL20250K-C) which were incubated 
overnight at 2-8° C. Patient samples, together with reference samples, were incubated for 
one hour after which FXI:ag levels could be determined by the purified peroxidase labeled 
detection antibody (CL20250K-C). Being an o-phenylenediamine based antibody kit, we 
measured light absorbance at 490 NM and signal strengths were converted to FXI:ag levels 
expressed as percentage of a reference sample for which pooled normal plasma was used. 
The lab technician was unaware of case status of the plasma samples measured. 
FXI:C levels were measured by a one-stage clotting assay with factor XI-deficient plasma, 
respectively, and automated activated partial thromboplastin time (APTT; Organon 
Teknika, Boxtel, the Netherlands) on a STA (Diagnostica Stago, Boehringer Mannheim).
18
 
FXI activation was measured as a C1-esterase inhibitor FXIa:C1-inh and or anti-trypsin 
inhibitor FXIa:AT-inh) complex. These complexes were measured by an ELISA, as described 
earlier.
17,19
 The FXIa protein-inhibitor assays both use the XI-5 mAB as antigen, which 
recognises both the native and activated form of FXI.
16
 R11 mAB which binds to native, 
complexed and inactive C1-inhibitor, was used as conjugate for the FXIa:C1-inh assay; mAb 
AT-15, which is directed against complexed AT, was used as conjugate in the FXIa:AT-inh 
assay.
23,24
 All conjugates where biotinylated with EZLink N-hydroxysuccinimide ester-biotin 
according to instructions from the manufacturer (Pierce, Rockford, IL, USA). Absorbance 
was read at 450 nm on an EL 808 Ultra microplate reader (Bio-tek Instruments 
Inc.,Winooski, VT, USA). Results were expressed as a proportion of fully activated normal 
pooled plasma, activated by adding kaolin (final concentration 5 mg mL
–1
).  
Statistical analyses Characteristics of the RATIO participants are summarised as mean and 
corresponding standard deviation (SD) or median or the cut-off values for the first and 




Ratios (OR)  and corresponding 95% confidence intervals (95%CI) as measures of rate ratios 
associated with high levels of FXI:ag (i.e. ≥90
th
 percentile of FXI:ag level in controls). These 
ORs were obtained for three models. Model 1 included the variables area of residence, 
year of event and age (on a continuous scale) to account for the frequency matching 
procedure. Model 2 additionally included smoking behaviour, diagnosis of hypertension, 
diabetes and hypercholesterolaemia as potential confounders. Model 3 included FXIa:AT-
inh measurements, to asses whether the associations found in model 2 truly reflect the 
effect of high FXI:ag or whether the observed effect, in part or in whole, can be explained 
by increased FXI activation. Quartile analyses were performed to investigate potential dose 







 percentile of controls. To answer our second research question, we determined 
the Pearson’s correlations coefficient and the more conservative Spearman’s Rank 
correlation coefficient between FXI:ag, FXI:C and FXIa:AT-inh levels in the control group. 
Because FXI:AT-inh and FXI:C1-inh are not normally distributed, all levels were first 
logtransformed for these analyses. Additionally, we analysed the relationship between high 
levels (i.e. ≥ 90
th
 percentile) of FXI:ag, FXI:C and measures of FXI activation by calculating an 
odds ratio as measure of association. All analyses were performed with SPSS statistics  
Table 2. Levels of FXI:ag in relation to cardiovascular risk factors 
 
Mean difference 
(95% confidence interval) 
cardiovascular risk 
factor * 
FXI:ag levels in 
control group†  
Crude Adjusted for age 
Hypertension - 115 ref Ref 
Hypertension + 117 2 (-6 to 11) 1 (-8 to 9) 
    
Diabetes - 115 ref Ref 
Diabetes +  118 3 (-13 to 20) -2 (-17 to 14) 
    
Hypercholesterolaemia - 115 ref Ref 
Hypercholesterolaemia+ 117 12 (0 to 24) -7 (-18 to 5) 
    
Oral contraceptives use- 118 Ref Ref 
Oral contraceptives use+ 110 -8 (-12 to -4)  -1 (6 to 3) 
    
Smoking - 117 ref Ref 
Smoking + 115 -2 (-7 to 4) -3 (-8 to 2) 
 
* self reported history - measured in the year prior to the event 




(version 18.0, IBM SPSS statistics, Chicago, Ill, USA) or Stata (version 11.2, Statacorp, 
College Station, Tx, USA).  
Results 
Traditional risk factors, such as smoking and oral contraceptive use, were as expected more 
common among the two case groups than among controls (table 1). The FXI:ag levels per 
case group are displayed in figure 1. The mean level of FXI:ag was 115% in the control 
group, 126% in the myocardial infarction group (mean difference 11%, 95%CI 6% to 15%) 
and 132% in the ischaemic stroke case group (mean difference 16%, 95%CI 12% to 21%). 
FXI:ag levels increased with increasing age (increase of 0.9% FXI:ag per year, 95%CI 0.7 to 
1.2%). Table 2 shows the FXI:ag levels in the control group in relation to traditional risk 
factors: oral contraceptive use was associated with a reduced FXI:ag level (mean difference 
-8%, 95%CI -12% to -4%), which was mainly explained by a difference in age for oral 
contraceptive users and non-users (mean difference after adjustment for age (-1%, 95%CI -
6% to 3%). Hypercholesterolemia was associated with an increase (mean difference 12%, 
95%CI 0% to 24%).  
The risks associated with high levels of FXI:ag are displayed in table 3: high levels of FXI:ag 
(i.e. ≥90
th
 percentile of controls) increased the risk of myocardial infarction slightly (OR 
1.55, 95%CI 0.89-2.69), whereas the risk of ischaemic stroke was 2.5 fold increased 
(adjusted OR 2.65, 95%CI 1.51-4.66). Quartile analyses showed that the risk of ischaemic 
stroke increased in a dose-dependent way (increasing risks with increasing levels), whereas 
such a relationship was not present for the effect on the risk of myocardial infarction (see 
table 4). The inclusion of FXIa:AT-inh in the regression models, both as continuous variable 
and dichotomised with the 90
th
 percentile of controls as cut-off value, did not change these 
results. The addition of FXIa:C1-inh instead of FXI-AT-inh resulted in similar results (data 
not shown). Table 5 shows the correlations between the several measures of FXI from the 
control group: FXI:ag was, as expected, strongly correlated to FXI:C (Pearson’s correlation 
coefficient 0.68, 95%CI 0.61-0.70, Spearman’s correlation coefficient 0.68, p<0.001). Not 
surprisingly, the two measures of FXI activation, FXIa:C1-inh and FXIa:AT-inh were also 
correlated (Pearson’s correlation coefficient on log transformed data 0.61, 95%CI 0.56-
0.66, Spearman’s Rank correlation coefficient = 0.24, p<0.001).  In our risk analyses we 
focussed on extreme levels of FXI. Therefore, we determined whether people with high 













































MI, myocardial infarction; IS, ischaemic stroke; cont: control group. FXI:ag levels per case group, expressed 
as percentage of pooled normal plasma. Subjects with high levels of FXI:C (panel A, data not available for 
ischaemic stroke) and FXIa:AT-inh (panel B) are marked in red.  
Table 3. High levels of FXI:ag and the risk of myocardial infarction and ischaemic stroke 
 
MI, myocardial infarction; IS, ischaemic stroke; p90, 90th percentile of control group; 
p10, 10th percentile of control group; ref, reference group;95%CI, 95% confidence 
interval; N, number; OR, odds ratio; prop, proportion. Model 1: adjusted for 
stratification factors (i.e. age, index year, area of residence). Model 2: additionally 
adjusted for hypertension, diabetes, hypercholesterolaemia, smoking. Model 3: 
additionally adjusted for FXIa:AT-inh as measure of FXI activation. The addition of 
FXIa:C1-inh as a measure of FXI activation resulted in similar results (data not shown). 
  Control  Case groups 
 FXI:ag N prop  N prop OR1 (95%CI) OR2 (95%CI) OR3 (95%CI) 
<p90 557 0.90  158 0.81 1 [ref] 1 [ref] 1 [ref] 
MI 
≥p90 61 0.10  36 0.19 1.61 (1.00-2.61) 1.55 (0.86-2.69) 1.49 (0.85-2.61) 
             
<p90 557 0.90  122 0.75 1 [ref] 1 [ref] 1 [ref] 
IS 





Table 4. Dose response analyses for levels of FXII, FXI and PK and the risk of myocardial 
infarction and ischaemic stroke. 
 
 Control  Myocardial infarction  Ischaemic stroke 
 N prop  N prop OR1 95%CI OR2 95%CI  N prop OR1 95%CI OR2 95%CI 
Q1 147 0.24  28 0.14 1 [ref] 1 [ref]  19 0.12 1 [ref] 1 [ref] 
Q2 160 0.26  39 0.20 1.17 (0.67-2.05) 1.12 (0.60-2.05)  24 0.15 1.04 (0.52-2.08) 0.76 (0.36-1.64) 
Q3 156 0.25  43 0.22 1.12 (0.64-1.95) 0.98 (0.64-1.95)  51 0.31 2.38 (1.27-4.45) 2.03 (1.04-3.96) 
Q4 154 0.25  84 0.43 2.01 (1.20-3.36) 1.74 (0.97-3.13)  69 0.42 3.14 (1.70-5.83) 2.50 (1.30-4.82) 
                 
 
MI, myocardial infarction; IS, ischaemic stroke; p90, 90th percentile of control group; p10, 10th 
percentile of control group; ref, reference group;95%CI, 95% confidence interval; N, number; OR, odds 
ratio; prop, proportion. Proportions might not addup to one due to rounding. Model 1: adjusted for 
stratification factors (i.e. age, index year, area of residence). Model 2: additionally adjusted for 
hypertension, diabetes, hypercholesterolaemia, smoking. 
 
Table 5. Association between different measures of FXI in the control group 
 
  FXI:ag FXI:C FXI:C1-inh FXI:AT-inh 
FXI:ag NA r: 0.68 (<0.00) r: -0.04 (p=038) r: -0.07 (p=0.08) 
FXI:C OR:  11 (p<0.00) NA r: -0.01 (p=0.70) r: 0.02 (p=0.54) 
FXI:C1-inh OR: 0.60 (p=0.33) OR 0.66 (p=0.43) NA r: 0.24 (p<0.00) 
FXI:AT-inh OR: 0.28(p=0.06) OR: 1.07 (p=0.89) OR: 41 (<0.00) NA 
 
This table shows the Spearman’s rank correlation coefficient (r) in the upper right part of the table and 
the odds ratio (dichotomised at 90
th
 percentile of controls) in the lower left corner. NA, not applicable; 
OR, odds ratio 
Table 6. Interaction analyses of extreme levels of FXI:ag and the risk of myocardial 
infarction and ischaemic stroke 
 
 See table 4. Additional adjustments for measures of FXIa:AT-inh or FXIa:C1-inh did not alter these 
results (results not shown). 
  Control  Myocardial infarction  Ischaemic stroke 
P90 OC N prop  N prop OR2 (95%CI)  N prop OR2 (95%CI) 
- - 366 0.59  95 0.49 1 [ref]  61 0.37 1 [ref] 
- + 191 0.31  63 0.32 1.82 (1.12-2.95)  61 0.37 2.26 (1.33-3.81) 
+ - 47 0.08  23 0.12 1.47 (0.75-2.88)  18 0.11 1.85 (0.87-3.93) 




While controls with high FXI:ag were more likely to have high levels of FXI:C than those 
with normal FXI:ag; they were not more likely to have high levels of FXI activation. This can 
also be appreciated from figure 1: the women with high levels of FXIa:AT-inh are depicted 
in red and do not cluster in the top region of FXI:ag levels. 
To investigate the interrelated effects of high levels of FXI:ag and oral contraceptives on 
risk, women were categorised according to the combination of their risk factors yielding 4 
categories: exposed to OC use (-/+), to high FXI:ag levels (≥90
th
  percentile) (+/-), none (-/-) 
or both (+/+). For myocardial infarction, the risk for those who were exposed to both risk 
factors was 3-fold increased compared with the risk of those exposed to neither risk factor 
(table 6). This corresponds with what would be expected based on the effects of the two 
risk factors separately (only OC use: OR 1.82, 95%CI 1.12-2.95 and only high FXI:ag: OR 
1.47, 95%CI 0.75-2.88). For ischaemic stroke the joint presence of oral contraceptive use 
and high FXI:ag was associated with a 9-fold increased risk, which was substantially higher 
than expected based on only oral contraceptive use  (OR 2.26, 95%CI1.33-3.81) and only 
high FXI:ag (OR 1.85, 95CI% 0.87-3.93), again all relative to women with neither risk factor.   
Discussion 
Our results indicate that high antigen levels of FXI increase the risk of ischaemic stroke in 
young women. The risk increases gradually with increasing FXI:ag levels and is markedly 
increased in oral contraceptive users. The effect on the risk of myocardial infarction is only 
small, and in line with our previous report on FXI:C. Adjustment for FXI inhibitor-
complexes, which are indicative of a heightened state of protein activation, did not affect 
the relative risks. This indicates that both high FXI antigen levels, as well the process 
leading to an increased FXI activation, increase the risk of ischaemic stroke. 
In order to answer the question whether the different measurements of FXI reflect a 
property, we compared the different measurements in the control group. FXI:ag and 
FXIa:AT-inh are not clearly associated, as can be seen in table 4. However, FXI:ag and FXI:C 
are positively associated, as has been reported before.
25
 This is reflected in the odds ratio 
of 11, which is substantially lower than the odds ratio of 41 for the relation between  
FXIa:AT-inh and FXIa:C1-inh, the two measures designed to measure the same FXI 
property. The lack of a strong  association between FXI:ag and FXI:C  explains why these 




Our quartile analyses indicate that high FXI:ag levels increase the risk of myocardial 
infarction about 70%, which is in line with our previous report on FXI:C.18 Reanalyses of 
the FXI:C data showed that extreme levels of FXI:C (i.e. ≥ 90th percentile of controls) were 
associated with 30% increase in risk (OR 1.27, 95%CI 0.77-2.09) which was attenuated after 
adjustment for confounders (OR 0.94, 95%CI 0.53-1.67). Such a decrease is not found for 
the FXI:ag analyses, which could point to residual confounding or indeed a differential 
effect. But the broad confidence intervals, as well as the lack of a dose response 
relationship make it difficult to determine whether these risk estimates truly differ. 
Additionally, prekallikrein, another intrinsic coagulation protein, is homologous to FXI, also 
complicating causal inference from these associations of polyclonal measurements of FXI. 
In short, although our data do not allow strong conclusions on the differences or 
similarities of FXI:ag and FXI:C, we can conclude that the increase in risk of myocardial 
infarction associated with these FXI measurements is only small. Together with the 
observation that FXI activation, as measured by protein-inhibitor complexes, is not related 
to the risk of myocardial infarction (FXIa:C1-inh OR 0.94, 95%CI 0.49-1.82, FXIa:AT-inh OR 
0.94, 95%CI 0.49-1.82), we conclude that FXI is not related to the risk of myocardial  
infarction in young women. Contrastingly, based on the analyses of FXI:ag and FXIa protein-
inhibitor complexes, we conclude that FXI is associated with ischaemic stroke risk. 
Previous studies in men have shown different results: a case-control study including 560 
men with myocardial infarction and 646 control subjects showed that FXI:C levels were 
associated with an increased risk of myocardial infarction, especially in the young (highest 
vs lowest quintile analyses, adjusted for confounders OR 2.5, 95%CI1.2-5.1 and when 
restricted to men <50 years OR 19, 95% 2 - 182).
8
 Data from the NPHS-II showed that 
neither FXIa:AT-inh nor FXIa:C1-inh were associated with myocardial infarction or stroke in 
middle aged men.
19
 However, this study also included haemorrhagic stroke which hampers 
causal inference on the relation with ischaemic stroke. Other studies showed that FXI, as 
measured with several assays, was associated with ischaemic stroke incidence, stroke 
subtype and severity.
25–27
 A striking observation comes from a small study which compared 
middle-aged women suffering from coronary artery disease with controls.
28
 This showed 
that FXI:C levels were higher in patients than in controls, but that this effect could have 
been driven by the presence of hypercholesterolaemia. A case-control study into the role 
of FXI:C on ischaemic stroke risk even suggested that there might be a synergistic effect 






 This specific interplay of FXI and 
dyslipidaemia is, however, not likely to play a role in our study since we included young 
women with a low hypercholesterolaemic burden. It might, however, be important in 
explaining the differences between our results and the results of other studies. 
Besides the possible link to dyslipidaemia, differences in the aetiology of myocardial 
infarction and ischaemic stroke could explain the differences between our risk estimates 
for the two diseases. FXI is first and most of all a coagulation factor and is a well-
established risk factor for deep venous thrombosis in genetic studies and studies using pre-
event and post-event blood measurement of FXI.
7,32–34
 Furthermore, FXI deficient patients 
have a reduced risk of ischaemic stroke and venous thrombosis but not myocardial 
infarction,
4–6
 which leads to the idea that ischaemic stroke in young women, in contrast to 
myocardial infarction, can be regarded as a thrombotic disease caused by a 
hypercoagulable state.  
Since FXI can theoretically be targeted by new drugs to reduce its thrombotic potential 
without an increased risk of severe bleeding, FXI targeted treatments might be successful 
in primary or secondary prevention of ischaemic stroke.
2
 Several animal studies 
corroborate this idea: FXI antisense oligonucleotides counteract FXI transcription, and 
reduce antigen levels of FXI which reduces clotting propensity without a major increase in 
bleeding risk in mice and cynomolgus monkeys.
35,36
 A non-peptide serine protease inhibitor 
has been shown to be a selective irreversible inhibitor of FXIa. This compound, identified as 
BMS-262084, has achieved antithrombotic efficacy in both a venous and arterial 
thrombosis rabbit model with a minimal increase in bleeding tendency.
37
 Our results 
indicate that the risks associated with high levels of FXI:ag are independent of a heightened 
state of protein activation as measured by protein-inhibitor complexes. These complexes 
could only reflect an increased procoagulant activity, with no direct causal effect for high 
levels of FXIa:C1-inh or FXIa:AT-inh. This implies that the new FXI-targeted compounds, 
which target different properties of FXI, might very well differ in their safety and efficacy.  
Our study has some limitations. Being a case-control study, blood samples were by 
definition collected after the event. Therefore, differences in levels of blood markers could 
be the consequence of the disease instead of the cause. Although we cannot rule out such 
a mechanism, we think that this possibility is very limited for several reasons. The blood 




event). Also, FXI:ag levels were not associated with the time interval between event and 
blood draw (data not shown). Our results indicate that high levels of FXI:ag more than 
double the risk of ischaemic stroke. Although this study excluded women with an overt 
cardiac source of their ischaemic stroke, we cannot distinguish the several other subtypes 
of ischaemic stroke.
38
 Similarly, our results come from a study which only includes young 
women (under 50 years) and only investigated the risk of a first non-fatal ischaemic stroke. 
Therefore, additional research is needed to see whether FXI contributes evenly to the risk 
of the different subtypes, different patient populations and the risk of recurrence. The 
results of the research addressing these questions will help to identify a group of patients 
that could benefit optimally of targeting FXI as a possible new anticoagulation strategy. 
Conclusion In short, high antigen levels of FXI increases the risk ischaemic stroke and 
affects the myocardial infarction risk only minimally. The effect is independent of an 
increased state of FXI activation, which can be regarded as a measure of a procoagulant 
state and as such is also related to an increased risk of ischaemic stroke. These findings 
suggest that transcription, activity and activation of FXI may be targets for the 
development of new antithrombotics for use as possible treatments in primary or 
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Introduction High levels of activated intrinsic coagulation proteins increase the risk of 
ischaemic stroke but not myocardial infarction in young women. This study aims to 
determine whether the antigen levels of coagulation factor XII (FXII) and prekallikrein (PK) 
are risk factors for both myocardial infarction and ischaemic stroke. 
Methods The RATIO study included young women (<50 years) with myocardial infarction 
(N=205), ischaemic stroke (N=175) and 638 healthy frequency-matched controls. Antigen 
levels of FXII and prekallikrein (PK) were measured and expressed as percentage of pooled 
normal plasmas. Odds ratios (OR) and corresponding 95% confidence intervals (95%CI), 
adjusted for matching factors, were calculated for high levels (≥ 90
th
 percentile of controls) 
as measures of rate ratios. 
Results Traditional risk factors were more common in cases than in healthy controls. 
Antigen levels for FXII and prekallikrein related poorly with the levels of the activated form 
of the protein as measured by protein-inhibitor complexes. If anything, high levels of FXII 
increased the risk of MI moderately and but not of IS (OR 1.6, 95% CI 0.9-2.7 for MI and OR 
1.1, 0.6-2.1 for IS). PK was not associated with an increased risk (MI 1.3, 0.8-2.15; IS 0.7, 
0.4-1.4). 
Conclusion The lack of a strong correlation between antigen level and activated protein-
inhibitor complexes, the low risk for IS conferred by high FXII and PK antigen levels, as well 
as a lack of attenuation after adjustments suggest that our previous result could be driven 
by a higher activation rate of the intrinsic coagulation proteins, instead of the protein level 
itself. 




The intrinsic coagulation system has long been regarded to play only a minor role in blood 
haemostasis.
1
 Activation of these proteins was thought to be mainly an in vitro artefact, 
caused by the negative surface provided by for example glass or kaolin.
2,3
 Recent 
biochemical and animal studies, however, implicated the intrinsic coagulation system in 
several mechanisms relevant for thrombus formation.
4–9
 
Coagulation factor XII, also known as Hageman factor, is a serine protease of which the 
activation occurs in two steps yielding α-FXIIa and subsequently β-FXIIa (or FXII fragment, 
or Hageman fragment), each with different functions.
1
 Transcription of FXII may be 
influenced by female hormones due to an estrogen receptive element in the promoter 
region of F12, the gene encoding FXII.
10
 Negatively charged surfaces such as platelet 
derived polyphosphates act as a scaffold on which FXII and cofactors can co-localize and be 
activated.
2,11–17
 The polyphosphate mechanism, which is not unlike the activation of FXII by 
bacteria, provides the link between primary and secondary haemostatic processes.
18–21
 
Activation of FXII and subsequently prekallikrein can lead to several distinct actions under 
which clot propagation, bradykinin formation, complement activation, neutrophil 
aggregation and promotion of fibrinolysis through activation of plasminogen.
1,3,16,22–25
 
Differentiation between these actions might be caused by the size of the negatively 
charged surface on which the activation reactions occur, as well the different actions of α-
FXIIa and β-FXIIa.
3,26–28
 Also, activated FXII can bind to fibrinogen, thereby altering the clot 
structure which is another pathway by which the intrinsic coagulation system is involved in 
the mechanisms underlying thrombotic diseases.
29
  
Prekallikrein, the zymogen form of kallikrein, is also a serine protease with 4 apple domains 
similar to FXI (58% homology).
1
 FXII can convert prekallikrein to kallikrein (α-FXIIa when 
bound to a surface and β-FXIIa in the fluid phase), where high molecular weight kininogen 
(HMWK) is a co-factor by providing a site on negatively charged surfaces. Kallikrein can 
activate FXII amplifying the activation cascade, and together they can convert plasminogen 
into plasmin providing a link to the fibrinolytic system.
22,25,30–32
 
Deficiency of FXII or prekallikrein is rare and without overt bleeding diathesis.
33
 Somewhat 
paradoxically, John Hageman, the first patient identified with this trait died of a massive 
pulmonary embolus after he sustained pelvic fractures.
34,35
 An Austrian epidemiological 




were found in the categories with its highest and lowest levels, resulting in a U-shaped 
curve.
36
 FXIIa-alpha (a subform of activated FXII) in patients with acute coronary syndrome 
upon admission was an predictor for all cause mortality, especially in patients with low 
troponin levels (<0.05ng/mL).
37
 Clinical studies on the effect of plasma kallikrein are scarce. 
A quartile analyses (high vs low) of the amidolytic activity of prekallikrein measured with a 
chromogenic substrate, was associated with a 5-fold increase in myocardial infarction 
risk.
38
  A case-control study found elevated levels of HMWK and normal levels of 
prekallikrein in patients with deep vein thrombosis.
19
 This is in contrast with results from 
the Northwick Park Heart study, that implicated low levels of FXIIa protein-inhibitor 
complexes as a risk factor for coronary heart disease and stroke, whereas low levels of 




RATIO study Results from the RATIO study showed that the presence of protein-inhibitor 
complexes indicative of an increased state of activation of the intrinsic coagulation proteins 
is associated with ischaemic stroke. Women with high levels of these complexes of factor 
XI, XII and kallikreine (i.e. above the ≥90
th
 percentile of controls) have a 2-5 fold increase in 
risk of ischaemic stroke, but not myocardial infarction.
40
 It is, however, unclear to what 
extent these measures of protein activation are increased due to a higher activation rate of 
the proteins or a higher availability of the zymogen form. This study aims to determine to 
what extent the risk of myocardial infarction and ischaemic stroke in young women are 
affected by antigen levels of FXII and PK. 
Methods 
Study design & participants We used data from the RATIO study, a nationwide population-
based case-control study focused on the identification of risk factors for myocardial 
infarction and ischaemic stroke in young women. 
41–43
 Two hundred-and-forty-eight 
women under 50 years and diagnosed with myocardial infarction as well as 203 young 
women with ischaemic stroke were recruited for the first phase of the study. Healthy 
women were requested to participate in the study as control, yielding 925 control subjects 
frequency-matched on age, area of residence and index year (year of event for cases and 
corresponding date for controls). The second phase of the study included the collection of 
biologic samples (blood and buccal swabs for DNA extraction). An additional 50 ischaemic 
stroke cases were recruited to increase the power of the study finally yielding blood 
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Table 1.  Characteristics of RATIO participants 
 
N = number, SD = standard deviation, FXII:ag = antigen level of coagulation factor XII, PK:ag = antigen 









Mean age 43 (6.1) 39 (7.9) 39 (7.9) 
Caucasian ethnicity 195 (95%) 168 (95%) 602 (94%) 
History of *       
   Hypertension (N, %) 53 (26%) 50 (29%) 40 (6%) 
   Diabetes (N, %) 
 
10 (5%) 7 (4%) 10 (2%) 
   Hypercholesterolaemia (N, %) 21 (10%) 14 (8%) 19 (3%) 
Oral contraceptives use (N, %) * 81 (40%) 92 (53%) 213 (33%) 
Smoking (N, %) * 169 (82%) 105 (60%) 270 (42%) 
    FXII:ag 
† 
Mean (SD) 127 (44) 125 (41) 126 (40) 
PK:ag† Mean (SD) 135 (32) 128 (34) 130 (32) 
samples from 205 myocardial infarction cases, 175 ischaemic stroke cases and 638 healthy 
controls available for measurement of antigen levels of FXII, FXI and PK. 
Measurements Antigen levels of FXII and PK were measured with polyclonal antibody 
sandwich ELISA assays, which are commercially available from Cedarlane (Cedarlane inc., 
Burlington, Ontario, Canada). These polyclonal antibody kits use purified coating IgG 
antibodies targeted against FXII (CL20055K-C) or PK (CL20090K-C) incubated overnight at 2-
8°. These kits also provide purified o-phenylenediamine-based detection antibodies 
(CL20055K-D for FXII and CL20067K-D for PK) of which light absorbance can be measured at 
490 NM. Signal strengths were converted to levels expressed as percentage of normal 
pooled plasma. Each sample was diluted in duplo and the lab technician was unaware of 
the case or control status of the measured blood samples. 
Protein-inhibitor complexes of FXIIa and kallikrein were determined with a C1-esterase 
inhibitor assay (FXIIa:C1-inh andKAL:C1-inh). These complexes were measured by an ELISA, 
as described earlier.
39
 In short, for the FXIIa:C1-inh ELISA we used mAB KOK 12 which is 
specific for complexed C1-esterase inhibitor as antigen and mAb F3 which recognises FXII 
as well as α-FXIIa and β-FXIIa subsequently as conjugate. The KAL:C1-inh assay uses the 
same antigen, but uses mAb K15 which is directed against prekallikrein and kallikrein as 
conjugate.
44,45
 All conjugates where biotinylated with EZLink N-hydroxysuccinimide ester-




Absorbance was read at 450 nm on an EL 808 Ultra microplate reader (Bio-tek Instruments 
Inc.,Winooski, VT, USA). Results were expressed as a proportion of fully activated normal 
pooled plasma; activation was performed by adding an equal volume of 0.2 mg mL
–1
 
dextran sulphate (Mr 500 000; Sigma Chemical Co., St Louis, MO, USA) in the FXIIa:C1-inh 
and KAL:C1-inh assay. Activation was stopped by adding three volumes of phosphate-
buffered saline (PBS) containing 0.1 mg mL–1 soybean trypsin inhibitor (Sigma Chemical 
Co.) and 0.05% (w/v) polybrene (Sigma Chemical Co.).  
Statistical analyses Participants’ characteristics are summarised as means and 
corresponding standard deviation (SD) or median and the cut-off values for the first and 
third quartile (Q1-Q3). Linear regression was used to calculate the levels of FXII:ag and 
PK:ag in relation to cardiovascular risk factors. Logistic regression models were used to 
obtain Odds Ratios (OR and corresponding 95% confidence intervals (95%CI) as measures 
of rate ratios. Three models were used: model 1 includes the variables area of residence, 
year of event and age on a continuous scale to account for the frequency-matching 
procedure; model 2 additionally included smoking behaviour, diagnosis of hypertension, 
diabetes and hypercholesterolaemia as putative confounders; model 3 also includes high 
levels (i.e. >90
th
 percentile) of FXIIa:C1-inh or kal:C1-inh to determine whether the results 
were mediated by a state of increased protein activation. For each protein we assessed 
whether low levels (<10
th
 percentile of controls) and high levels (≥90
th
 percentile of 
controls) were associated with altered risk of myocardial infarction and ischaemic stroke. 
Quartile analyses were performed to investigate the shape of the association; the cut-offs 






 percentile of controls. To 
investigate the relation between the antigen levels and measures of protein activation ( 
levels of FXIIa:C1-inh and KAL:C1-inh) we calculated Spearman’s rank correlation 
coefficient as well as odds ratios to determine the relation between high levels. 
Participants with unsuccessful measurements of FXII:ag and PK:ag were excluded from 
analyses when appropriate.  
Results 
As expected, classical risk factors were more common in the two case groups than in the 
control group (table 1). FXII:ag measurements were available for 195 myocardial infarction 
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Table 2. Levels of FXII:ag and PK:ag in relation to cardiovascular risk factors 
 
 Hypertension Diabetes  Hypercholest
erolaemia 
OC use smoking age 
change/year 
FXII:ag 1 % -13 % 22% 12% -5% -0.3% 
 (-12% to 15%) (-40% to 13%) (4% to 41%) (5% to 19%) (-13% to 2%) (-0.7% to 0.1) 
       
PK:ag -1% -5% 17% 4% 2% 0.3% 
 (-11% to 10%) (-24% to 14%) (2% to 31%)   (-2% to 9%) (-4% to 9%) (-0.1% to 
0.6%) 
 
Differences are expressed as absolute changes in levels as expressed as percentage of pooled 
normal plasma. FXII:ag = antigen level of coagulation factor XII, PK:ag = antigen level of 
prekallikrein 
cases, 163 ischaemic stroke cases and 617 controls. PK:ag measurements were available 
for 194 myocardial infarction cases, 163 ischaemic stroke cases and 616 controls. Mean 
FXII:ag levels were equal amongst all three groups, PK:ag levels were slightly increased in 
myocardial infarction cases compared with controls (mean difference 6%, 95%CI 1% to 
11%). 
A history of hypertension and smoking status did not substantially affect the levels of both 
FXII:ag and PK:ag, as can be seen in table 2. Women previously diagnosed with diabetes 
showed a decrease in FXII:ag, whereas diagnosed hypercholesterolaemia was associated 
with an increase of both FXII:ag and PK:ag levels. Oral contraceptive use was associated 
with an increase of FXII:ag, also after adjustment for age. As can be seen in table 3, antigen 
levels of FXII were slightly negatively related with FXII activation levels. This inverse 
relationship was most pronounced for extreme levels (i.e. ≥90
th
 percentile of controls): no 
control subject had both high antigen levels and high activation levels. Antigen levels of PK 
were not associated with KAL:C1-inh levels. However, PK:ag was moderately associated 
with FXI:ag levels (Pearsons ‘s correlation coefficient 0.31, 95%CI 0.24 - 0.38, Spearman’s 
correlation coefficient 0.32, p<0.001). The same pattern arises from figure 1, in which all 
the antigen levels of all participants are depicted; high levels of protein activation are 
marked in red. 
Levels of FXII:ag did not clearly affect the risk of myocardial infarction or ischaemic stroke: 
high levels of FXII:ag (i.e. ≥90
th
 percentile of control group) did not increase the risk of 
myocardial infarction (OR 1.18, 95% 0.62-2.25) nor the risk of ischaemic stroke (OR 0.99, 





Figure 1. Levels of FXII and PK per case group 
 
Antigen levels of coagulation factor XII and prekallikrein per case group, expressed 
as percentage of pooled normal plasma. Patients with high levels of activated factor 
FXII (for FXII:ag analyses) or kallikrein (for PK:ag analyses) are indicated in red. MI, 









































Table 3. Correlation between antigen levels and activated protein-inihibitor complexes in the 
RATIO control group 
 




 PK:ag NA 
r: -0.03  
(p=0.42) 
FXIIa:C1-inh 









Panel A: relation between FXII and log transformed levels of activated FXII, Panel B: relation between 
antigen levels of PK and log transformed levels of activated kallikreine. Associations are expressed as 
Spearman’s non parametric correlation coefficient (r) for continuous values and as an odds ratio (OR) for 
high levels. No odds ratio could be calculated for the FXII measurements, because no control subject had 
both high antigen levels and high activation levels.
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risk of both myocardial infarction (OR 1.46, 95%CI 0.77-2.75) and ischaemic stroke (OR 
1.49, 95%CI 0.77-2.87) by about 50 percent, but there was no pattern of increasing risk 
with increasing levels in the quartile analyses (table 5). Adjustment for FXIIa:C1-inh levels 
did not change the results. PK:ag levels showed a different picture for myocardial infarction 
risk compared with ischaemic stroke risk: increased levels were mildly associated with the 
risk of myocardial infarction (OR 1.54, 95%CI 0.82-2.89), but not at all with the risk of 
ischaemic stroke. Low levels were associated with  decreased risk of myocardial infarction 
(OR 0.60, 95%CI 0.28-1.28), but, if anything, increased the risk of ischaemic stroke (OR 
1.32, 95%CI 0.66-2.65). The quartile analyses showed that women in the highest quartile 
had a twofold increase in myocardial infarction risk compared with the lowest quartile 
although a clear pattern of risk with level was absent. Again, adjustment for KAL:C1-inh 
levels did not affect the estimates. 
Discussion 
Our results indicate that levels of FXII:ag do not have a clear impact on the risk of 
myocardial infarction or ischaemic stroke in young women. PK:ag levels are, if anything,  
related to the risk of myocardial infarction, but not ischaemic stroke. The antigen levels of 
FXII and PK levels are not positively associated with the presence of protein-inhibitor 
complexes indicative of a state of increased protein activation, which previously were 
shown to be related to a 2- to 5-fold increase in ischaemic stroke risk, but not myocardial 
infarction risk. 
FXII:ag and PK:ag levels were influenced by the presence of cardiovascular risk factors, 
although for some risk factors the prevalence was so low in our control group that no 
definite conclusions can be drawn. Only smoking and oral contraceptive use were 
sufficiently prevalent in sufficient numbers to draw conclusions: smoking did not affect 
FXII:ag or PK:ag levels substantially. Oral contraceptive use increased FXII:ag levels by 12%, 




Previous research has indicated that increased levels of FXII activation, as measured by 
FXIIa:C1-inh, were associated with an increased risk of ischaemic (about twofold) whereas 
high KAL:C1-inh levels were associated with a twofold increased risk of myocardial 
infarction and a fivefold increased risk of ischaemic stroke.
40
 Combined with the current 
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protein presence. This leaves the question how an increase in protein-inhibitor complexes 
can be interpreted. Perhaps these increased levels reflect a more general notion of an 
activated coagulation system.  Or, although not likely, perhaps it can be explained by an 
increase in activation rate of the zymogen, for example by a gain of function mutation in 
F12 or KLKB1, the genes encoding FXII and prekallikrein. 
Our study has some limitations. The collection of blood samples in the RATIO study was, 
dictated by the use of a case-control design, after the event. This harbours the possibility of 
reverse causation, a situation in which an effect of the disease is mistaken for the cause of 
the disease. This is, however, especially a problem when blood is drawn in the acute phase 
of the disease. In our study blood was drawn at a minimum of 23 months after the event, 
minimising the possibility of reverse causation. Also, our case-control study only included 
survivors of myocardial infarction and ischaemic stroke. This selection will only affect the 
external validity of our study if FXII:ag and PK:ag levels affect the case fatality rate without 
having a major effect on nonfatal diseases, a scenario that we deem unlikely.  
Conclusion Antigen levels of coagulation factor XII and prekallikrein are not associated with 
a major effect on the risk of either myocardial infarction or ischaemic stroke. Previous 
research showed that the presence of protein-inhibitor complexes of these proteins was 
associated ischaemic stroke risk, but not with myocardial infarction; the antigen levels do 
not correlate with these measures of protein activation. We conclude that the previously 
observed effect is not caused by an increased availability of the protein, and that an 
increased activation rate may explain these previous findings. Additional research is 












Table 6. interaction analyses for extreme levels of FXII and PK in combination with oral contraceptive use 
 
 
All odds ratios are adjusted for stratification factors (i.e. age, area of residence and index year). OR1 is additionally adjusted for 
hypertension, diabetes and hypercholesterolaemia. OR = odds ratio, N = number, ref = reference category, OC=oral contraceptive 
use in the year prior to index year, FXII:ag = antigen level of coagulation factor XII, PK:ag = antigen level of prekallikrein. 
   Control  Myocardial infarction  Ischaemic stroke 
 ≥p90 OC N prop  N prop OR (95%CI) OR1 (95%CI)  N prop OR (95%CI) OR1 (95%CI) 
                   
- - 385 0.62  107 0.55 1 [ref] 1 [ref]  70 0.43 1 [ref] 1 [ref] 
- + 171 0.28  62 0.32 2.24 (1.49-3.38) 1.85 (1.16-2.93)  77 0.47 3.17 (2.01-5.01) 3.26 (1.97-5.39) 






+ + 33 0.05  14 0.07 2.98 1.40-(6.32) 2.1 (0.89-4.94)  7 0.04 1.55 (0.60-3.97) 1.34 (0.47-3.81) 
                   
- - 371 0.60  108 0.56 1 [ref] 1 [ref]  73 0.45 1 [ref] 1 [ref] 
- + 184 0.30  62 0.32 2.02 (1.34-3.03) 1.69 (1.06-2.67)  76 0.47 2.60 (1.65-4.08) 2.54 (1.55-4.17) 





+ + 21 0.03  14 0.07 4.24 (1.92-9.38) 4.31 (1.59-11.7)  8 0.05 2.36 (0.89-6.25) 3.00 (1.10-8.19) 
                   
 ≤p10                  
 
                  
- - 385 0.62  107 0.55 1 [ref] 1 [ref]  70 0.43 1 [ref] 1 [ref] 
- + 171 0.28  62 0.32 2.27 (1.52-3.60) 1.85 (1.17-2.92)  77 0.47 2.41 (1.52-3.82) 2.32 (1.40-3.84) 






+ + 33 0.05  14 0.07 3.14 (1.19-8.26) 3.45 (1.15-10.3)  7 0.04 6.15 (2.39-15.9) 7.31 (2.69-19.9) 
                   
- - 371 0.60  108 0.56 1 [ref] 1 [ref]  73 0.45 1 [ref] 1 [ref] 
- + 184 0.30  62 0.32 2.07 (1.39-3.08) 1.74 (1.11-2.72)  76 0.47 2.54 (1.62-3.99) 2.56 (1.56-4.21) 





+ + 21 0.03  14 0.07 2.82 (1.07-7.41) 1.93 (0.64-5.84)  8 0.05 5.64 (2.08-15.3) 4.80 (1.64-14.0) 
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Introduction High molecular weight kininogen (HMWK) deficiency is associated with an 
increased aPTT, but not with a bleeding diathesis. HMWK is a cofactor of the intrinsic 
coagulation system and as such a pivotal element in the activation of these proteins. 
Additionally, it is involved in other biologic processes such as inflammation. It is unknown 
whether HMWK levels affects the risk of myocardial infarction (MI) and ischaemic stroke 
(IS).  
Methods HMWK levels were measured in the RATIO case-control study, which includes 
young women with MI (N=205), IS (N=175) and 638 healthy controls. Antigen levels of 
HMWK were measured with a polyclonal ELISA-based assay and expressed as percentage 
of pooled normal plasma. Odds ratios (OR) and 95% confidence intervals (95%CI) were 
calculated by means of logistic regression as measures of rate ratios.  
Results Mean HWMK levels were similar in MI cases and controls (117%) and slightly 
higher in IS cases (121%). High levels of HWMK (i.e. ≥90
th
 percentile of controls) were 
associated with an increase in risk of IS (ORadjusted 1.82, 95%CI 1.00-3.29), whereas the risk 
of MI was not affected (ORadjusted1.05, 0.57-1.91). If anything, low levels (≤10
th
 percentile) 
were associated with a small increase in risk of both MI and IS.  
Conclusions High levels of HWMK increase the risk of IS in young women, whereas its role 





Cardiovascular disease is a major cause of morbidity and mortality in high income 
countries.
1
 Arterial thrombosis is a major contributor to this burden; peripheral arterial 
disease, myocardial infarction (MI) and ischaemic stroke (IS) all occur when a thrombus is 
lodged in an artery which subsequently reduces the blood flow to downstream tissue. As 
multicausal cardiovascular diseases, MI and IS share several risk factors. These include, but 
are not restricted to, classical risk factors such as hypertension, hypercholesterolemia, 
obesity, smoking and diabetes.
1
 Other factors related to primary and secondary 
haemostasis are also known to be associated with an increase in risk for both MI and IS.
1–6
 
An emerging body of evidence suggests that the intrinsic coagulation proteins are involved 
in the aetiology of cardiovascular diseases. This is in contrast with prior beliefs: despite a 
relation with the aPTT, deficiencies of coagulation Factor XII and prekallikreine are not 
related with a bleeding diathesis, whereas coagulation factor XI (FXI) deficiency can result 
in a mild bleeding phenotype. Therefore, these proteins were regarded as unimportant in 
haemostasis.
7
 Murine and other laboratory studies indicate that these proteins indeed are 
not involved in regular haemostasis, but are involved in pathological processes leading to 
thrombosis.
8–12
 Clinical studies also suggest that the intrinsic coagulation proteins are 
involved in the development of human disease.
13–18
  Striking results come from studies on 
FXI deficiency which is relatively common among Ashkenazi Jews. This trait confers a 
reduced risk of ischaemic stroke and deep venous thrombosis, but not of myocardial 
infarction.
19–21
 A similar pattern is observed in other studies: evidence of an increased state 
of activation of the intrinsic coagulation proteins was associated with ischaemic stroke, but 
not myocardial infarction.
22
 This contrasts with middle-aged men in whom the same 
activation markers were associated with both stroke and coronary heart disease.
23
 
High molecular weight kininogeen (HMWK) is a cofactor of FXI and prekallikrein; both 
enzymes are noncovalently bound to HMWK in the circulation through one of the 4 apple 
domains present in these structurally homologous proteins.
24–27
 HMWK also interacts with 
platelets: it can bind to platelets through the glycoprotein Ib-V-IX receptor complex on 
platelets, providing a link between primary and secondary haemostasis.
28
 Additionally, 
HWMK may interact with other surfaces such as endothelium and neutrophils, which 
confirms the pleiotropic role of HWMK in biological systems.
29
 The activated intrinsic 




activation by FXIIa and the formation of bradykinin through HMWK splicing by kallikrein, 
which is formed from its precursor prekallikrein by FXIIa.
25,27
 Several recent studies indicate 
that certain circumstances would favor one of these actions. Misfolded proteins can 
activate FXII which leads to kallikrein formation without activation of coagulation.
30
 Also, 
HMWK can be activated by prekallikrein leading through FXII independent bradykinin 
formation.
25
 Both mechanisms need a negatively charged surface to facilitate protein-
protein interactions and HMWK is thought to facilitate this binding, promoting the 
activation of the intrinsic coagulation system.
27,29,31
 These surfaces include well-established 
activators such as kaolin and glass, but also nucleic acids and polyphosphates released 
from activated platelets.
31,32
 Studies focused on the role of polyphosphates indicate that 




HMWK is part of this intrinsic coagulation system, but is also involved in other biological 
systems related to cardiovascular diseases.
34
  Cleavage of HMWK by kallikrein leads to the 
formation of vasoactive substance bradykinin and cleaved kininogen, which are involved in 
the innate inflammatory response, blood pressure control,  brain edema, the renin-
angiotensin system and endothelial cell differentiation.
35–38
 HMWK has been sparsely 
studied in a clinical setting. It was found to be 10% higher in patients suffering from venous 
thrombosis than in blood donors,  suggesting that it is associated with an increased clotting 
potential.
14
 The relation with myocardial infarction was also studied; two small studies 
showed that HMWK levels were lower in patients than healthy controls.
39,40
 However, 
sample collection in these small studies occurred within hours after the disease onset. 
Since HWMK levels may be affected by the acute phase these results cannot be easily 
interpreted. 
Previous results from the RATIO study showed that increased levels of activated protein-
inhibitor complexes are associated with ischaemic stroke but not myocardial infarction.
22
 
Of the antigen levels of these proteins, only high levels of FXI were clearly associated with 
an increase in ischaemic stroke. This study is designed to determined whether HMWK, as 
co-factor for the activation steps in this system, is also linked to the risk of myocardial 




Material and Methods 
Study design & participants The RATIO study is a population-based case-control study, 
originally set up to investigate the association between the use of oral contraceptives and 
incident arterial thrombosis. Details of this study have been published before.
2,41,42
 In short, 
women under the age of 50 years who where diagnosed using standard criteria with 
myocardial infarction, ischaemic stroke or peripheral arterial disease in one of the 16 
participating centers were eligible to participate. Healthy controls, frequency-matched on 
age (5 years categories), area of residence and index date, were contacted via random digit 
dialing. This analysis focuses on myocardial infarction and ischaemic stroke. During the first 
phase of RATIO we included 248 cases with myocardial infarction, 203 cases with ischaemic 
stroke and 925 frequency-matched controls. During the second phase of the study, in 
which all participants were recontacted to provide either a blood sample or buccal swabs 
for DNA extraction. Ultimately, blood samples of 205 myocardial infarction cases, 175 
ischaemic stroke cases and 638 healthy controls were available. The study was approved 
by institutional review committees of the participating hospitals and all subjects gave 
informed consent.  
Measurements HMWK levels were measured with a sandwich ELISA based assay using a 
polyclonal, commercially available antibody kit optimised to reduce signal to noise ratio  
(CEDARLANCE inc., Burlington, Ontario, Canada). This kit uses a purified coating antibody 
 Table 1. Characteristics of participants 
 
 





 quartile.* in the year prior to event (cases) or index year(controls). † levels are expressed as 








Mean age 43 (6.1) 39 (7.9) 39 (7.9) 
Caucasian ethnicity 195 (95%) 168 (95%) 602 (94%) 
History of *       
   Hypertension (N, %) 53 (26%) 50 (29%) 40 (6%) 
   Diabetes (N, %) 
 
10 (5%) 7 (4%) 10 (2%) 
   Hypercholesterolaemia (N, 
%) 
21 (10%) 14 (8%) 19 (3%) 
Oral contraceptives use (N, %) 
* 
81 (40%) 92 (53%) 213 (33%) 
Smoking (N, %) * 169 (82%) 105 (60%) 270 (42%) 
    HMWK † Mean (SD) 117% (21%) 121% (25%) 117% (22%) 





Table 2. Levels of HMWK in relation to baseline characteristics in the control group 
 
HMWK  levels in control group* 
10
th
 percentile  92% 
25
th
 percentile 103% 
50
th
 percentile (median) 115% 
75
th
 percentile 131% 
90
th
 percentile 145% 
       
Risk factor HMWK levels* 
Mean (SD) 
difference (95% CI) 
Hypertension - 117% (21%) [ref] 
Hypertension + 118% (20%) 1 %(-6% to 8%) 
       
Diabetes - 117% (21%) [ref] 
Diabetes + 131% (23%) 14% (1% to 27%) 
       
Hypercholesterolaemia- 117% (21%) [ref] 
Hypercholesterolaemia+ 126% (21%) 8% (-1% to 18%) 
       
Oral contraceptive use - 118% (22%) [ref] 
Oral contraceptive use + 116% (19%) -2% (-6% to 1%) 
       
Smoking - 118% (20%) [ref] 
Smoking + 116% (21%) -2% (-6% to 2%) 
    
Age†    0.4% (0.2% to 0.6%) 
 
Abbreviations: HMWK  = High molecular weight kininogen, SD = standard deviation, 95% CI = 
95% confidence interval.* levels are expressed as percentage of HMWK levels in normal 
pooled plasma. Percentages might not add due to rounding.† difference is expressed in the 
increase of HMWK levels per year. 
 
 
targeted against HMWK, incubated overnight at 2-8° C (CL20027K-C), in combination with a 
purified peroxidase labeled detection antibody (CL20027K-D). Being an o-
phenylenediamine based antibody kit, we measured light absorbance at 490 NM and signal 
strengths were converted to HMWK levels expressed as percentage of normal pooled 
plasma. Data on medical history, oral contraceptive use and other patient characteristics 
were obtained by questionnaire and reflect the year prior to the event (for the cases) or 
the frequency-matched index date (controls) unless stated otherwise.  
Statistical analyses Odds Ratios (ORs) as measures of rate ratios and corresponding 95% 
confidence intervals (95%CIs) were calculated by means of logistic regression; all models 




frequency-matching procedure. Traditional risk factors, i.e. hypertension, diabetes, 
smoking and hypercholesterolaemia were additionally included in subsequent models as 





 percentile of the control group were used as cutoff values for low and high 







percentile of controls were used to investigate possible dose response associations. 
Results 
As expected, traditional risk factors such as hypertension, diabetes and 
hypercholesterolemia were more frequent in the cases than the control group (Table 1). 
The mean HMWK levels in the control group (117%) and MI case group (117%, mean 
difference 0%, 95%CI -4 %to 3% ) were similar, whereas the levels were slightly increased in 
the IS case group (121%, mean difference 4%, 95%CI 0% to 8%). Table 2 shows HMWK 
levels in relation with classical risk factors in the control group. The levels were higher in 
those suffering from diabetes (mean difference 14%, 95%CI 1% to 27%) and 
hypercholesterolemia (mean difference 8%, 95%CI -1% to 18%), whereas hypertension, 
previous OC use and previous smoking habits were not associated with substantial changes 
in HMWK levels. 
The risk of myocardial infarction was not affected by  high levels (≥p90) of HWMK 
(unadjusted OR 1.26, 95%CI 0.75-2.10; adjusted OR 1.05, 95%CI 0.57-1.91) (table 3). There 
was an association with the risk of ischaemic stroke, which remained after adjustment for 
all confounders (adjusted OR 1.82, 95%CI 1.00-3.29). Low levels of HMWK were weakly 
associated both with the risk of myocardial infarction and ischaemic stroke (MI: adjusted 
OR 1.39, 95%CI 0.74-2.61; IS: 1.49, 95%CI 0.77-2.89). Table 4 shows that there was no clear 
pattern of increasing risk with increasing levels for myocardial infarction, while the risk of 
ischaemic stroke was best represented by a U-curve. A post-hoc analysis with 5 categories 
can be found in table 5. 
Interaction analyses with oral contraceptive use in the year prior to the event are shown in 
table 5. As expected, the risk in the group of women who were only exposed to oral 
contraceptive use but had normal HWMK levels (i.e. the  -/+ group) was about two- 
threefold increased for both myocardial infarction and ischaemic stroke when compared 
with women with neither risk factor. The risks associated with high HWMK levels and no 




Table 4. HWMK levels categorised in quartiles in relation to the risk of myocardial infarction and ischaemic 
stroke 
 
See table 3 for description 
 Control  Myocardial infarction  Ischaemic stroke 
 N %  N % OR1 95%CI OR2 95%CI  N % OR1 95%CI OR2 95%CI 
Q1 154 0.25  53 0.27 1 [ref] 1 [ref]  41 0.25 1 [ref] 1 [ref] 
Q2 146 0.24  39 0.20 0.75 (0.46-1.24) 0.77 (0.44-1.37)  26 0.16 0.57 (0.32-1.03) 0.51 (0.27-0.97) 
Q3 157 0.25  55 0.28 0.82 (0.51-1.31) 0.97 (0.56-1.67)  39 0.24 0.67 (0.38-1.17) 0.71 (0.38-1.30) 
Q4 161 0.26  47 0.24 0.72 (0.44-1.17) 0.75 (0.42-1.33)  57 0.35 1.01 (0.60-1.71) 1.00 (0.56-1.78) 
Table 3. High and low levels of HWMK and the risk of myocardial infarction and ischaemic stroke 
 
  Control  Myocardial infarction  Ischaemic stroke 
  N %  N % OR1 (95%CI) OR2 (95%CI)  N % OR1 (95%CI) OR2 (95%CI) 
High <p90 554 0.90  169 0.87 1 [ref] 1 [ref]  137 0.83 1 [ref] 1 [ref] 
 ≥p90 64 0.10  25 0.13 1.26 (0.75-2.10) 1.05 (0.57-1.91)  29 0.17 1.69 (0.99-2.89) 1.82 (1.00-3.29) 
                  
Low >p10 557 0.90  170 0.88 1 [ref] 1 [ref]  143 0.88 1 [ref] 1 [ref] 
 ≤p10 61 0.10  24 0.12 1.69 (0.98-2.89) 1.39 (0.74-2.61)  20 0.12 1.62 (0.88-2.99) 1.49 (0.77-2.89) 
 
Abbreviations: OR = odds ratio, 95% CI = 95% confidence interval, ref = reference group, p10 = 10
th
 percentile of control 
group, p90 = 90
th
 percentile of control group.  OR1 = odds ratios adjusted for stratification factors (i.e. age, area of 
residence and index year). OR2 = odds ratios additionally adjusted for potential confounders (i.e. hypertension, diabetes and 
hypercholesterolemia). Percentages might not add due to rounding. 
Table 5. Interaction analyses with OC use 
 
 
Abbreviations: OC = oral contraceptive use. See table 3 for further description. 
   Control  Myocardial infarction  Ischaemic stroke 
 ≥p90 OC N %  N % OR1 95%CI OR2 95%CI  N % OR1 95%CI OR2 95%CI 
- - 366 0.59  104 0.54 1 [ref] 1 [ref]  61 0.31 1 [ref] 1 [ref] 
- + 188 0.30  65 0.34 2.06 (1.37-3.09) 1.75 (1.11-2.77)  73 0.38 2.87 (1.80-4.56) 2.87 (1.73-4.78) 









+ + 17 0.03  11 0.06 4.90 (2.04-12) 2.90 (1.01-8.26)  11 0.06 4.34 (1.71-11) 3.89 (1.47-10) 
 
    
 
             
 ≤p10 OC                 
- - 368 0.60  108 0.56 1 [ref] 1 [ref]  72 0.44 1 [ref] 1 [ref] 
- + 189 0.31  62 0.32 2.03 (1.35-3.06) 1.64 (1.03-2.61)  71 0.44 2.61 (1.66-4.14) 2.46 (1.47-4.07) 













risk for myocardial infarction was not affected, whereas the risk for ischaemic stroke 
remained doubled. The risk associated with the combination of OC use and low HMWK was 
increased 4.5 fold for myocardial infarction and 6.5 fold for ischaemic stroke. 
Discussion 
This study indicates that extreme levels of HMWK are associated with an increased risk of 
ischaemic stroke, whereas the risk of myocardial infarction is only mildly increased with 
low levels of HMWK. Analysis by HMWK levels suggested a U-shaped curve for ischaemic 
stroke. The increase in risk was pronounced higher in women with oral contraceptive use. 
When these results are compared with our previous results on the intrinsic coagulation 
proteins, some similarities can be seen: high levels of HMWK, which could result in more 
activation of the intrinsic coagulation system, are related to an increased risk of ischaemic 
stroke, whereas the risk of myocardial infarction is not affected. However, the U-shaped 
risk curve observed for HMWK levels and the risk of ischaemic stroke does not readily 
comply with this notion. Moreover, due to different roles of HWMK we cannot draw strong 
conclusions on whether this increase in ischaemic stroke only reflects the activation rate of 
the intrinsic coagulation proteins. 
Our study is the first to investigate the role of HWMK levels in plasma in relation to both 
myocardial infarction and ischaemic stroke. Our results are not in line with previous studies 
which focused on myocardial infarction.
39,40
  However, since the blood samples in these 
small studies were collected in the acute phase, their results are subject to reverse 
causation and should therefore not be interpreted causally. We did not identify prior 
TABLE 6. HWMK levels categorised in quintiles in relation to the risk of myocardial infarction and 
ischaemic stroke 
 Control  Myocardial infarction  Ischaemic stroke 
 N %  N % OR1 95%CI OR2 95%CI  N % OR1 95%CI OR2 95%CI 
Q1 123 0.20  43 0.26 1.33 (0.77-2.29) 1.19 (0.63-2.23)  34 0.21 1.53 (0.81-2.90) 1.51 (0.76-3.00) 
Q2 119 0.19  37 0.22 1.02 (0.58-1.78) 1.03 (0.54-1.94)  21 0.13 0.88 (0.44-1.75) 0.74 (0.35-1.57) 
Q3 119 0.19  36 0.22 1 [ref] 1 [ref]  26 0.16 1 [ref] 1 [ref] 
Q4 128 0.21  37 0.22 0.85 (0.49-1.49) 0.88 (0.47-1.66)  30 0.18 0.90 (0.47-1.72) 0.87 (0.43-1.75) 
Q5 129 0.21  41 0.25 0.98 (0.57-1.70) 0.92 (0.49-1.74)  52 0.32 1.85 (1.02-3.39) 1.85 (0.96-3.57) 




studies which focused on the relation of plasma levels of HMWK and ischaemic stroke. 
However, some studies on tissue kallikrein levels as well as the bradykinin-receptor 
indicate that bradykinin is involved in stroke aetiology through the exacerbation of stroke 
related brain oedema.
38,43,44
 Although the biological mechanisms that were investigated as 
well as the outcome in these studies are not directly comparable to our study, they do 
suggest that HMWK and especially activation of bradykinin plays a role in the 
pathophysiology of ischaemic stroke. Unfortunately, our current observational 
epidemiological study cannot discriminate between the possible mechanisms by which 
HWMK exerts its risk increasing action and further study is needed to elucidate the 
underlying mechanisms.  
Remarkable results come from the interaction analyses. The analysis of high HMWK levels 
in combination with oral contraceptive use showed that the observed effect on ischaemic 
stroke was present for both users and non-users. All other analyses (i.e. low HMWK levels 
and the risk of ischaemic stroke, low HMWK levels and the risk of myocardial infarction, 
high HMWK levels and the risk of myocardial infarction) suggested an increase in risk only 
for women who were used oral contraceptives. This difference could explain in part why 
there is a difference in the risks conferred by high HWMK levels between myocardial 
infarction (OR 1.05) and ischaemic stroke (OR 1.82). The value of this observation, 
however, is unclear; although it is unlikely that bias could be the sole explanation for this 
observation, there is also no strong direct biological evidence why certain HMWK 
concentrations would only be harmful in combination with oral contraceptive use. 
Our case-control study has some limitations. A major problem in case-control studies in 
particular is the possibility of reverse causation where cause and effect are mistaken for 
each other. It is unclear whether HMWK increases or decreases after a major event and 
could therefore be considered an acute phase reactant which could lead to reverse 
causation. Our blood samples have been drawn a minimal of 23 months after the event, 
i.e., after the acute phase, which renders reverse causation unlikely. Survival bias may also 
play a role in case-control studies. In this study design, blood samples could only be drawn 
after the event. Therefore, patients who died shortly after the initial diagnosis were not 
included. This selection of survivors could influence our results only if the etiologic role of 
HMWK is different between fatal and non-fatal disease. We believe that HMWK levels are 
not likely to have a large effect on case fatality rate. If such an effect exists, we hypothesise 




indicated that bradykinin is associated with worse stroke outcome.
38,43,44
 Therefore, the 
results as presented are at most an underestimation of the true effect. Another problem 
could be confounding; a mechanism in which an observed effect is not caused by the 
exposure of interest but by a third factor related to the exposure of interest. In our study, 
strong cardiovascular risk factors (i.e. hypertension, diabetes, hypercholesterolemia, age) 
were not or only slightly associated with HMWK levels. Therefore we added these risk 
factors as putative confounders in our fully adjusted model of which the results did not 
differ substantially from the unadjusted model. We cannot rule out that our analyses are 
still confounded to some extent, but we expect that the observed effects cannot be 
completely explained by confounding mechanisms. 
Conclusion Our study shows that both high and low levels of HMWK are associated with 
increased risk of ischaemic stroke in young women. The risk of low HWMK is only present 
within oral contraceptive users, whereas the risk of increased HWMK was also present in 
women who did not use oral contraceptives. HWMK does not seem to have a major impact 
on the risk of myocardial infarction. Further research is needed to determine the exact 
underlying mechanism and the role of oral contraceptive use in the causal relation 
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The aim of aetiologic studies in epidemiology is to investigate whether factors are causally 
related to diseases and therefore become a potential target for therapeutic interventions. 
Mendelian randomisation enables estimation of causal relationships in observational 
studies with genetic variants as instrumental variables. An instrumental variable is a 
variable that can be considered to mimic the coin toss in a randomised study. Given the 
random assignment of alleles in gamete formation, the use of genetic variants is an 
alternative method to control for confounding. This chapter describes the approach of 





While a randomised controlled trial (RCT) is an unbeatable standard in intervention studies, 
RCTs might be inappropriate or even impossible to conduct when studying the effect of 
factors potentially involved in the aetiology of disease.
1
 Observational study designs are 
the obvious means for studying these types of research questions, each with their own 
strengths and weaknesses.
2,3
 Despite the valuable contribution of observational studies in 
understanding the aetiology of diseases, these studies are limited for making causal 
inference. Exposures that seemed to affect the risk of disease in observational studies 
turned out later to be non-causal (i.e. only a risk marker), as no or reverse effects of 
interventions on the presumed cause of the disease was shown in later RCTs. A likely 
explanation for the initially suggested relationships is ‘residual confounding’, caused by an 
incomplete or a lack of measurement of relevant identified or unidentified confounding 
factors. Moreover, the findings could be due to ‘reverse causation’, being the (subclinical) 
presence of disease influencing the presence of the exposure under investigation, rather 
than vice versa.
4
 The subclinical presence of cancer, for instance, might cause leanness, 
instead of resulting from it, although leanness might be observed prior to cancer diagnosis 
(Figure 1). Observational studies, however, enable the estimation of causal relationships  
when an ‘instrumental variable’ is available that mimics the coin toss in a randomised 
study reducing confounding.
5
 The use of ‘genetic variants’ as an instrumental variable in 





This chapter describes the approach of Mendelian randomisation used to make causal 
inference in observational studies, and its underlying rationale and assumptions. All 
concepts in italics are briefly defined in the glossary.  
Example 1: Are low serum cholesterol levels a causal risk factor for cancer? The concept 
of Mendelian randomisation was originally suggested by Katan in 1986 in the debate on 
the hypothesis that low serum cholesterol levels (exposure) directly increase the risk of 
cancer (outcome).
9
 In order to investigate whether the association between low serum 
cholesterol levels and cancer is causal, Katan suggested making use of the data of the 
apolipoprotein E (ApoE) gene. This gene is known to affect serum cholesterol levels, with 




hypothesised that, if the low serum cholesterol is a causal risk factor for cancer, an 
increased risk of cancer should be observed in individuals carrying the ApoE2 variant.  
Rationale The main rationale in Mendelian randomisation is that, if an exposure is causally 
related to an outcome, a genetic variant, which is associated with the exposure, should 
have a similar relation to the outcome as the supposedly causal exposure itself. In contrast, 
if the genetic variant turns out to be not related to outcome, a causal role of the genetic 
product (i.e. the exposure) is less likely. In theory, the exposure of interest in Mendelian 
randomisation studies can be any property, but in general, protein levels as measured in 
blood are studied. In the study of Katan, the genetic variant ApoE2 was suggested for its 
association with the lower levels of serum cholesterol. Persons carrying the ApoE2 variant 
are lifelong exposed to lower cholesterol levels; if low cholesterol is indeed a causal risk 
factor for cancer, an increased risk of developing cancer would be expected in the carriers 
of the ApoE2 variant. A recent publication, however, clearly showed that carriers of the 
ApoE2 variant are not more susceptible to develop or die from cancer, ruling out low 
cholesterol as a causal risk factor for cancer.
10
  
The use of a genetic variant as an instrumental variable for causal reasoning, whether it is a 
single-nucleotide polymorphism (SNP), a haplotype or a deletion, is directly based on the 
independent assortment of alleles. According to Mendel's second law (Gregor Mendel, 
1822–1884), an individual's genotype is randomly assigned from his/her parental 
genotypes at gamete formation. In this respect, an observational study investigating the 
effect of a genetic variant has important similarities with an RCT studying a treatment 
effect. In Figure 2, both study designs are shown. The randomisation of treatment in an 
ideal RCT guarantees that all differences in patient characteristics are due to chance, so no 
confounding by indication is present. The differences observed during follow-up can be 
regarded as the likely sole effect of the treatment that was allocated in a randomised 
manner. Similarly, the random assortment of alleles guarantees that, when comparing 
patients according to a genetic variant, the differences in patient characteristics are due to 
chance except for the differences that result from the genetic variant. As such, 
confounding is eliminated. Moreover, since the genetic makeup is fixed at conception, a 
genetic variant cannot be  influenced by the (subclinical) presence of disease, thereby 





Figure 1. An association between an exposure and an outcome in observational studies 




















Figure 2. Parallel between RCT and Mendelian randomisation 
 
Parallel between randomised control trials (panel A) and Mendelian randomisation (panel 
B), with in the diagram of Mendelian randomisation the original idea of Katan as an 
example.  
 








Differences in other causes of disease are due to chance





















Framework The framework of a Mendelian randomisation study is summarised in Figure 3 
together with the text that describe the associations as examined in the studies used as 
examples in this chapter. Mendelian randomisation in its most basic form is to study  the 
causal relationship between the exposure levels and the outcome (blue arrow) with a 
genetic variant known for influencing the exposure levels under investigation (red arrow) 
as an instrumental variable, by estimating the association between the genetic variant and 
the outcome (green arrow).  In a more sophisticated approach, a quantitative analysis of  
the three associations is done. Given the observed association in the data between the 
genetic variant and the outcome and between the exposure level and the outcome, the 
expected associations can be calculated under the assumption that the exposure levels are 
causally related to the outcome. Under this assumption, the association between the 
genetic variant and the outcome (green arrow) is expected to be equal to the association 
between exposure levels and outcome (blue arrow) if a genetic variant would explain 
100% of the variance in the exposure levels (red arrow). This relation between the 
exposure of interest and its proxy is also known as the instrument strength and can be 
Figure 3. Framework of a Mendelian randomisation study; the table describes the associations 







blue arrow red arrow green arrow 




cholesterol levels – 
cancer 
ApoE genotype – 
cholesterol levels 
ApoE genotype – cancer 
CRP levels – ischaemic 
heart disease 
CRP genotype  –  
CRP levels 





Cholesterol levels – 
ischaemic heart disease 
ApoE genotype – 
cholesterol levels 
ApoE genotype – ischaemic 
heart disease 
    
 
 
The blue arrow (also denoted by a small letter b) represents the association between the exposure of 
interest and the outcome of the study. To determine whether this association indeed is a causal one, 




estimated for example with the F statistic.
11
 A much more realistic scenario is that the 
genetic variant explains does not explain 100% of the variance in the exposure levels. In 
this case, the expected associations can be calculated in two stage regression analyses.
6
 If 
the observed and expected associations between the genetic variant and the outcome and 
between the exposure level and the outcome are not similar (in direction and magnitude), 
this indicates that the observed association between the exposure levels and the outcome 
could be due to residual confounding and/or reverse causation. For more detailed methods 
for calculating the expected  associations please refer to Lawler et al.
6
 The use of this 
formal way of Mendelian randomisation analyses does require the presence of a strong 
instrument or, which is most often the case, a large study to circumvent the lack of a 




Assumptions Figure 4 depicts the three assumptions that are underlying a Mendelian 
randomisation  study. The first assumption is that there is a robust association between the 
genetic variant and the exposure levels, i.e. the chosen instrument must not be weak. In 
order to ensure this, the association should preferably be demonstrated in independent 
(healthy) populations and confirmed in own data. More robust associations between 
genotype and exposure levels might be obtained with haplotypes or a genetic score as the 
instrumental variable instead of a single genetic variant (Figure 4, presence of association 
A). Also, additional variables which are not on the causal path can be used to minimise the 
variance of the exposure of interest to be explained by its instrument.
11,12
 Where this first 
assumption can be evaluated, the other assumptions are about the absence of pleiotropic 
effects of the genetic variant which in theory cannot be verified empirically.  
The second assumption is that the genetic variant is not associated with factors that 
confound the association between the exposure levels and outcome. The association 
between a genetic variant and a confounding factor can be direct, namely if the 
confounding factor itself is regulated by the genetic variant, or indirect when neighbouring 
variants (i.e. variants that are in linkage disequilibrium with the variant used as 
instrumental variable) regulate one or more confounding factors (Figure 4, absence of 
association B).  
In the third assumption, the genetic variant is assumed to be independent of the outcome 




Figure 4. Assumptions made in a Mendelian randomisation study 
 
 
Three assumption may not be violated in order to yield an unbiased result from Mendelian randomisation 
analyses, denoted by a capital letter: A) presence of a robust association between genetic variant and 
exposure (no weak instrument) B) absence of association, direct and indirect, between genetic variant and 
confounding factors (no pleiotropy / no confounding such as population stratification nor canalisation) C) 
absence of other pathways between genetic variants and outcome (no pleiotropy) 
is assumed to be exclusively related to the outcome via the exposure levels and that there 
are no other pathways to the outcome. Otherwise, the observed association between the 
genetic variant and the outcome also includes the impact of the variant on the outcome via 
other pathways. As such, this association does not prove that the particular exposure levels 
under investigation are causally related with the outcome (Figure 4, absence of association 
C). Knowledge of the function of the genetic variant and its neighbouring variants is 
needed to evaluate whether 
the assumptions are likely to hold in a particular Mendelian randomisation study. When 
these assumptions hold, Mendelian randomisation can be used to test the null hypothesis 
that the exposure levels of interest are not associated with the outcome. The assumption 
that all associations are linear and unaffected by statistical interactions is needed when 
aiming at a precise estimate of the size of the causal effect. Although several approaches 
can be used to determine whether the assumptions are likely to hold, some of the 
assumptions can never be checked empirically, because they are based on the absence of a 
effect. Nonetheless, if thoroughly investigated and critically evaluated, Mendelian 
randomisation can be a valuable technique in causal inference.
13
 
Some additional issues are relevant to mention in the context of Mendelian randomisation 
studies, as they may in part be underlying causes invalidating the assumptions. The first 




when the allele frequencies of the genetic variant and the distribution of the exposure 
levels (or outcome) vary substantially between the different subgroups in the study 
population.
6
 In that case, an association is induced between the genetic variant and the 
exposure levels (or outcome) at the population level. This phenomenon can be regarded as 
confounding by ethnicity. Population stratification is unlikely to be a problem in practice, 
except in extreme situations,
14
 and can be overcome by studying populations that are 
homogeneous with respect to ethnicity. A second issue is the possibility that a lifelong 
genetic (or environmental) exposure has induced developmental compensation via 
alternative pathways. This is known as ‘canalisation’ and may invalidate the estimation of 
associations like those in Figure 3. In this perspective, it is worthy to note that Mendelian 
randomisation studies and RCTs are different in this respect: in RCTs, the random allocation 
treatment is normally done in adulthood, after the developmental period, while the 
random allocation of alleles takes place at conception, allowing the possibility of 
canalisation. It is, however, unclear how important this issue is in practice.
6
 
Finally, as for all genetic association studies, relatively large sample sizes are required for 
Mendelian randomisation studies. The sample size highly depends on both the frequency 
of the genetic variation used as instrument, and the expected effect size of the association 
of interest between the genetic variant, the exposure and outcome. Conventional sample 
size calculations can be performed in order to get an approximation of the required sample 
size. Studies that are underpowered might be unable to observe small (but existing) 
effects, incorrectly suggesting that an association between an exposure and outcome is not 
causal. This encourages enlarged sample sizes through collaboration between research 
groups and by the setting up of well-defined cohorts. In addition, the evidence of the 
different studies can be combined in meta-analyses. 
Example 2: Is CRP a causal risk factor for ischaemic vascular disease? The study of Zacho 
and colleagues shows an interesting application of the Mendelian randomisation approach. 
They aimed to test whether the observed association between the elevated levels of C-
reactive protein (CRP) and increased risk of ischaemic vascular disease (i.e. ischaemic heart 
disease and ischaemic brain disease) is a causal association.
15
 So, the exposure levels under 
investigation were CRP levels, and the outcome was ischaemic vascular disease. As the 
instrumental variable, they used four polymorphisms in the CRP gene that partially affect 
plasma CRP levels and combined them to one variable with nine genotype combinations. 




[95% confidence interval (CI) 1.6–2.9] and the risk of ischaemic brain disease was 60% 
increased  [95%CI 1.1-2.5] in persons with CRP levels >3 mg/L as compared with persons 
with CRP levels <1 mg/L (adjusted for age, sex and statin use); this is the blue arrow in the 
framework of Figure 3 and 4. Moreover, the data confirmed that the CRP levels are 
regulated by the CRP genotype (red arrow): a difference of up to 64% in CRP levels among 
the genotype combinations. With these findings, an expected ischaemic heart disease 
relative risk of 1.32 (1.26–1.39) can be calculated for the genotype combination that was 
related to the highest CRP levels. However, no increased risk for ischaemic heart disease 
was observed for any of the CRP genotype combinations (green arrow). The results for 
ischaemic brain disease follow the same pattern. These findings suggests that the observed 
increased risk of ischaemic vascular disease associated to elevated CRP levels does not 
reflect a causal relationship, and the CRP is a mere risk marker for this outcome. In the 
same study, a proof of principle of the Mendelian randomisation approach was given, with 
the ApoE genotype as the instrumental variable for examining the causality of the 
association between cholesterol levels and ischaemic heart disease.
15
 The increased risk for 
the outcome was expected across the ApoE genotypes [up to 1.12 (1.06– 1.17)] and was 
also observed [up to 1.35 (1.12–1.61)]. These results suggest that the association between 
cholesterol levels and ischaemic heart disease is indeed a causal one, although the 
difference in magnitude of effect could suggest the presence of residual confounding. 
Conclusion Mendelian randomisation enables to study the hypothesis that an observed 
association between the exposure levels, as determined by the genetic variant used as the 
instrumental variable, and the outcome is causal. As such, it is a unique approach for 
providing more insights into potential causal relationships in aetiologic research using 







Alleles:  variant forms of a gene at a locus; a single allele is 
inherited from each parent. 
Canalisation:  developmental compensation in response to disruptive 
influences on normal development from genetic and 
environmental forces. 
Gene:  stretch of DNA which encodes for a particular protein. 
Genetic variants:  variation in genes, including single-nucleotide 
polymorphisms, and insertion or deletions of stretches 
of DNA. Genotype: genetic makeup of an individual with 
regard to genetic variants. 
Linkage:  tendency of DNA to be co-inherited due to their close 
physical proximity; linkage disequilibrium (LD) is a 
measure of linkage and indicates whether a non-random 
association between two alleles at different loci is 
present 
Locus:  physical location of a gene or other genetic marker 
Haplotypes:  combinations of SNPs; usually, a limited number of 
haplotypes can be used to cover most of the genetic 
variation within a population due to linkage 
Pleiotropy:  phenomenon in which a genetic variant has multiple 
distinct phenotypic effects 
Population stratification:  a form of confounding by race due to differences in 
allele frequencies in subgroups in a population 
SNP: or Single-Nucleotide Polymorphism. A genetic variant in 
which one specific nucleotide in the DNA is altered 
Instrumental variable:  a variable in non-experimental data that can be 
considered to mimic the coin toss in a randomised study 
Residual confounding:  confounding remaining after incomplete adjustment for 
confounders due to lack of measurement of relevant 
identified or unidentified confounding factors 
Reverse causation:  (subclinical) presence of disease, or its effects, alters the 
exposure under investigation, rather than vice versa, i.e. 
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Introduction Confounding by common causes and reverse causation have been proposed 
as explanations of the association of high fibrinogen levels and cardiovascular disease. 
Genetic variants, such as plasma levels, can alter fibrinogen characteristics and are not 
subject to these problems. 
This study aims to determine the fibrinogen plasma levels for genotypic variants in 
fibrinogen-alpha (FGA Thr312Ala, rs6050) and fibrinogen-beta (FGB -455G/A, rs1800790) 
and whether these variants are associated with myocardial infarction and ischaemic stroke 
in young women. 
Methods Fibrinogen genotypes were determined in a population-based case-control study 
including women aged 18-50 years; 218 cases with myocardial infarction, 190 cases with 
ischaemic stroke and 767 healthy controls. Fibrinogen levels were determined in the 
control population. Blood samples were available for 205 cases with myocardial infarction, 
175 ischaemic stroke cases and 638 patients. 
Results The FGB -455G/A variant increased plasma fibrinogen levels, whereas the FGA 
Thr312Ala variant lowered plasma fibrinogen levels, albeit to a modest extent. The risk of 
ischaemic stroke was altered when the homozygote minor allele was compared with the 
homozygote major allele. The FGA Thr312Ala single-nucleotide polymorphism (SNP) was 
associated with a decrease in risk [odds ratio (OR) 0.43; 95% confidence interval (CI) 0.21 - 
0.87], whereas the FGB -455G/A SNP might have increased the risk (OR 1.76; 95% CI 0.7 - 
4.03). The risk of myocardial infarction was not altered for either SNP (FGA Thr312Ala, OR 
0.98, 95% CI 0.40 - 2.40; FGB -455G/A, OR 0.98, 95% CI 0.40 - 2.40).  
Discussion With the genetic variations as markers of plasma fibrinogen levels alterations, 
thereby ruling out confounding and reverse causation, our results suggest that plasma 






Fibrinogen is an acute phase coagulation factor produced by hepatocytes and is activated 
by thrombin to form fibrin monomers and polymers. It is covalently cross-linked by 
coagulation Factor XIIIa to form a fibrin mesh of which is the main constituent of blood 
clots. Fibrinogen consists of three pairs of polypeptide chains, denoted (Aα / Bβ / γ), which 
are linked in the central domain. All three genes for these polypeptide chains are located in 
the fibrinogen module located on the short arm of chromosome 4.
1,2
  
High fibrinogen levels have been associated with cardiovascular diseases in large studies 
such as the Framingham Study and Northwick Park Heart study and further in meta 
analyses such as the one by the Fibrinogen Studies Collaboration.
3–5
 Results from the RATIO 
study also showed high fibrinogen to be associated with myocardial infarction (3.5-4.5 g/L 
vs. <2.5 g/L OR 2.1; 95% confidence interval  1.2 to 3.6).
6
  
However, the acute phase property of fibrinogen together with the associations with 
environmental risk factors of cardiovascular disease (e.g. smoking / oral contraceptive (OC) 
use) make it difficult to determine whether fibrinogen is either a cause or a mere marker of 
increased.
7–9
 This question can be addressed by means of Mendelian randomisation, a 
process which uses genetic variation a as marker for lifelong exposure to altered protein 
levels, in this case an increase of fibrinogen.
10,11
 With these genetic variants as markers for 
fibrinogen levels confounding by extraneous factors and reverse causation are virtually 
excluded as possible explanations of the association. The genetic marker might also be in 
linkage disequilibrium with another variation causing variation in the plasma fibrinogen 
level. Common genetic variants in the fibrinogen module have been associated with 
increased fibrinogen plasma level and therefore can be used as markers of lifelong 
increased levels of plasma fibrinogen.
12–14
 This current study uses the fibrinogen-Aα (FGA) 
Thr312Ala (rs6050) single- nucleotide polymorphism (SNP) as a marker of decreased 
plasma fibrinogen levels, and fibrinogen-Bβ (FGB -455G/A) (rs1800790) as a marker for an 
increase in level. 
In spite of the associations between FGA Thr312 as well as FGB -455A and increased levels 
of plasma fibrinogen, no association was found for these SNPs or associated haplotypes 
with myocardial infarction and ischaemic stroke in the Cardiovascular Health Study.
14
 
Similar results were obtained earlier in the Copenhagen City Study, the SMILE study, the 




are associated with increased plasma fibrinogen level, but not with cardiovascular 
disease.
12,13,15,16
 Another study, however, found an increase in myocardial infarction risk for 
carriers of the Bcl I β-chain fibrinogen polymorphism (rs209502) which is also a marker of 
increased plasma fibrinogen levels.
17
 This SNP is almost completely in linkage 
disequilibrium with the FGB - 455G/A SNP (|D’| = 0.96 in the ECTIM study).
18
 
The FGA Thr312Ala SNP has also been associated with a decreased risk of pulmonary 
embolism as well with a lower risk of post-stroke mortality in patients with atrial fibrillation 
but not of deep venous thrombosis. These decreases in risk are not likely to be caused by 
increases in plasma fibrinogen level, but through the changes in the mechanical properties 
of the clot by the genetic variant. The FGA Thr312Ala variant alters clot stability by 
affecting FXIII cross-linking making carriers of the FGA Thr312 less prone to 
embolisation.
19,20
 This study assessed the risk implications of genetic variations in the 
fibrinogen module on myocardial infarction and ischaemic stroke in young women. We 
estimated the risks for carriers of the genetic variants FGA Thr312Ala and FGB - 455G/A as 
markers for altered fibrinogen levels for myocardial infarction and ischaemic stroke.  
Methods 
Study design & participants The Risk of Arterial Thrombosis In relation to Oral 
Contraceptives (RATIO) study is a multicenter population-based case-control study. It 
consists of three sub-studies which included cases with myocardial infarction, ischaemic 
stroke and peripheral arterial disease and frequency-matched controls. The study was 
initiated to evaluate the risk of  myocardial infarction and ischaemic stroke due to oral 
contraceptives of different generations (1990  -  1995).
21–23
  Blood and buccal swabs were 
collected during the second phase of the study in order to study prothrombotic conditions 
of the coagulation system (1998  -  2002). Informed consent was obtained from all 
participants and the study was approved by the medical ethics committees of the 
participating hospitals. For the current study we used data from the myocardial infarction 
and ischaemic stroke sub-studies. 
Patient selection has been described in detail previously. 
21–24
 In summary, we included 
women aged 18 to 50 years old who presented with myocardial infarction or ischaemic 
stroke to one of the sixteen participating hospitals in the Netherlands between 1990 and 
1995. Myocardial infarction was diagnosed by the presence of clinical symptoms, elevated 




stroke were confirmed by either computed tomography (CT) or magnetic resonance 
imaging (MRI). Controls were approached by random digit dialing, and matched on age, 
area of residence and year of event. A standardised questionnaire on (familial) medical 
history, use of oral contraceptives, smoking habits and participant characteristics was filled 
in by all participants. Some of these questions were targeted at the year prior to the event 
for cases. Controls were asked to answer these same questions for a particular year (index 
year) to ensure comparability. Blood or buccal swaps were collected for DNA analysis from 
218 myocardial infarction cases, 190 ischaemic stroke cases and 767 controls. 
Measurements and definitions DNA was isolated from 10 ml EDTA-augmented blood or 
buccal swabs and amplified by polymerase chain reaction. Two SNPs in fibrinogen Aα 
(Thr312Ala, rs6050) and fibrinogen Bβ (-455G/A, rs1800790) were genotyped with the 5’ 
nuclease / Taqman Assay.
25
 Polymerase chain reactions based on fluorescent allele specific 
oligonucleotide probes (assay-by-design / assay-on-demand; Applied Biosystems, Foster 
city, USA)  were performed on a PE9700 thermal cycler (Biozym, Hessisch Oldendorf, 
Table 1. Characteristics of RATIO participants 
 
All data are with respect to the year of event (cases) or index date (controls). Data are 
missing on ethnicity for one ischaemic stroke (IS) case and four controls, on history of 
hypertension for four controls, on history of diabetes for one myocardial infarction (MI) case 
and three controls, on hyperlipidaemia for one MI case and five controls, on oral 
contraceptive use for six controls, on smoking for six controls, and on alcohol use for one IS 









Mean Age (SD) 43 (6) 39 (8) 39 (8) 
Caucasian ethnicity 207 (95%) 182 (96%) 732 (94%) 
 History of *    
 Hypertension 55 (25%) 55 (29%) 47 (6%) 
 Diabetes 
 
11 (5%) 8 (4%) 
 
10 (1%) 
 Hypercholesterolaemia 23 (11%) 15 (8%) 22 (33%) 
Oral contraceptives use * 86 (39%) 98 (52%) 272 (35%) 
Smoking *  181 (83%) 115 (61%) 319 (42%) 
alcohol use 
 
   
 never 83 (38%) 89 (47%) 227 (30%) 
 0-15 glasses per week 
 
128 (59%) 84 (44%) 500 (65%) 




Germany) and fluorescence endpoint reading for allelic discrimination was performed on a 
ABI 7900 HT (Applied Biosystems). Primers and probe sequence are available upon request. 
During genotyping, technicians were unaware of outcome status. Fibrinogen in the control 
population was determined according to Von Clauss using the reagents of Behringwerke 
AG (Marburg, Germany). 
Statistical analyses Logistic regression was used to obtain odds ratios as measures of rate 
ratios and accompanying 95% confidence intervals (95% CI) for the relation between 
genetic variants in the fibrinogen gene and myocardial infarction ischaemic stroke. Odds 
ratios were adjusted for the three stratification variables age (as a continuous variable), 
area of residence and index event. Differences in fibrinogen plasma levels and 
corresponding 95% CI were calculated per genotype. Expected relative risks corresponding 
the observed fibrinogen differences were based on hazard ratios from a meta analysis.
5
 For 
all analyses, the homozygote carriers of the major allele were used as the reference group. 
Women with missing data were excluded from analysis when appropriate. 
Results 
Study participants Table 1 shows the baseline characteristics of the study participants. 
Known risk factors, such as hypertension, diabetes and hyperlipidaemia, were more 
prevalent in both case groups than in controls. A larger proportion of patients than of 
controls were smokers. The overall call rate of the genotyping was 97% for the two SNPs, 
and the success rate was irrespective of case - control status. The allele frequencies of the 
variants were 0.31 for FGA Thr312Ala and 0.19 for FGB - 455G/A. The likelihood of 
departure from Hardy - Weinberg equilibrium (HWE) was determined in the control 
population, and was P = 0.043 for FGA Thr312Ala and P = 0.84 for FGB - 455G/A. 
Genetic variants and fibrinogen plasma levels Plasma fibrinogen levels were available for 
602 control women. The mean fibrinogen level in this population was 3.20 g/L. The plasma 
fibrinogen levels per genotype as well as the associated expected relative risks are shown 
in Table 2. L Levels were lower in carriers of the FGA  -  455G/A variant (3.15 g/L for carriers 
vs 3.24 g/L for non-carriers, 95% CI of difference -0.20 to 0.02 g/L). Levels were higher for 
carriers of the FGB Thr312Ala variant (3.32 g/L for carriers vs 3.13 g/L for non-carriers, 95% 




Table 2. Mean fibrinogen plasma levels per genotype 
 
Fibrinogen was measured in 602 control women. The expected relative risk (RR) was calculated on the basis of the hazard ratio 
(HR) per increase of fibrinogen plasma level of 1 g L)1 for (non)-fatal coronary heart disease [i.e. HR 2.93; 95% confidence 
interval (CI) 2.59 - 3.31] and (non)-fatal stroke (i.e. HR 2.77; 95% CI 2.17 - 3.53) for ages 40 - 59 years reported by the Fibrinogen 
Studies Collaboration.
5
 MI, myocardial infarction; IS, ischemic stroke; RR, relative risk; OR, odds ratio; Ref, reference; FGA, 
fibrinogen-Aα; FGB,  fibrinogen-Bβ. 
        N fibrinogen level difference 95% CI of difference expected RR 
FGA Thr312Ala SNP (rs6050)      MI IS 
  Thr / Thr     319 3.24 g/L  ref - - - 
  Thr / Ala     237 3.14 g/L  -0.06 -0.21 to 0.01 g/L 0.90 (0.80-1.01) 0.90 (0.81-1.01) 
  Ala / Ala     46 3.20 g/L  -0.04 -0.25 to 0.17 g/L 0.96 (0.76-1.20) 0.96 (0.77-1.19) 
           
FGB -455G/A SNP (rs1800790)       
  G / G     397 3.13 g/L ref -   
  A / G     184 3.30 g/L 0.17 g/L 0.05 to 0.28 g/L 1.20 (1.01-1.35) 1.19 (1.05-1.33) 
  A / A     21 3.50 g/L 0.37 g/L 0.06 to 0.67 g/L 1.49 (1.06-2.05) 1.46 (1.04-1.98) 
                    
Genotype analyses The genotype distribution among case groups and controls, aswell as 
the risk per genotype with the homozygote major allele genotype as reference, are shown 
in Table 3. After adjustment for the stratification variables, no effect on myocardial risk 
was observed for the FGA Thr312Ala variant (OR 0.82; 95% CI 0.49 - 1.39) but a decreased 
risk was found for ischaemic stroke (OR 0.43; 95% CI 0.21 - 0.87) when the homozygote 
minor allele genotype was compared with the homozygote major allele genotype. The 
homozygote carriers of the FGB -455G/A variant also showed no altered risk of myocardial 
infarction (OR 0.98; 95% CI 0.40 - 2.40). If anything, the risk of ischaemic stroke was 
increased (OR 1.76; 95% CI 0.77 - 4.03). No substantial effect on myocardial infarction or 
ischaemic stroke was observed for heterozygotes when compared with those with the 
homozygote major alleles for the FGA Thr312Ala SNP or the FGB -455G/A SNP.  
The results of this per-genotype analysis are consistent with the risks when one assumes a 
recessive inheritance pattern: homozygous minor allele genotype of the FGA Thr312Ala 
SNP, when compared with the homozygous major allele genotype combined with the 
heterozygote genotype, lowered the risk of ischaemic stroke (OR 0.43; 95% CI 0.21 - 0.85), 
but not of myocardial infarction (OR 0.91; 95% CI 0.55 - 1.53). The homozygous minor allele 
genotype of the FGB -455G/A SNP tended to elevate the risk of ischaemic stroke (OR 1.84; 
95% CI 0.81 - 4.19) but not of myocardial infarction (OR 0.94; 95% CI 0.39 - 2.29) when 
compared with the homozygous major allele and heterozygote genotype combined. A 




Table 3. Genotype distribution and the relative risk of MI and IS 
      Genotype distribution   OR (95%CI) 
FGA Thr312Ala SNP (rs6050) MI   IS   Control   MI   IS  
  Homozygote major allele  Thr/Thr 121 56%  97 53%  370 49%   1  [ref]  1  [ref] 
  Heterozygote  Thr/Ala 81 33%  74 40%  295 39%   0.76  0.54 - 1.07 1.00  0.69 - 1.46
  Homozygote minor allele  Ala/Ala 24 11%  12 7%  89 12%   0.82  0.49 - 1.39 0.43  0.21 - 0.87
                                           FGB -455G/A SNP (rs1800790)                            
  Homozygote major allele G/G 135 64%  122 67%  483 66  1  [ref]  1  [ref] 
  Heterozygote A/G 70 33%  60 27%  221 30%  1.15  0.80 - 1.62 0.85  0.57 - 1.27
  Homozygote minor allele A/A 7 3%  10 5%  29 4%  0.98  0.40 - 2.40 1.76  0.77 - 4.03
                                              Percentages might not add up to 100%, because of rounding. Single-nucleotide polymorphism (SNP) determination was either 
unsuccessful or ambiguous in seven control women, one myocardial infarction (MI) case and seven ischaemic stroke (IS) cases for the 
fibrinogen-Aα (FGA) Thr312Ala SNP. The fibrinogen-Bβ (FGB) -455G/A SNP determination did not succeed in 34 controls, six MI cases 
and eight IS cases. ORs were calculated per genotype, with the homozygote major allele genotype as reference, and are adjusted for 
matching factors (i.e. age, area of residence, and year of event). 
SNP was observed on myocardial infarction (OR 0.77; 95% CI 0.56 - 1.07) or on ischaemic 
stroke (OR 0.86; 95% CI 0.60 - 1.22). The FGB -455G/A SNP also showed no effect on either 
myocardial infarction (OR 1.13; 95% CI 1.13 - 1.58) or ischaemic stroke (OR 0.94; 95% CI 
0.64 - 1.37).  
Smoking  and oral contraceptive use OC use in the year of the event increased the crude 
risk of myocardial infarction and ischaemic stroke two-fold to three-fold (OR 2.3, 95% CI1.6 
- 3.3, for myocardial infarction; OR 2.6, 95% CI 1.7 - 3.9, for ischaemic stroke). Smoking in 
the year prior to the event also increased arterial thrombotic risk (OR 7.1, 95% CI 4.7 - 10.7, 
for myocardial infarction; OR 2.2, 95% CI 1.6 - 3.3, for ischaemic stroke). These effects 
showed no marked interaction with the effects of the SNPs (not shown).  
Discussion 
We used two genetic variants in the fibrinogen module as markers of decreased (FGA 
Thr312Ala) and increased (FGB -455G/A) plasma fibrinogen levels. We found that the 
effects of these SNPs on fibrinogen levels in our control population were according to the 
literature, albeit to a modest extent. Both genetic variant SNPs as markers of altered 
fibrinogen levels also altered the risk the risk of ischaemic stroke in the expected direction; 
FGA Thr312Ala decreased the risk twofold (OR 0.43; 95% CI 0.21 - 0.87), and FGB -455G/A 
possibly increased this risk (OR 1.76; 95% CI 0.77 - 4.03). Neither SNP affected the risk of 
myocardial infarction. These altered risks were greatest in the per-genotype analysis, with 
similar results being obtained, assuming a recessive inheritance pattern. Smoking and the 




fibrinogen, increased the risk of both myocardial infarction and ischaemic stroke, but 
showed no marked interaction with the FGA Thr312Ala and FGB -455G/A SNPs, possibly 
because of lack of power. 
We used a Mendelian randomisation line of thought to rule out any confounding by 
environmental factors and to ascertain whether the role of fibrinogen is a cause or a 
consequence. For this process, it is necessary to establish the relationship between genetic 
variants and plasma fibrinogen level, either from the literature or in the control population; 
both the FGA Thr312Ala and FGB -455G/A SNPs have been found to alter fibrinogen plasma 
levels. 
12,13,15,19,26,27
 We showed similar effects of the genetic variants in our control 
population, albeit to a modest extent. The expected increase in risk based on the increase 
in fibrinogen levels associated with these genetic variants is 4 - 49%, which is lower than 
the increase in risk that we established. These calculations are based on the hazard ratios 
from the meta-analysis by the Fibrinogen Studies Collaboration, focusing on coronary heart 
disease and stroke in the age group 40 - 59 years.
5
 This meta-analysis also includes studies 
with participants aged 18 - 90 years, with an emphasis on the elderly. The effect of 
fibrinogen on the risk of arterial thrombosis is larger in the young, which might explain why 
the effect was larger in the young women in our study.  
This fair-sized population-based case - control study for young women with myocardial 
infarction or ischaemic stroke provides a unique opportunity to determine (genetic) risk 
factors for this specific group that may be indicative of risk factors in older age categories. 
Nonetheless, our subgroup analyses (i.e. smoking and OC use analyses) had limited 
numbers for some subgroups. For this reason, we chose to use a dominant inheritance 
pattern. The dilution of effect that is observed in the risk analysis with a dominant 
inheritance pattern could therefore also affect these subgroup analyses. However, 
numbers were limited and strong conclusions cannot be drawn. We can therefore only 
conclude that there is no evidence for a strong interaction between the environmental 
factors and genetic variants. 
The control population can be considered not to be in HWE because a P-value of 0.043 was 
calculated for the FGA Thr312Ala SNP. As our controls were sampled from the entire 
Netherlands through random digit dialing, we consider this slight deviation of the HWE to 
be probably due to chance. We chose to study two SNPs in the fibrinogen module that are 




causal for this change in plasma level, but they could also be in linkage with other genetic 
traits that influence fibrinogen levels (e.g. Bcl I β-chain fibrinogen polymorphism). These 
other traits could potentially affect the plasma fibrinogen levels, still leaving our SNPs as 
proper markers of lifelong exposure to altered fibrinogen levels. The used SNPs could also 
be in linkage with genetic variations that result in functionally different fibrinogen and alter 
the risk via a mechanism other then altered plasma fibrinogen levels. This might be the 
case for the FGA Thr312Ala SNP. It has been negatively associated with venous 
thromboembolism, pulmonary  embolism and poststroke mortality in patients with atrial 
fibrillation and ischaemic stroke.
19,20,27,28
 This increase in risk might be caused by the 
changed characteristics of the fibrin fibers, which make the clot more prone to 
embolisation.
20
 This increase in risk is in contrast with our results. But as the stroke cases 
included in our study are primarily of non-cardiac origin, we feel that the FGA Thr312Ala 
variation is a marker not of decreased disposition to embolisation but primarily of lower 
fibrinogen plasma levels. Nevertheless, conclusions based on the FGA Thr312 results 
should be drawn cautiously. The large individual-participant meta-analysis by the 
Fibrinogen Studies Collaboration showed a similar increase in risk for all major 
cardiovascular diseases, including non-fatal ischaemic stroke and myocardial infarction. 
The difference between our results (different effects of fibrinogen on the risks of 
myocardial infarction and ischaemic stroke) and those of the Fibrinogen Studies 
Collaboration (similar effects of fibrinogen on the risks of those diseases) might be due to 
confounding and reverse causation, problems that are resolved by the use of Mendelian 
randomisation in our study. Earlier studies with the same approach also showed an 
association of the FGB -455G/A SNP and increased plasma fibrinogen levels, but failed to 
show an association with myocardial infarction or ischaemic stroke.
13–15,27,29
 These studies 
mainly included middle-aged to old subjects, in contrast to our young female population: 
the older age, and hence more developed stage of atherosclerosis, of the previously 
studied populations might explain why no direct relationship between the genetic variants 
and arterial thrombosis were found. If it is present at all, we hypothesize that our cases 
have minimal late stage atherosclerosis, because of their young age; only 11% of the 
myocardial infarction cases and 8% of the ischaemic stroke cases were reported to be 
diagnosed with hyperlipidaemia at the time of the event. Fibrinogen levels and other 
coagulation factors might therefore play a more pronounced role in arterial thrombosis in 




cofactor in thrombosis initiated by subclinical atherosclerosis. This may be even more the 
case for the development of ischaemic stroke than for myocardial infarction. 
Because of the use of a detailed questionnaire in the first phase of this case-control study, 
we were able to include only survivors of myocardial infarction and ischaemic stroke; fatal 
events could not be included, possibly leading to a survivor bias. Even if there is a 
difference between the aetiologies of fatal and non-fatal arterial thrombosis, we 
hypothesize that the effect of fibrinogen, or any other risk factor, is more pronounced in 
the fatal events. Therefore, if our study is affected by this survivor bias, this bias is likely to 
have led to an underestimation of the true effect of fibrinogen levels.  
Conclusion In conclusion, this study showed an association between the FGA Thr312Ala 
SNP and a decreased risk of ischaemic stroke. If anything, the FGB -455G/A SNP was 
associated with an increase in risk. The direction of the effects is in accordance with the 
effects of the two SNPs on plasma fibrinogen levels. Neither SNP affected the risk of 
myocardial infarction. The FGA Thr312Ala SNP could also be a marker of altered clot 
characteristics, and the effect of the FGB -455G/A SNP has not been established firmly, 
which makes the interpretation of the increased risk associated with this variant difficult. 
Taking survivor bias into account, as well as the non-cardiac origin of the ischaemic stroke 
included in this study and the fact that the SNPs used in this study are proper markers of 
altered fibrinogen levels, we conclude that fibrinogen probably plays a causal role in the 
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Genetic variants of 
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young women 
 









Introduction Coagulation factor XIII is involved in the crosslinking of fibrin molecules and 
determines the architecture of the fibrin mesh. Genetic variation  in FXIII could lead to 
differences in clot structure and density. Previous research indicated that genetic variation 
in genes coding for FXIII increased the risk of ischaemic stroke (IS) nine-fold (204Phe 
carriers: OR 9.1; 5.5-15). This study aims to determine whether genetic variation in genes 
coding for FXIII confers a similar increase in risk of myocardial infarction (MI) as with IS.  
Methods We determined the four genetic variants in the MI arm (N=218) and control 
group (N=767) of the RATIO study, a population-based case-control study into risk factors 
for myocardial infarction and ischaemic stroke in young women (18-50 years). Odds ratios 
(OR) with 95% confidence intervals were calculated as measures of rate ratios assuming a 
dominant inheritance pattern.  
Results FXIIIA Pro564Leu moderately increased the risk of MI by 40% (564Leu carriers: OR 
1.4; 1.0-1.9). This increase in risk was confined to heterozygotes. The other SNPs did not 
alter MI risk (FXIIIA 34Leu carriers: OR 1.1; 0.8-1.5, FXIIIA 204Phe carriers: OR 0.8; 0.4-1.7 
and FXIIIB 95Arg carriers: OR 0.8; 0.5-1.2). 
Discussion FXIII SNPs do not play a major role in the aetiology of myocardial infarction 
whereas they do in IS. This pattern is consistent with earlier results from the RATIO study: 






Several proteins are involved in thrombus formation. Coagulation factor XIII is, upon 
activation by thrombin, responsible for the crosslinking of fibrin monomers.
1
 The 
importance of FXIII and its role in haemostasis is demonstrated by the bleeding diathesis of 
FXIII deficient patients.
2
 The protein consists of four chains which are encoded on different 
chromosomes: two B-chains (encoded on chromosome 1q31 - q32.1) which have no 
enzymatic activity and serve as carriers of the A-chains, and two A-chains (chromosome 
6p25 - p24) that consist of the protransgluteminase which is involved in the crosslinking. 
This process determines clot structure and  clot permeability and resistance to shear stress 
and fibrinolysis, factors that are of possible importance in pathologic mechanisms 
underlying thrombotic disease.
3–6
  Genetic variants in one of the two genes which encode 
for coagulation factor XIII (F13A1 and F13B) have been shown to be associated with an 
altered risk of both arterial and venous thrombosis thrombosis.
7–9
 We previously showed 
that one of these four genetic variants, the F13A1 204Phe SNP, was associated with a 9-
fold increased risk of ischaemic stroke in young women. Oral contraceptives use further 
increased this risk (odds ratio 20; 95% confidence interval 9-46).
10
 
Since ischaemic stroke (IS) and myocardial infarction (MI) are both manifestations of acute 
forms of arterial thrombosis, we hypothesised that the risk of MI is also increased by these 
genetic variants of FXIII. We therefore set out to assess the relationship between these 
four SNPs in the FXIII genes and the risk of MI in the RATIO study.  





N= 218  N=767 
Age Mean, SD 42.9 6.0  38.6 8.0 
Caucasian Ethnicity N, (%) 207 (95)  723 (94) 
History of  Hypertension N, (%) 55 (25)  47 (6) 
 Diabetes N, (%) 11 (5)  10 (1) 
 Hyperlipidaemia N, (%) 23 (11)  22 (3) 
Oral Contraceptive use N, (%) 86 (39)  272 (36) 
Smoking  N, (%) 181 (83)  319 (42) 






Study design & participants The Risk of Arterial Thrombosis In relation to Oral 
contraceptives
 
(RATIO) study is a multicenter, population-based case-control
 
study. The 
study consists of 3 arms, on MI, IS and peripheral arterial disease, of which details have 
been published earlier.
11–13
 In short, for this study we included 218 women aged 18 to 50 
years who were hospitalised
 
for a confirmed first MI in one of 16 participating hospitals.  
Random digit dialling yielded 767
 
women aged 18 to
 
50 years who served as controls; the 
control group
 
was frequency-matched to the patients for age (in five-year categories), 
residence, and
 
index year. Furthermore, the women did not have a history of coronary 
heart disease, cerebrovascular
 
event, or peripheral vascular disease. All participants filled 
in a questionnaire on possible risk factors and medical history focused on cardiovascular. 
diseases and provided DNA. Informed consent
 
was obtained from all participants in 




of 4 genetic variants was genotyped with the 5' nuclease/TaqMan
 
assay: Val34Leu (rs5985), Tyr204Phe (rs3024477), and Pro564Leu
 
(rs5982) variants in the 
FXIII subunit A gene (F13A1) and the His95Arg
 
variant (rs6003) in the FXIII subunit B gene 
(F13B). Primer sequences, probe
 
sequences, and restriction enzymes used are available on 
request. Laboratory technicians were unaware of case-control status
 




Statistical Analysis The effect of the genetic variation in the genes encoding for FXIII on the 
risk of MI was assessed by the calculation of odds ratios as measures of rate ratios with the 
corresponding 95% confidence intervals with logistic regression. Odds ratios were 
calculated per genotype and according to dominant inheritance pattern and were adjusted 
for the stratification factors age (on a continuous scale), area of residence and index year.  
Results  
The baseline characteristics of patients and controls are displayed in table 1. As expected, 
patients reported more cardiovascular risk factors than controls. Genotype distributions 
and corresponding odds ratios are shown in table 2. The overall call rate was 97.8% (range,
 
96.1% - 98.7%). No deviation from Hardy-Weinberg equilibrium was found in the control 
women for any of the genotypes. Only the F13A1 564Leu variant of the F13A1 gene was 
associated with an increased risk of 40% (OR 1.40; 95% confidence interval 1.01 – 1.93) in 
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0.09 185 (86)  28 (13)  3 (1)  609 (83)  112 (15)  9 (1)  0.79 0.50 - 1.24 
AA = major allele homozygote (non-carrier), AB = heterozygote (carrier), BB = minor allele homozygote (carrier). Allele frequency in 
control population. Odds ratios are calculated for carriers of the gene variant (i.e. dominant inheritance pattern is assumed) and are 
adjusted for the stratification factors age, calendar year of the index event, and area of residence. 
 
variant was confined to the heterozygous carriers (1.46; 1.05 – 2.03): the homozygous 
carriers of the minor allele had the same risk of disease as the homozygous carriers of the 
major allele (0.96; 0.40 - 2.28). The variants F13A1 Val34Leu, F13A1 Tyr204Phe and F13B 
His95Arg SNPs did not affect the risk of MI in both the dominant and the per genotype 
analyses. 
Discussion  
The F13A1564Leu variant is the only variant that affected the risk of MI in our study. This 
SNP has been associated with both a lower FXIII plasma level and an increase FXIII 
activity.
14,15
 This, together with the lack of dose response, does not add to a plausible 
biologic mechanism which explains the increase in risk of MI in heterozygotes, nor does the 
absence of an effect in homozygotes. This suggests that the minor increase in risk we 
observed for the heterozygous genotype is a false positive finding. 
An earlier study on FXIII SNPs suggested an increase risk of IS for F13A1 34Leu and F13A1 
204Phe, but not for MI.
7
 However, due to the limited number of cases (68 MI cases and 36 
IS cases) no definite conclusions could be drawn. The modest protective effect of F13A1 
34Leu variant on MI could not be replicated, probably due to lack of power.
8
 Earlier results 
from the RATIO study showed a nine-fold increased risk of ischaemic stroke for carriers of 
the F13A1 204Phe whereas carriers of the F13B 95Arg variant had a 1.7 fold increase in the 
risk of myocardial infarction.
10
 
Conclusion Although myocardial infarction and ischaemic stroke are both acute 




though the exact underlying causal mechanism cannot be established from these data, 
these differences in effects suggest that FXIII has a different role in the aetiology of MI and 
IS. Further study into the differences between the aetiology of myocardial infarction and 
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Introduction Reduced overall fibrinolytic capacity increases the risk of myocardial 
infarction (MI), as demonstrated previously in studies which included primarily men. We 
aimed to determine the influence of altered fibrinolysis on the risk of MI and ischaemic 
stroke (IS) in young women. 
Methods The RATIO study is a population-based case-control study including young 
women with MI (n=205), IS (N=175) and 638 matched healthy controls. Fibrinolytic 
potential was determined with a tissue factor/tissue plasminogen activator induced clot-
lysis assay. Odds ratios (OR) and corresponding confidence intervals adjusted for 
cardiovascular risk factors were obtained with logistic regression as measures of rate 
ratios. Clot-lysis time (CLT) was divided into tertiles based on the control group (T1-T3), 
with the middle tertile (T2) as reference. 
Results Hypofibrinolysis (prolonged CLT) was associated with an increase in risk of MI (T3 vs 
T2, OR 2.8;95%CI 1.7-4.7). Hyperfibrinolysis (decreased CLT) only a small effect (T1 vs T2, 
1.6; 0.9-2.9). Hypofibrinolysis did not affect the risk of IS significantly (T3 vs T2, 1.5; 0.7-
3.0), whereas hyperfibrinolysis increased this risk substantially (T1 vs T2, 4.1; 2.1-8.0). Oral 
contraceptive use and smoking further increased these risks. 
Discussion Hypofibrinolysis increases the risk for MI in young women, a finding similar to 
previous studies. Counter-intuitively, hyperfibrinolysis increased the risk of IS fourfold, 
which suggests that MI and IS have different aetiologies. 
 




Cardiovascular disease places a large burden on western societies, both on the healthcare 
systems as well as on the quality of life. The two major forms of arterial thrombosis are 
myocardial infarction and ischaemic stroke.
1
 Arterial thrombosis is most prevalent in the 
elderly; risk factors, such as diabetes, hypertension and hypercholesterolaemia are also 
more common with progressing age. Because the prevalence of these ‘traditional’ risk 




An increased capacity to form blood clots leading to a procoagulant state may increase the 
risk of arterial thrombosis.
2
 A procoagulant state may not solely be the result of an 
increased propensity to initiate or propagate clot formation, but can also result from a 
decreased ability to dissolve these newly formed clots.
3
 The main fibrinolytic factor is 
plasmin, which degrades fibrin and thereby dissolves the clot. The zymogen of plasmin, 
plasminogen, can be activated by tissue plasminogen activator (tPA) or urokinase.
4
 Plasmin 
itself can be inhibited directly by α2-antiplasmin. Furthermore, plasminogen activator 
inhibitor 1 (PAI-1) decreases the formation of plasmin by direct inhibition of tPA and 
urokinase. Thrombin Activatable Fibrinolysis Inhibitor (TAFI) also hampers fibrinolysis by 
altering the fibrin structure and thereby reducing binding and activation of plasminogen. 
Individual factors of the fibrinolytic system, especially PAI-1 and TAFI, have been linked to 
myocardial infarction and ischaemic stroke although results have been inconclusive and 
contradictory as was reviewed by Meltzer et al.
5
  
Besides individual factors, clot lysis assays can be used to asses the fibrinolytic capacity. 
Some studies, but not all, indicate an association between the euglobin clot lysis time or 
dilute whole blood clot lysis time and myocardial infarction. This association might be most 
pronounced in patients with minimal atherosclerosis.
5,6
 Studies on ischaemic stroke are 
limited.
7,8
  However, these global tests in these studies do not reflect all the appropriate 
components of the fibrinolytic system. A previously described test takes all primary 
components of the fibrinolytic system (plasminogen, alpha2-antiplasmin, PAI-1 and TAFI) 
into account and therefore reflects the true global plasma fibrinolytic potential better.
9,10
 
The main determinant of this test is the level of PAI-1, followed by plasminogen TAFI, 
prothrombin, and α2-antiplasmin levels.
10




time (CLT)  is associated with venous thrombosis, especially in combination with other risk 
factors such as oral contraceptives.
11,12
 
Hypofibrinolysis is also associated with different cardiovascular diseses: prolonged CLT 
(fourth quartile vs. first quartile) was associated with a twofold increase in risk of 
myocardial infarction for men aged <50 years, whereas no such association was found for 
men aged ≥50.
12,13
 Another case-control study with 330 young patients with coronary heart 
disease, ischaemic stroke (including transient ischaemic attack) and peripheral arterial 
disease also showed an increased risk for the combined endpoint arterial thrombosis with 
increasing clot lysis time.
14
 The inclusion of both sexes (37% men) and the broad case 
definitions make it difficult to draw conclusions for some subanalyses, such as an 
interaction analysis focussing on oral contraceptive use and smoking.  We therefore set out 
to determine whether abnormal fibrinolysis, both hyper- and hypofibrinolysis, is associated 
with both myocardial infarction and ischaemic stroke in young women and whether other 
risk factors influence this risk.  
Methods 
Study design & participants The RATIO (Risk of Arterial thrombosis in relation to oral 
contraceptives) study is a multicenter case-control study set up to identify risk factors for 
arterial thrombosis in young women, and has been described in detail earlier.
15–17
 In short, 
young women (18-50 years) diagnosed with a form of arterial thrombosis in the 16 
participating hospitals including eight academic medical centres in the Netherlands, were 
approached to participate. Diagnosis of myocardial infarction was based on the presence of 
symptoms, elevated cardiac-enzyme levels, and electrocardiographic changes, whereas 
ischaemic stroke was diagnosed on the basis of medical history, neurological examination, 
and CT or MRI scan by experienced neurologists in the participating centres. Women 
without a history of arterial thrombosis were approached by random digit dialling and 
frequency-matched with the case groups on age (in five year categories), year of event and 
area of residence.  All participants were asked to fill out a standardised questionnaire on 
several topics such as demographic characteristics, medical history among which oral 
contraceptive use in the year prior to event or comparable time frame for healthy controls. 
Measurements Citrated plasma used for these measurements was not thawed previously. 
Clot lysis time was assessed by measuring the changes in plasma turbidity during tissue-
factor induced clot formation and subsequent lysis by exogenous t-PA.
9
 In short, 50 μl of 
CLOT LYSIS TIME 
 
137 
mixture containing phospholipid vesicles (40% L-α-dioleoylphosphatidylcholine, 40% L-α-
dioleoylphosphatidylethanolamine and 20% L-α-dioleoylphosphatidylserine in a final 
concentration of 10 μmol/l), t-PA (final concentration 56 ng/ml), tissue factor (final dilution 
1/1000) and CaCl2 (final concentration 17 mmol/L) diluted in HEPES buffer [25mmol/L 
HEPES (N-2-hydroxytethylpiperazine-N’2ethanesulfonic acid) 137mmol/L NaCl, 3,5 mmol/L  
KCl, 3 mmol/L CaCl2, 0,1% bovine serum albumin, pH 7,4] was added to 50 μl of citrated 
plasma, all in a 96-well microtiter plate. After thorough mixing, the plate was placed in a 
Spectramax 340 kinetic microplate reader at 37º C (molecular devices corporation, Menlo 
Park, CA, USA). Optical density (OD) was measured every 20 seconds at 405 nm, resulting 
in a clot-lysis turbidity profile. Clot-lysis time is defined as the time from the midpoint of 
the clear to the maximal turbid transition, representing clot formation, to the midpoint of 
the maximum turbid to clear transition, representing clot lysis. The laboratory technician 




 at moment of event (cases) or index date (controls).
2
 in the year prior to event (cases) 
or index year (controls). 
3





  percentile, CLT = Clot-lysis time, NA = not applicable. Clot-lysis time 
measurements were unavailable or missing for 8 controls, 3 cases in the myocardial 












 42 39 39 
Caucasian ethnicity 195 (95%) 167 (97%) 602 (94%) 
 History of 
2
    
 Hypertension 53 (26%) 50 (29%) 40 (6%) 
 Diabetes 
 
10 (5%) 7 (4%) 
 
10 (2%) 
  hypercholesterolaemia 21 (10%) 14 (8%) 19 (3%) 
Oral contraceptives use 
2
 81 (40%) 92 (53%) 231 (33%) 
Smoking 
2
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was unaware of the case-control status of the 
samples.  
Statistical analyses To assess clot lysis time in 
relation to arterial thrombosis we calculated the 
mean difference and corresponding 95% 
confidence interval (CI) of clot lysis time in the 
control and case groups with the t-test for 
independent samples. To further study the effect 
of both hypo- and hyperfibrinolysis clot lysis time 
was divided into three categories based on the 
tertiles of the control group. Logistic regression 
models were used to obtain odds ratios and 
corresponding 95% CIs as measures of rate ratios 
with normofibrinolysis, defined as the middle 
tertile as the reference category. The covariates in 
these models included at least the stratification 
factors age (on a continuous scale), index year and 
area of residence. Furthermore, smoking status, 
body mass index, hypertension, diabetes and 
hypercholesterolemia were considered as 
confounders and included in subsequent models. 
Since triglyceride levels could also affect clot lysis 
time, we also additionally included log 
transformed trigyceride levels in the model.
11,13
 
Triglyceride data were only available for the 
myocardial infarction and control groups. 
Results 
As expected, known cardiovascular risk factors 
such as smoking and diabetes were more 
prevalent in the two case groups than in the 
controls (table 1). Since age was a matching 
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MI = Myocardial infarction, IS = Ischaemic stroke, CON = controls 
The clot lysis time of all participants are shown, stratified per case 
group. The horizontal lines represent the mean clot lysis time for 
each case group. 
re
spect to age. Clot-lysis time was higher among myocardial infarction cases than in controls 
(mean difference 10.8 minutes, 95% CI 7.2 to 14.5). CLT in ischaemic stroke cases was 
shorter (mean difference 3.7 minutes, 95% CI -2.0 to 9.4). Figure 1 shows the clot-lysis time 
for each participant with the horizontal lines indicating the mean, stratified per case group.   
With the middle category as reference, hypofibrinolysis (or the third tertile and longest 
CLT) was associated with a threefold increase in risk of myocardial infarction (OR 3.15, 95% 
CI 2.04 - 4.86; table 2). Adjustment for confounders, including triglyceride levels, decreased 
this risk slightly (OR 2.84, 95% CI 1.69 - 4.76). Hyperfibrinolysis, or the first tertile and 
shortest CLT, was not clearly associated with myocardial infarction. The effects were more 
pronounced in women younger than 40 years (table 3). Hypofibrinolysis (T3) increased the 
risk of ischaemic stroke about twofold (OR 2.07, 95% CI 1.24-3.48), but this risk greatly 
decreased after adjustment for confounders (OR 1.50, 95% CI 0.74 - 3.05). Hyperfibrinolysis 




adjustment. The risks were most pronounced in the young (see table 3). Upon exclusion of 
oral anticoagulant users (16 ischaemic stroke cases and 19 myocardial infarction cases) 
these results were largely the same (data not shown). 
Oral contraceptive use within the subgroup of participants with normofibrinolysis increased 
the risk of both myocardial infarction and ischaemic stroke (table 4) about two- to fourfold  
(T2/- OC vs. T2/+ OC OR 2.4, 95% CI 1.0 - 5.6 for myocardial infarction and OR 3.7, 95% CI 
1.3 - 11 for ischaemic stroke). This was also true for smoking (T2/- smoking vs. T2/+ 
smoking OR 3.3, 95 %CI 1.4 - 7.7 for myocardial infarction and OR 1.9, 95% CI 0.7 - 5.3 for 
ischaemic stroke). The risk of smoking was highest in women with abnormal clot lysis time 
when compared with women with normofibrinolysis and who did not smoke (T3/+ smoking 
OR 14, 95% CI 6.2-31 for myocardial infarction and T1/+ smoking OR 7.2, 95% CI 2.7 - 19 for 
ischaemic stroke). 
Discussion 
Our study indicates that hypofibrinolysis increases the risk of myocardial infarction in 
young women. Counter intuitively, we found that hyperfibrinolysis was associated with an 
increased risk of ischaemic stroke. Furthermore, the use of oral contraceptives increased 
the risk in all strata of CLT. 
A decreased fibrinolytic capacity is a plausible causal risk factor for thrombosic events and 
the results for myocardial infarction are in correspondence with current knowledge and 
the results in earlier studies.
13,14
 Our results, unexpectedly, indicate also that 
hyperfibrinolysis increases the risk of ischaemic stroke. This finding could be due to chance, 
but also raises the question whether the observed association reflects a causal mechanism 
in which an altered fibrinolytic capacity plays a role in the aetiology of ischaemic stroke or 
whether it can be explained by other mechanisms. For instance, hyperfibrinolysis in 
patients suffering from atrial fibrillation could increase the risk of cardioembolic stroke as 
theoretically an increased potential to dissolve blood clots can lead to instable clots and 
subsequent embolisation. However, the RATIO study excluded patients with an an overt 
cardiac source and therefore we feel that this mechanism cannot explain our results. 
Our counter-intuitive findings on hyperfibrinolysis and ischaemic stroke are not necessarily 
in contrast with previous findings. The 4G/5G polymorphism of the PAI-1 promotor, which 
is associated with low levels of circulating PAI-1 (with carriers of the 5G allele having lower 
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Table 3. Risks of myocardial infarction and ischaemic stroke; younger vs older 
 MYOCARDIAL INFARCTION  ISCHAEMIC STROKE 
Odds ratio (95% confidence interval) 
Model 2 
 Odds ratio (95% confidence interval) 
Model 2 
 
<40 years ≥ 40 years  <40 years ≥ 40 years 
T1 3.8 (1.2 - 12) 1.0 (0.5 - 2.4)  7.7 (2.4 - 24) 2.8 (1.1 - 7.2) 
T2 1    [REF] 1   [REF]  1   [REF] 1    [REF] 
T3 7.8 (2.5 - 24) 2.3 (1.2 - 4.2)  2.8 (0.8 - 10) 1.0 (0.4 - 2.5) 
T1 = 1
st
 tertile of clot-lysis time, or hyperfibrinolysis. T2 = 2
nd
 tertile of clot-lysis time, or 
normofibrinolysis. T3 = 3
rd
 tertile of clot-lysis time, or hypofibrinolysis. Tertiles are based 
on clot-lysis time in control group. Odds ratios and corresponding confidence intervals are 
calculated with the middle category as reference and with smoking, body mass index, 
hypertension, diabetes and hypercholesterolaemia as covariables (‘model 2’). 
Table 4. Interaction analyses; oral contraceptive use and smoking behaviour 
 MYOCARDIAL 
INFARCTION 
 ISCHAEMIC STROKE 
 
TERTILE OC USE CONTROLS 
# OR (95%CI)  # OR (95%CI) 
T1 - 119 15 1.5 (0.6 - 3.5)  31 6.2 (2.4 - 16) 
T1 + 88 21 3.8 (1.6 - 8.9)  38 9.1 (3.4 - 25) 
T2 - 127 19 1 [REF]  17 1  [REF] 
T2 + 82 18 2.4 (1.0 - 5.6)  17 3.7 (1.3 - 11) 


















T3 + 40 41 7.4 (3.3 - 17)   31 7.0 (2.4 - 21) 






   
  
T1 - 129 7 0.7 (0.2 - 1.9)  34 3.0 (1.2 - 7.8) 
T1 + 78 29 6.5 (2.7 - 16)  35 7.2 (2.7 - 19) 
T2 - 110 9 1 [REF]  13 1 [REF] 
T2 + 99 28 3.3 (1.4 - 7.7)  21 1.9 (0.7 - 5.3) 








T3 + 92 109 14 (6.2- 31)  40 4.8 (1.8 - 13) 
 
See table 3 for description. All presented ORs are from model 2;smoking was only included in 




levels), has been suggested to be associated with an increased risk of ischaemic stroke.
18,19
 
PAI-1 is one of the main determinants of CLT and is known to have functions, other than 
decreasing fibrinolytic potential, which could explain our findings.
10
 One of these functions 
is the so-called tPA-serpin axis which is involved in neuronal damage after cerebral 
ischaemia.
20
 Animal studies suggest that endogenous tPA or rtPA used as treatment after 
ischaemic stroke could lead to an N-Methyl-D-aspartic acid-mediated Ca2+ influx which 
enhances neuronal damage. PAI-1, a serpin which inhibits tPA, could counteract this 
mechanism. Therefore, low levels of PAI-1, reflected by hyperfibrinolysis in our study, 
could lead to neuronal damage. In addition, high PAI-1 has been shown to be related to a 
decreased tendency of plaque rupture.
20
 Although atherosclerosis is not abundantly 
present in these young women, low levels of PAI-1 could be related to increased tendency 
of plaque rupture and subsequent thrombus formation and then increase the risk of 
ischaemic stroke of atherosclerotic origin. So, the observed association between low CLT 
and increased risk of ischaemic stroke in our study does not necessarily reflect a causal role 
of increased fibrinolytic tendency but can also indicate other causal mechanisms that 
include low levels of PAI-1. Given this uncertainty, we can still conclude that our results 
suggest a clear difference in the aetiology of myocardial infarction and ischaemic stroke. 
Our study has some limitations and strengths: we cannot stratify our results according to 
the subtype of stroke (e.g. TOAST criteria) which hampers the interpretation of the 
results.
21
 It is possible that our results reflect the causal mechanism of only one stroke 
subtype, which would imply that the effect for that subtype would even be stronger. 
Furthermore, due to the case-control design of this study it cannot be ruled out that the 
differences in clot-lysis time between the case groups are a consequence of the disease or 
disease treatment, instead of a cause (i.e. ‘reverse causation’). A major source of this bias 
is the use of blood samples taken during the acute phase of the disease, directly after the 
event. However, since blood was drawn after the acute phase (mean 82 months, at least 
23 months after the event), it is unlikely that the results are explained by this 
phenomenon. Other sources of this bias, such as changes in cardiovascular risk factors 
after the event, would have led to an underestimation of the true effect and are not likely 
to exert a different effect between patients suffering from myocardial infarction and 
ischaemic stroke. Also, treatment initiated after the event could have introduced a bias: 
since antihypertensive drugs and statins might increase clot lysis and hence decrease clot 
lysis time, the effect of clot lysis time on myocardial infarction might be underestimated 
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whereas the effect on ischaemic stroke might be overestimated.
22
 Because treatment 
strategies largely overlap for these two diseases it is not likely that our main finding, the 
difference in effect of clot lysis time between myocardial infarction cases and ischaemic 
stroke cases, is to be explained by this potential source of bias. Our study only includes 
patients that survived a first event which may affect the results. Therefore our results only 
apply to those who survived their first event. If the effect of clot lysis time leads to a more 
severe forms of disease, our results are an underestimation of the true effect. 
The secondary analyses regarding oral contraceptive and smoking yield six strata and this 
results in small numbers of participants per stratum, as is reflected by the wide confidence 
intervals. Therefore, these analyses provide some idea into the associations with the 
combination of risk factors, but do not allow strong conclusions on the presence of 
interactions. Increased levels of triglycerides could confound the relation between clot-lysis 
time and arterial thrombosis.
13
 Unfortunately, triglyceride levels were not available for the 
ischaemic stroke analyses. However, adjustment for triglyceride levels in the myocardial 
infarction analyses only minimally changed the point estimates. Therefore, it is unlikely 
that effects observed in the ischaemic stroke analyses can be attributed entirely to 
triglycerides levels.  
Conclusion We found that in young women hypofibrinolysis increased the risk of 
myocardial infarction whereas hyperfibrinolysis increased the risk of ischaemic stroke. 
Although the results obtained from the ischaemic stroke analyses are not easily interpreted 
and causal conclusions on the mechanism by which hyperfibrinolysis increases the risk of 
ischaemic stroke cannot be drawn, these results indicate that myocardial infarction and 
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Introduction VWF and ADAMTS13 are major determinants of platelet adhesion after vessel 
injury. In the present study, we aimed to determine whether VWF or ADAMTS13 plasma 
antigen levels influence the risks of ischaemic stroke (IS) or myocardial infarction (MI) in 
young women and how these risks are affected by oral contraceptive use.  
Methods VWF and ADAMTS13 plasma antigen levels were measured in a frequency-
matched case-control study young (18-49 years) women including 205 MI patients, 175 IS 
patients and 638 controls.  
Results Increasing levels of VWF and decreasing levels of ADAMTS13 were associated with 
the risk of IS and MI in a dose-dependent manner. Having both high VWF and low 
ADAMTS13 resulted in an odds ratio (OR) of 6.9 (95% confidence interval [95% CI], 2.0-
23.0) for IS and 11.3 (95% CI 3.6-35.2) for MI. Use of oral contraceptives increased the risk 
of IS and MI associated with high VWF (OR = 12; 95% CI 5.5-26.2 and OR = 7.5, 95% CI 3.6-
15.7, respectively) and the risk of IS associated with low ADAMTS13 (OR = 5.8, 95% CI 2.7-
12.4).  
Discussion We conclude that high VWF and low ADAMTS13 plasma levels both increase the 
risk of IS and MI. The risks associated with high VWF or low ADAMTS13 levels are further 
increased by the use of oral contraceptives. 
 




VWF is a plasma glycoprotein synthesised by endothelial cells and megakaryocytes
1
; it is a 
major determinant of platelet adhesion after vessel injury and consequently of clot 
formation and circulates in plasma at approximately 10 µg/mL as multimers with a 
molecular weight(MW)ranging from 500-20 000 kDa.
1,2
 High-MW forms of VWF are stored 
in Weibel-Palade bodies in endothelial cells and also in platelet α-granules.
3,4
 These VWF 
stores are secreted into plasma after endothelium or platelet activation.
5,6
 The multimeric 
composition of plasma VWF is regulated by ADAMTS13 (a disintegrin and 
metalloproteinase with the thrombospondin type I repeat 13), which preferentially cleaves 
the large VWF multimers into smaller, less prothrombotic variants. ADAMTS13 is a 
metalloproteinase synthesised mainly by hepatocytes, but also by endothelial cells and 
megakaryocytes.
7–9
 It circulates in plasma at a concentration of approximately 1 µg/ mL.10 
The clinical importance of VWF and ADAMTS13 in regulating haemostasis is highlighted by 
the bleeding and thrombotic diseases associated with their respective deficiencies. VWD is 
characterised by a qualitative or quantitative deficiency in VWF resulting in impaired 
platelet tethering. This is the most common inherited bleeding disorder in humans.
11
 
Conversely, thrombotic thrombocytopenic purpura, which is characterised by a deficiency 




Cardiovascular disease (CVD) is a leading cause of disability and death in both developed 
and developing countries, and is predicted to affect an increasing number of people 
worldwide over the next decades.
13
Ischaemic stroke (IS) and myocardial infarction (MI) are 
among the most common CVD manifestations. Prospective studies investigating the risk of 
CVD associated with increased VWF antigen levels have been performed, generally in 
individuals over the age of 45 years. Some prospective studies have investigated the risk of 
coronary heart disease, atrial fibrillation, or IS and did not find an association with VWF 
antigen levels
14–17
; however, other studies investigating the risk of CVD, angina pectoris, 
hemorrhagic stroke, or IS did find this association.
17–20
 Several case-control studies have 
been carried out, and, although some controversy exists, many report an association of 




However, in certain case-control 
studies, blood sampling was performed during the acute phase of the thrombotic event. 
This makes it difficult to determine whether the observed increase in VWF levels are a 




are increased during the acute phase after stroke or MI, possibly as a consequence of 
damage to the endothelium.
28,29
 This may even be the case in prospective studies, in which 
VWF levels could be the result of vessel wall damage that predisposes to disease.  
A small number of studies have investigated the association of ADAMTS13 with IS and MI, 
with conflicting outcomes. Studies investigating ADAMTS13 antigen levels during the acute 
phase (0-14 days) of MI found decreased levels of ADAMTS13.
26,29
It is, however, difficult to 
establish whether this was a cause or a consequence of the event. Other studies evaluating 
the association between ADAMTS13 antigen levels and MI between 1 and 9 months after 





levels. Only 1 study looked at the association between ADAMTS13 antigen levels and a 
subgroup of IS patients, and found no association.
30
  
In the present study, we have reinvestigated whether plasma VWF and ADAMTS13 levels 
are associated with the risk of IS and MI in the previously published RATIO case-control 
study.
31–33
 This study included only young women (18-50 years), so the findings were 
presumably less complicated by age-related deterioration of the vasculature. Blood was 
taken well after the acute phase of the event, meaning that VWF and ADAMTS13 antigen 
levels should have returned to those before the event, ensuring they were not influenced 
by acute-phase post event endothelial damage. We also investigated the combined effect 
of both VWF and ADAMTS13 levels on the risks of IS and MI, and how the risk was affected 
by use of oral contraceptives. 
Methods  
Study design and participants Study design and details of the RATIO case-control study 
have been extensively described elsewhere.
31–33
 Briefly, women between 18 and 49 years 
of age with a first event of IS (N = 175) or MI (N = 205) were included. IS was diagnosed 
based on clinical symptoms, neurologic examination, and computed tomography or 
magnetic resonance imaging. Exclusion criteria were haemorrhagic stroke, transient 
ischaemic attack, venous sinus thrombosis, carotid artery dissection, history of 
cardiovascular or cerebrovascular disease, severe illness, cognitive impairment, and 
aphasia. MI was diagnosed based on clinical symptoms, elevated cardiac- enzyme levels, 
and electrocardiographic changes. Blood samples were collected after a median of 95 
months (range, 23-146 months) for IS and 69 months (range, 38-117 months) for MI, 
ensuring that plasma proteins should not have been influenced by any acute-phase protein 
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response to the thrombotic event. The control group (N = 638) was frequency-matched 
based on age, area of residence, and index year. Plasma samples from 167 IS patients, 202 
MI patients, and 626 patients were available for analysis in the present study. The presence 
of conventional risk factors for CVD, such as hypertension, hypercholesterolaemia, 
diabetes, and smoking, and the use of oral contraceptives were based on the year before 
the event/index year. Our study protocol was approved by the ethical committees of the 
participating hospitals and informed consent was obtained from all participants in 
accordance with the Declaration of Helsinki. 
Measurements VWF plasma antigen levels were determined through an in-house ELISA. A 
polyclonal rabbit anti-VWFAb (3.1 µg/mL; Dako) was immobilised in a 96-well Maxisorp 
microplate (Nunc) in 50mM carbonate buffer, pH 9.6, at 4°C overnight. Washing steps were 
performed in triplicate with 300 µL/ well of PBS with 0.1% Tween-20 (PBST) between each 
step. All steps were carried out at room temperature on a shaker. Wells were blocked with 
2.5% BSA(Sigma-Aldrich) in PBSTfor 2 hours. A standard curve of 0-125 ng/mL was made 
with normal control plasma (Technoclone), and samples were diluted 1:320 in 1% BSA in 
PBST and added to the wells in triplicate. Bound VWF was detected with 1.1 µg/mL of HRP-
conjugated polyclonal Ab against VWF (Dako) for 1 hour. The plate was developed with 100 
µL/well of o-phenylenediamine dihydrochloride (Sigma-Aldrich) for 3 minutes, and the 
reaction was stopped with 50 µL/well of 2.5M H2SO4 and the absorbance read at 492 nm. 
The inter- and intra-assay coefficients of variation were 6.4% and 6.3%, respectively. 
ADAMTS13 plasma antigen levels were determined with an in-house ELISA as described 
previously.
24
 A polyclonal rabbit Ab (5 µg/mL,depleted of anti–TSP2-4 Abs) against 
ADAMTS13 was immobilised in a 96-well Maxisorp microplate (Nunc) in 50mM carbonate 
buffer, pH 9.6, at 4°C overnight. Washing steps were performed in triplicate with 300 
µL/well of PBST between each step. All incubations were carried out at room temperature 
on a shaker. Wells were blocked with 2.5% BSA in PBS for2 hours. A standard curve of 0-
108 ng/mL was made with normal control plasma (Technoclone) and samples were diluted 
1:25 in 1% BSA in PBS and added to the wells in triplicate. Bound ADAMTS13 was detected 
with 0.2 µg/mL of biotinylated polyclonal Ab against the TSP2-4 domains of ADAMTS13 for 
2 hours. Wells were incubated with streptavidin-HRP (GE Healthcare) diluted 1:1000 for 1 
hour and the plate was developed with 100 µL/well of o-phenylenediamine 












Age, median 43 39 39 
Caucasian ethnicity 195 (95%) 167 (95%) 602 (94%) 
Oral contraceptive use* 81 (40%) 92 (53%) 213 (33%) 
Hypercholesterolemia* 21 (10%) 14 (8%) 19 (3%) 
Hypertension* 53 (26%) 50 (29%) 40 (6%) 
Diabetes* 10 (5%) 7 (4%) 10 (2%) 
Smoking* 169 (82%) 101 (58%) 270 (42%) 
* in the year prior to event / index year 
of 2.5M H2SO4 and the absorbance was read at 492 nm. Inter- and intra-assay coefficients 
of variation were 6.9% and 7.3%, respectively.  
Statistical analyses Odds ratios (ORs) and corresponding 95% confidence intervals (95% CI) 
were calculated as measures of rate ratios for MI and IS by unconditional logistic 
regression. The lowest quartile and > 90
th
 percentile (p90, VWF analyses), or the highest 
quartile and < 10
th 
percentile (p10, ADAMTS13 analyses) of the control group was used as a 
reference category. Adjustments for stratification variables (i.e. age, index year, and area 
of residence) were made in the first model, OR1. Additional adjustments for potential 
confounders (hypercholesterolemia, hypertension, diabetes, and smoking) were included 
in the second model, OR2. To assess the risk of IS and MI associated with the presence of a 
combination of multiple risk factors (eg, VWF, ADAMTS13, and oral contraceptives), 
dummy variables were created. To calculate the joint risk conferred by these risk factors, > 
p90 was used as a cut-off for VWF and < p10 as a cut-off for ADAMTS13. The joint category, 
representing no exposure to any of these risks, was used as a reference category. All 
statistical analyses were performed using SPSS Version 19 (IBM SPSS statistics, Chicago, Ill, 
USA). 
Results 
Decreased levels of ADAMTS13 conferred an increased risk for both IS and MI (Table 2). An 
OR1 of 3.1 (95% CI 1.8-5.5) for IS and an OR1 of 1.8 (95% CI 1.1-3.0) for MI was conferred by 
the lowest quartile (Q1) ofADAMTS13. After adjustment, the OR2 for IS did not change, 
although the OR2 for MI decreased. The OR1 values for high VWF for IS and MI were 3.2 
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Figure 1. Distribution of VWF and ADAMTS13 per casegroup 
 
 VWF and ADAMTS13 plasma levels in controls (●), ischaemic stroke pa$ents (▲) and myocardial 
infarction patients (◊). A) VWF plasma levels. B) ADAMTS13 plasma levels. C) VWF plasma levels 
of controls plotted against ADAMTS13 plasma levels. No significant correlation between VWF and 
ADAMTS13 antigen levels was observed (Pearson r 0.07). IS, ischaemic stroke; MI, myocardial 




Table 2. Risk of ischaemic stroke and myocardial infarction in relation to VWF and 
ADAMTS13 plasma levels 
 

















Q1 156 13 1 [ref] 1 [ref] 20 1 [ref] 1 [ref] 
Q2 157 22 1.4 (0.7-3.1) 1.6 (0.7-3.6) 35 1.6 (0.9-3.0) 1.7 (0.9-3.4) 




Q4 156 82 5.9 (3.0-11.7) 6.7 (3.2-13.8) 87 3.7 (2.1-6.5) 4.2 (2.2-8.0) 
          
Q4 156 61 3.1 (1.8-5.5) 3.1 (1.6-5.8) 63 1.8 (1.1-3.0) 1.4 (0.8-2.4) 
Q3 157 45 2.4 (1.4-4.4) 3.0 (1.6-5.7) 50 1.2 (0.8-2.0) 0.9 (0.5-1.6) 










Q1 156 28 1 [ref] 1 [ref] 45 1 [ref] 1 [ref] 
 
ORs were calculated by logistic regression and were adjusted for age, year of event/index year and 
area of residence. OR2 were also adjusted for hypercholesterolemia, hypertension, diabetes and 
smoking. Q denotes quartile; Ref denotes reference; 95%CI denotes the 95% confidence interval.    
Table 3. Risk of ischaemic stroke and myocardial infarction following combination of two risk 
factors 
 






















        
- - 507 107 1 (ref) 1 (ref)  130 1 (ref) 1 (ref) 
- + 57 20 2.2 (1.2-4.1) 2.0 (1.1-3.8)  21 1.6 (0.9-2.8) 1.4 (0.8-2.5) 
+ - 57 31 3.2 (1.8-5.5) 3.1 (1.7-5.5)  39 2.6 (1.6-4.2) 2.6 (1.6-4.3) 
+ + 5 9 6.9 (2.0-23.0) 5.8 (1.7-20.2)  12 11.3 (3.6-35) 9.8 (3.1-31) 
          
VWF 
 <p90 
OC use         
- - 372 65 1 (ref) 1 (ref)  92 1 (ref) 1 (ref) 
- + 192 62 2.2 (1.3-3.5) 2.0 (1.2-3.3)  59 2.2 (1.5-3.4) 2.1 (1.4-3.3) 
+ - 45 14 1.8 (0.9-3.8) 1.6 (0.8-3.5)  29 2.7 (1.5-4.7) 2.8 (1.5-5.0) 
+ + 17 26 12.0 (5.5-26) 11.4 (5.2-25)  22 7.5 (3.6-16) 7.1 (3.3-15) 
          
ADAMTS13 
>p10 
OC use         
- - 384 69 1 (ref) 1 (ref)  103 1 (ref) 1 (ref) 
- + 180 69 2.6 (1.7-4.3) 2.6 (1.6-4.1)  66 2.6 (1.7-3.9) 2.5 (1.6-3.8) 
+ - 33 10 2.0 (0.9-4.6) 1.8 (0.8-4.3)  18 2.5 (1.3-4.9) 2.3 (1.1-4.5) 
+ + 29 19 5.8 (2.7-12.4) 5.1 (2.4-11.2)  15 3.0 (1.4-6.2) 2.7 (1.3-5.7) 
 
See table 2 for description  
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(95% CI 1.9-5.3) and 3.0 (95% CI 1.9-4.7), respectively, and the OR1 values for low 
ADAMTS13 were 2.3 (95% CI 1.3-4.0) and 2.0 (1.2-3.2), respectively. Further adjustment 
(OR2) did not change the estimates appreciably. Quartile analyses of ADAMTS13 levels 
showed no clear dose response for MI. Because VWF and ADAMTS13 are functionally 
linked to each other in vivo, we investigated whether having both high VWF levels and low 
ADAMTS13 levels further increases the risk of IS and MI. The second row in table 3 shows 
the OR1 and OR2 for IS and MI conferred by low ADAMTS13:Ag levels only, and the third 
row shows the OR1 and OR2 conferred by high VWF levels only. These results were similar 
to those obtained before stratification, suggesting that VWF and ADAMTS13 each act as 
risk factors. More importantly, table 3 shows that the joint effect of high VWF and low 
ADAMTS13 levels increased the risk of IS and MI, resulting in an OR1 of 6.9 (95% CI 2.0-
23.0) and 11.3 (95% CI 3.6-35.2), respectively (row 4). These associations were also seen 
after further adjustment.  
The use of oral contraceptives is known to be a risk factor for IS and MI, associated with an 
approximately 2-fold increased risk in young women.
31,32
 We therefore evaluated whether 
this risk was further increased by the concomitant presence of high VWF or low 
ADAMTS13. Strikingly, the interaction analyses (Table 3) showed that high levels of VWF 
plasma levels and oral contraceptive use yielded an OR1 of 12.0 (95% CI 5.5-26.2) for IS and 
an OR1 of 7.5 (95% CI 3.6-15.7) for MI. Similar results were obtained after adjustment for 
potential confounders (see OR2). Women on oral contraceptives with high levels of VWF 
were therefore > 5 times more likely to develop IS and >3 times more likely to develop MI 
than women on oral contraceptives with lower VWF antigen levels. Joint analysis of oral 
contraceptives use and ADAMTS13 Ag levels (Table 3) showed that the risk of IS and MI 
related to low ADAMTS13:Ag levels in women on oral contraceptives was 5.8 (95% CI 2.7-
12.4) and 3.0 (95% CI 1.4-6.2), respectively. The OR2 decreased slightly after adjustment. A 
joint effect of low ADAMTS13:Ag levels and use of oral contraceptives was therefore 
observed for IS but not for MI. 
Discussion 
In the present study, we measured plasma VWF and ADAMTS13 antigen levels in 167 
young women with IS, 202 young women with MI, and in 626 frequency-matched healthy 
controls. Quartile analysis showed a concentration-dependent association of VWF and 




of 6.7 (95% CI 3.2-13.8) for IS and 4.2 (95% CI 2.2-8.0) for MI. The lowest quartile of 
ADAMTS13 conferred an OR2 of 3.1 (95% CI 1.6-5.8) for IS and 1.4 (95% CI 0.8-2.4) for MI, a 
difference in strength which  suggests that ADAMTS13 has a differential effect on MI and 
IS. The risks of IS and MI were also evident in both OR models when using the 90
th
 
percentile and the 10
th
 percentile as cut-off values for VWF and ADAMTS13. Interestingly, 
as can be seen from the interaction analyses, risks of IS and MI were elevated both by high 
VWF and low ADAMTS13, even when mutually adjusted, which raises an important point 
when considering the relationship between VWF and ADAMTS13 plasma levels. Although 
ADAMTS13 regulates VWF multimeric size through proteolysis, we and others have found 
no association between ADAMTS13 antigen levels and VWF antigen levels.
24,25,30
 Whereas 
for ADAMTS13 it is reasonable to assume that antigen and activity levels are essentially 
synonymous in healthy volunteers and in patients with CVD, this is not the case when 
comparing VWF antigen and function. 
34,35
 One hypothesis is that the influence of 
ADAMTS13 concentration on the risk of IS and MI is manifest through the reduction of the 
multimeric sise of circulating VWF or the modulation of VWF function locally at the site of 
vessel damage. 
Joint analysis showed that having both high VWF and low ADAMTS13 increased the ORs 2- 
to 3-fold for IS and 4- to 7-fold for MI compared with having only one risk factor. The joint 
effect of high VWF and low ADAMTS13 was higher for MI (OR2 9.8) than for IS (OR2 5.8). 
However, because of the low number of individuals in this category the CIs were quite 
wide. Results from the joint analysis suggest that both VWF and ADAMTS13 are risk factors 
for IS and MI. In addition, the joint effect of high VWF and low ADAMTS13 supports 
previous findings suggesting that the ratio between VWF and ADAMTS13 in the same 
individual might be important.
36–38
 
Our finding that the joint risk of having both high VWF and low ADAMTS13 is higher than 
that of the individual risk factor is in agreement with a former study investigating the joint 
risk of VWF and ADAMTS13 in a broad group including a combination of patients with 
coronary heart disease, IS, and peripheral arterial disease.
30
 Our study differs from the 
previous one because it only includes young women and involves cases that are more 
precise in phenotype (either IS or MI) and therefore also more precise in the respective 
effect estimates. Other case-control studies have investigated the individual risks conferred 
by VWF or ADAMTS13 antigen levels. Our results showing that VWF is a risk factor for IS 
and MI are in agreement with previous studies. 
21–27
 Our results showing that low 
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ADAMTS13 levels are associated with MI is in agreement with the findings from the 
GLAMIS case-control study.
25
 Others did not find an association between low ADAMTS13 
and IS and MI, whereas one group found a positive association between ADAMTS13 
plasma levels and MI.
24,26,30
 The reason for the discrepancy with the latter finding is not 
known. Whereas our study shows an association of low ADAMTS13 plasma levels with IS 
and MI, CIs were sometimes wide after stratification. Because the association between low 
ADAMTS13 and the risk of IS and MI is relatively weak, it is possible that previous studies 
have failed to show an association because of a lack of power.  
Our results are consistent with recent in vivo studies in mice. It has been shown that 
VWF+/- and VWF-/- mice have a reduction in infarct volume of approximately 40% and 
50%-60%, respectively, compared with wild-type (WT) mice after the induction of IS.
39–41
 
The susceptibility of VWF-/- mice to IS was, however, restored after reconstitution of 
plasma VWF.
40,41
 These studies suggest that the lack of VWF or low VWF levels protects 
against IS, and that VWF plasma levels (and not VWF from endothelial cells or platelets) are 
important in the development of IS in mice. 
40,41
 In contrast, it has been found that 
ADAMTS13-/- mice were susceptible to larger infarctions than WT mice.39,42 Interestingly, 
infusion of ADAMTS13 into WT mice after ischaemic occlusion reduced the infarct volume 
by approximately 30%.
39
 Mice deficient in both ADAMTS13 and VWF had a phenotype 
similar to mice deficient in only VWF, showing that the action of ADAMTS13 is dependent 
on the presence of VWF.
39
  
By stratifying data according to oral contraceptive use, we showed that high VWF or low 
ADAMTS13 is associated with the risk of MI irrespective of oral contraceptive use; 
however, CIs were wide after stratification due to a loss in power, because only a small 
number of cases (14 and 10, respectively) were present in these strata. Joint analysis 
showed that patients with high levels of VWF who were on oral contraceptives had an 
approximately 11-fold higher risk of developing IS and an approximately 7-fold higher risk 
of developing MI than individuals with neither risk factor. Individuals with low ADAMTS13 
using oral contraceptives were approximately 5 times more likely to develop IS than 
individuals with none of the risk factors. However, the risk of MI in patients with low 
ADAMTS13 antigen levels was not increased by the use of oral contraceptives. These 
interaction analyses raise the question whether women starting with oral contraceptive 




screening strategy is not likely to be cost-effective. We performed some calculations using 
population statistics and the combination of high VWF and oral contraceptive use which 
yielded the highest increase in risk. With an annual incidence of myocardial infarction of 14 
per 100 000 women aged 18-50 per year,
43
 approximately 2700  women with high VWF 
levels should refrain from starting oral contraceptive use annually in order to prevent one 
case of myocardial infarction. However, since ‘high VWF’ in our study was defined as ≥90th 
percentile of the general population, ten times as many women should be screened to 
identify these women. Similarly, approximately 14 000 women need to be screened to 
prevent one case of ischaemic stroke annually.
44
 Although this is not a formal 
cost-effectiveness analysis, these numbers indicate that such a screening program is not 
warranted. The main reason for this, perhaps counterintuitive result given the high relative 
risks, is that for young women the incidence of myocardial infarction and ischaemic stroke, 
or any other disease for that matter, is very low. Therefore, it is not likely that any genetic 
or plasma marker based screening program used to determine which women could ‘safely’ 
start using oral contraceptives would ever be cost effective.
45,46
  
Our study has some limitations because of its design. Blood was drawn after the event and 
only in cases that were not fatal. Because blood was drawn long after the event (median 69 
months), it is unlikely that the antigen levels measured were influenced by the acute phase 
of the event. We cannot, however, exclude any chronic effect or account for potential 
reductions in exposure to environmental or behavioural risks after the event. Whereas 
VWF levels may be a result of vessel wall damage, this can even be the case in prospective 
studies. Association of genetic variations of VWF and ADAMTS13 with IS and MI might 
provide a means of excluding confounding and reverse causation. Preliminary support for 
associations between single nucleotide polymorphisms of VWF and ADAMTS13 and the risk 
of CVD has been provided by a few studies.
47–49
 However, large prospective studies 
evaluating single nucleotide polymorphisms will be required to establish the roles of VWF 
and ADAMTS13 in arterial thrombotic disease.  
Conclusion The present study is the first, to our knowledge, to examine the risk of IS and 
MI conferred by the combination of both high VWF and low ADAMTS13 antigen levels in 
young women. We believe that analysis in a young population is of interest because they 
have been exposed for a shorter time to cardiovascular risk factors than older individuals. 
Similarly, atherosclerosis is likely to play a smaller role in young individuals. We have 
shown here that in young women, high VWF and low ADAMTS13 plasma levels are both 
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associated with an increased risk of IS and MI, and that the use of oral contraceptives can 
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Background Myocardial infarction and ischaemic stroke are major clinical manifestations of 
the antiphospholipid syndrome, which is an autoimmune disease found mostly in young 
women. Although the presence of circulating antiphospholipid antibodies in individuals 
who have a thrombotic event is a prerequisite for the diagnosis of the antiphospholipid 
syndrome, the risk of myocardial infarction and ischaemic stroke associated with 
antiphospholipid antibodies in the general population is unclear. 
Methods We used the RATIO (Risk of Arterial Thrombosis In relation to Oral 
contraceptives), a large multicentre population-based case-control study including women 
aged under 50 years who were admitted to hospital at 16 centres with first myocardial 
infarction or ischaemic stroke and frequency-matched controls to measure markers of the 
antiphospholipid syndrome. Odds ratios and corresponding 95% confidence intervals were 
calculated as measures of rate ratios. 
Results Blood samples of 175 patients with ischaemic stroke, 203 patients with myocardial 
infarction, and 628 healthy controls were used in the present study. Lupus anticoagulant 
was found in 30 (17%) patients with ischaemic stroke, six (3%) patients with myocardial 
infarction, and four (0.7%) in the control group. The odds ratio for myocardial infarction 
was 5.3 (95% CI 1.4–20.8), which increased to 21.6 (1.9–242.0) in women who used oral 
contraceptives and 33.7 (6.0–189.0) in those who smoked. The odds ratio for ischaemic 
stroke was 43.1 (12.2–152.0), which increased to 201.0 (22.1–1828.0) in women who used 
oral contraceptives and 87.0 (14.5–523.0) in those who smoked. In women who had anti-
β2-glycoprotein I antibodies, the risk of ischaemic stroke was 2.3 (1.4–3.7), but the risk of 
myocardial infarction was not increased (0.9, 0.5–1.6). Neither anticardiolipin nor 
antiprothrombin antibodies affected the risk of myocardial infarction or ischaemic stroke. 
Conclusion Our results suggest that lupus anticoagulant is a major risk factor for arterial 
thrombotic events in young women, and the presence of other cardiovascular risk factors 





Cardiovascular diseases are the second most common cause of death in developed 
countries. Although the incidence of myocardial infarction and ischaemic stroke in 
individuals younger than 50 years is low, the burden of disease in young people is large. 
Myocardial infarction and ischaemic stroke are usually associated with several risk factors 
for cardiovascular disease, such as smoking, hypertension, diabetes, obesity, 
hyperlipidaemia, or a family history of cardiovascular disease.
1
 
The antiphospholipid syndrome is an acquired risk factor for thrombotic diseases. The 
antiphospholipid syndrome is more prevalent in young women than in the general 
population.
2
 It is characterised by vascular thrombosis or complications during pregnancy 
and a repeatedly positive test for antiphospholipid antibodies.
3
 There are several 
subpopulations of antiphospholipid antibodies; the coagulation inhibitor lupus 
anticoagulant and antibodies against the phospholipid cardiolipin or the plasma proteins 
β2-glycoprotein I and prothrombin are the antibody subpopulations most commonly tested 
for. 
Owing to its non-specific clinical symptoms, diagnosis of the antiphospholipid syndrome is 
dependent on the detection of antiphospholipid antibodies. Data on the risk of a first  
thrombotic event in the presence of antiphospholipid antibodies are inconclusive
4
 because 
most studies were done in selected populations of patients. Several studies have been 
done to assess the thrombotic risk associated with antiphospholipid antibodies in the 
general population.
5–11
 Although there is a general consensus from the results of these 
studies that the presence of antiphospholipid antibodies is independently associated with 
increased risk of thrombotic diseases, there is still debate on the value of measuring the 




We investigated whether the presence of specific antiphospholipid antibody 
subpopulations (lupus anticoagulant, anticardiolipin, or anti-β2-glycoprotein I and 
antiprothrombin antibodies) affects the risk of myocardial infarction or ischaemic stroke in 
young women. Furthermore, we studied the effect of smoking, hyperlipidaemia, diabetes, 
use of oral contraceptives,
13,14








 and the factor XIII 204Phe allele
19,20
 on the relation 
between antiphospholipid antibodies and myocardial infarction and ischaemic stroke.  
Methods 
Study design & participants The Risk of Arterial Thrombosis In relation to Oral 
contraceptives (RATIO) study is a multicentre, population-based, case-control study 
focussed on risk factors of myocardial infarction, ischaemic stroke and peripheral arterial 
disease in young women. Details of the study have been published previously. 
13,14,21
 The 
current study focuses on the two acute forms of arterial thrombosis i.e., myocardial 
infarction and ischaemic stroke. Eligible patients were recruited under all women under 50 
presenting with one these two diseases at one of the 16 participating centres. Myocardial 
infarction was confirmed by symptoms, elevated concentrations of cardiac enzymes, and 
changes seen on electrocardiograph; ischaemic stroke without an overt cardioembolic 
source was confirmed by medical history, physical examination, and CT or MRI scans, which 
were assessed by experienced neurologists at the participating centres.
13,14
 Exclusion 
criteria were transient ischaemic attack that lasted less than 24 h, haemorrhagic stroke, 
cerebral sinus venous thrombosis, carotid artery dissection, history of cardiovascular or 
cerebrovascular disease, aphasia or cognitive impairment that prevented completion of the 
questionnaire, or not speaking Dutch. Controls were approached by random digit dialling 
and frequency-matched to the cases on age, residence area, and index date of the event. 
The study was approved by the local medical ethics committee of all participating 
hospitals. Informed consent was obtained from all patients and controls, in accordance 
with the declaration of Helsinki. 
Measurements All patients and controls completed a standardised, structured 
questionnaire on several topics such as their use of oral contraceptives, smoking status, 
alcohol intake, weight, height, family and medical history. All antiphospholipid antibody 
tests were done at a central laboratory. All samples were measured masked to case or 
control status. Presence of lupus anticoagulant was detected with dilute Russell’s viper 
venom time (dRVVT) reagents (LA-screen and LA-confirm; Gradipore, Australia). This assay 
is based on a modification of the common pathway of coagulation. Plasma samples were 
thawed for the first time and diluted 1:1 (vol:vol) with pooled normal plasma from 173 
healthy volunteers. Coagulation was initiated by adding an equal volume of LA-screen 




prolonged coagulation time (LA-screen time >99th percentile of time recorded for 40 
healthy volunteers), LA-confirm assays were done. Normalised ratios for LA-screen and LA-






RATIO =  
where LAs (normal) is the mean LA-screen coagulation time of 40 healthy volunteers, and LAc 
(normal) is the mean LA-confirm coagulation time of 40 healthy volunteers. Samples were 
deemed positive for lupus anticoagulant when the ratios/c was 1.15 or higher, on the basis 
of the 99
th 
percentile of the value recorded for 40 healthy volunteers. This measurement is 
in accordance with current recommendations for testing for lupus anticoagulant.
3
 Human 
plasma-derived β2-glycoprotein I was purified as previously described.
22
 β2-glycoprotein I-
coated 96-well microtitre plates (Nunc MaxiSorp U96; Nunc, Wiesbaden, Germany) were 
washed and incubated for 1 h with plasma samples diluted 1:100 in PBST (phosphate-
buffered saline [10 mM phosphate, 140 mM NaCl, pH 7.35] with 0.1% Tween-20) at 
ambient temperature. After washing, plates were incubated with horseradish peroxidase-
labelled goat anti-human-IgG antibodies (Southern Biotech, Birmingham, AL, USA) and 
developed with Amplex Red reagent (Invitrogen, Paisley, UK). Fluorescence was measured 
Table 1. Characteristics of RATIO participants 
All data are in respect to the year of event (cases) or index date (controls). Data on ethnicity are missing 
for 1 ischaemic stroke case & 4 controls, on history of hypertension for 4 controls, on history of Diabetes 
for 1 myocardial infarction case & 3 controls, on hyperlipidaemia for 1 myocardial infarction case & 5 
controls, on oral contraceptive use for 6 controls, on smoking for 6 controls and on alcohol use for 1 








Age  (mean) 43 39 39 
 Caucasian ethnicity 195 (95%) 167 (97%) 602 (94%) 
History of *    
  Hypertension 53 (26%) 50 (29%) 40 (6%) 
  Diabetes 
 
10 (5%) 7 (4%) 
 
10 (2%) 
  Hypercholesterolaemia 21 (10%) 14 (8%) 19 (3%) 
 Oral contraceptives use * 81 (40%) 92 (53%) 213 (33%) 
 Smoking *  169 (82%) 101 (58%) 270 (42%) 




in a FluoSTAR OPTIMA reader (BMG Labtech, Offenburg, Germany). PBST was used for all 
washing procedures. Values are reported as percentage of a positive control. Cut-off was 
set at the 90th, 95th, or 99th percentile of the value recorded for the control group.  IgG 
anticardiolipin antibody concentrations were measured in plasma samples with a  
commercially available kit (Corgenix, Broomfield, CO, USA) in accordance with the 
instructions of the manufacturer. Measurements are reported as concentrations of 






 percentile of the 
concentration recorded for the control group. Concentrations of IgG antiprothrombin 
antibodies were measured as described previously
23
 and values were reported as a 







percentile of the control group. 
Statistical analyses Rate ratios of myocardial infarction and stroke associated with 
antiphospholipid antibodies were estimated with odds ratios and 95% CIs with 
unconditional logistic regression. ORs were adjusted for the stratifying variables: age 
(continuous variable), residence area (four categories), and index year (six categories). 
Furthermore, we calculated the risk of myocardial infarction and ischaemic stroke in the 
presence of combinations of antiphospholipid antibody subtypes. To assess the 
contribution of cardiovascular risk factors to the risk of myocardial infarction and ischaemic 
stroke in patients with antiphospholipid antibodies, we calculated ORs to compare 
exposure to a cardiovascular risk factor, antiphospholipid antibodies, or both with the 
absence of both. 
Results 
Blood samples from 203 cases with myocardial infarction, 175 cases with ischaemic stroke 
and 628 control women were available for the current analyses. Table 1 shows the 
characteristics of the study population. As expected, patients with myocardial infarction or 
ischaemic stroke had a higher prevalence of cardiovascular risk factors, such as 
hypertension, diabetes, hyperlipidaemia, oral contraceptive use, and smoking, than did the 
controls. All oral contraceptives were combinations of an oestrogen (ethinylestradiol) and a 
progestin (levonorgestrel, desorgestrel, lynestrenol, or cyproterone acetate).  
We analysed the effect of different antiphospholipid antibody subpopulations on the risk 
of myocardial infarction or ischaemic stroke after adjustment for the matching variables 




Table 2. Antiphospholipid syndrome markers and the risk of myocardial infarction and ischaemic stroke 
  Odds Ratio (95% CI)
§
 
 MI IS Controls Myocardial 
Infarction 
Ischaemic stroke 
Lupus anticoagulant      
(N) 202 175 627   
Ratios/c ≥ 1.15 6 30 4 5.3 (1.4 – 20.8) 43.1 (12.2 – 152) 
Ratios/c ≥ 1.20 5 19 2 11.7 (2.1 – 65) 48.3 (8.2 – 284) 
Ratios/c ≥ 1.30 4 10 0 NA NA 
Anticardiolipin IgG, 
cut-off (GPL) 
     
(N) 201 169 623   
≥14.6* 26 12 62 1.6 (0.9 – 2.6) 0.8 (0.4 – 1.7) 
≥16.9
†
 16 8 31 1.8 (0.9 – 3.4) 0.9 (0.4 – 2.2) 
≥24.5
‡
 2 6 6 1.5 (0.3 – 8.4) 1.9 (0.5 – 7.6) 
Anti-β2-Glycoprotein I IgG, cut-off (% of positive control)   
(N) 203 175 628   
>27.9
*
 18 39 62 0.9 (0.5 – 1.6) 2.3 (1.4 – 3.7) 
>37.7
†
 11 24 31 1.2 (0.6 – 2.6) 2.8 (1.5 – 5.3) 
>74.3
‡
 3 4 6 2.2 (0.5 – 10.3) 1.7 (0.4 – 7.9) 
Anti-prothrombin IgG, cut-off (% of positive control)   
(N) 203 175 628   
>31.8
*
 14 21 62 0.7 (0.4 – 1.2) 1.3 (0.7 – 2.4) 
>47.4† 7 13 31 0.8 (0.3 – 1.9) 1.8 (0.8 – 4.2) 
>85.9
‡
 3 4 6 1.8 (0.4 – 7.4) 2.6 (0.6 – 11.1) 
MI denotes myocardial infarction; IS denotes ischaemic stroke; CI denotes confidence interval; NA denotes 
not applicable; ref denotes reference category. All odds ratios are adjusted for age, residence area and 
index year.* value corresponding to the 90
th
 percentile of controls. † value corresponding to the 95
th
 
percentile of controls. ‡ value corresponding to the 99
th
 percentile of controls.  
30 (17%) patients with ischaemic stroke, whereas only four (0.6%) controls had lupus 
anticoagulant. The OR for myocardial infarction was 5.3 (95% CI 1.4–20.8) and the OR for 
ischaemic stroke was 43.1 (12.2–152.0) in women with lupus anticoagulant compared with 
women without. 23 patients with myocardial infarction and 22 patients with ischaemic 
stroke received vitamin K antagonists; after these patients were excluded, the OR for 
myocardial infarction was 4.6 (1.1–19.5) and the OR for ischaemic stroke was 45.7 (12.4–
169.0). When we used a more stringent cut-off for lupus anticoagulant (ratios/c ≥1.20), the 
ORs for myocardial infarction and ischaemic stroke were higher. None of the control 
women had lupus anticoagulant with the ratios/c ≥1.30 as the cut-off. Neither 
anticardiolipin nor antiprothrombin antibodies affected the risk of myocardial infarction or 
ischaemic stroke. In women with anti-β2-glycoprotein I antibodies, the risk of ischaemic 
stroke was 2.3 (1.4–3.7) compared with women without anti-β2-glycoprotein I antibodies; 
however, anti-β2-glycoprotein I antibodies did not affect the risk of myocardial infarction. 







































































































































































































































































   







   




























































































































   







   




























































































































   







   























































































































   







   













































































































   







   

















































































































































































































































subpopulation did not affect the risk of myocardial infarction or ischaemic stroke, 
compared with the risk in patients with only lupus anticoagulant. Adjustment for 
hypertension, diabetes, and hyperlipidaemia did not affect the relative risks for myocardial 
infarction or ischaemic stroke in women with antiphospholipid antibodies.  
We assessed the joint effect of additional cardiovascular risk factors in women with lupus 
anticoagulant compared with women without lupus anticoagulant and each cardiovascular 
risk factor (table 3). In women without lupus anticoagulant, the risk of myocardial 
infarction was 2.3 (95% CI, 1.6–3.4) in users of oral contraceptives and 6.4 (4.2–9.7) in 
smokers. In women with lupus anticoagulant, the OR for myocardial infarction for those 
who used oral contraceptives was 21.6 (1.9–242.0) and for those who smoked was 33.7 
(6.0–189.0). The factor V G1691A variant, the prothrombin G20210A variant, and the 
factor XIII 204Phe variant did not affect the risk of myocardial infarction. 
In women without lupus anticoagulant, the OR for ischaemic stroke was 2.9 (95% CI 1.8–
4.6) in users of oral contraceptives, 2.2 (1.5–3.4) in smokers, and 8.8 (4.9–15.9) in women 
with the factor XIII 204Phe variant. In women with lupus anticoagulant, the OR for 
ischaemic stroke was 201 (22–1828) in users of oral contraceptives, 87 (14.5–523) in 
smokers, and 81 (8.9–739) in women with the factor XIII 204Phe variant. The factor V 
G1691A and prothrombin G20210A variants had no effect on the risk of ischaemic stroke.  
Discussion 
We found that lupus anticoagulants were associated with an increased risk of myocardial 
infarction (OR 5.3) and ischaemic stroke (OR 43.1) in women younger than 50 years. 
Increased concentrations of anti-β2-glycoprotein I antibodies were associated with an 
increased risk of ischaemic stroke (OR 2.3) but not myocardial infarction. Neither 
anticardiolipin nor antiprothrombin antibodies alone increased the risk of myocardial 
infarction or ischaemic stroke. There were no indications that the presence of more than 
one subpopulation of antiphospholipid antibodies affected the risk of myocardial infarction 
or ischaemic stroke. Additional cardiovascular risk factors, such as use of oral 
contraceptives, smoking, or the factor XIII 204Phe variant, increased the risk of myocardial 
infarction or ischaemic stroke further in women who had lupus anticoagulant. The 
frequency of the factor V G1691A or the prothrombin G20210A mutations was too low in 
women with lupus anticoagulant to ascertain whether they had an effect on the risk of 




The RATIO study compared the characteristics of a large group of women who had had 
myocardial infarction or ischaemic stroke with those of a large population-based control 
group obtained through random-digit dialling. Diagnoses and the location of all ischaemic 
strokes were verified with CT or MRI, which reduces the risk of misclassification. The 
random-digit dialling procedure and the high response rate in the control group, which was 
not informed about the risk factors assessed in this study, such as oral contraceptive use or 
smoking, minimises the risk of participation bias in the control group.  
Our study has several limitations. All patients were survivors of a major arterial event who 
were admitted to hospital. If there is different survival rate for those with the 
antiphospholipid syndrome, our analyses which are limited to patients who survived 
potentially could lead to an over or underestimation of the true risk. This is, however, 
unlikely to have a major effect on our findings because ischaemic stroke and myocardial 
infarction are rarely fatal in young women.
24,25
 Furthermore, we cannot completely exclude 
recall bias, although structured questionnaires were used and colour photographs of 
contraceptive preparations were provided to help women recall the oral contraceptive 
they had used. Data on hypertension, diabetes, and hyperlipidaemia at the time of the 
event were collected with standardised questionnaires completed several years later.  
Correct handling of samples is important for the detection of lupus anticoagulant. Because 
plasma samples were obtained after only one centrifugation step, we cannot exclude the 
possibility that residual platelets were present in the sample. The handling of blood 
samples was standardised to exclude any possible effects of differences in sample handling 
between cases and controls. Another potential source of bias is anticoagulant treatment 
with vitamin K antagonists, which might interfere with the detection of lupus 
anticoagulant. Because lupus anticoagulants are phospholipid-dependent coagulation 
inhibitors, only longer than normal coagulation times that are corrected by the addition of 
excess phospholipids qualify as positive for lupus anticoagulant. Although all samples were 
mixed with normal pooled plasma to correct for possible deficiencies in coagulation 
factors, an international normalised ratio greater than 3·0 might not be corrected by 
phospholipids and might cause false-negative values for lupus anticoagulant rather than 
false-positive values. To exclude any effect of the use of vitamin K antagonists on the risk 




without the results from the patients treated with anticoagulants. This resulted in a slight 
decrease in the risk of myocardial infarction, but the risk of ischaemic stroke was not 
affected. We do not have data on vitamin K antagonist use in the control population; 
however, because the controls were women without a history of cardiovascular disease, it 
is highly unlikely that any of these women were on anticoagulant drugs. All blood samples 
were obtained several years after the thrombotic event. We can therefore only assume 
that the presence of antiphospholipid antibodies is associated with the event. Other 
researchers have shown 
the presence of antiphospholipid antibodies within hours after an arterial thrombotic 
event,
26
 although the development of antibodies generally takes days. Therefore, our data 
indicate a causal relation between antiphospholipid antibodies and thrombosis. Because 
only one blood sample was taken for each patient, we cannot exclude the possibility that a 
proportion of the anticardiolipin antibodies are transient infection-related antibodies. 
Two other studies compared the effects of antiphospholipid antibodies on the risk of 
ischaemic stroke
5
 or myocardial infarction
6
 in an unselected population of young women. 
In line with our results, each study reported an increased risk of an arterial thrombotic 
event associated with antiphospholipid antibodies, although the risks were attributed to 
different antiphospholipid antibody subpopulations. One of these studies
5
 reported a two-
fold increase in the risk of ischaemic stroke in the presence of lupus anticoagulant or 
anticardiolipin antibodies, whereas the presence of anticardiolipin antibodies was not 
associated with an increased risk of ischaemic stroke in our study. High titres of 
anticardiolipin antibodies (>40 GPL) were not detected in our study. Inclusion of patients 
with unconfirmed or cardioembolic strokes in this study might explain the low risk of 
stroke associated with lupus anticoagulant in this particular study. Another explanation is 
that the less specific aPTT-based lupus anticoagulant assay was used; this assay depends on 
the intrinsic pathway of coagulation and is therefore more sensitive for phospholipid 
independent coagulation inhibitors than is the dRVVT.
27
 
One study in young women
6
 reported a two-fold increased risk of myocardial infarction if 
anti-β2-glycoprotein I antibodies, but not anticardiolipin antibodies, were detected. The 
presence of anti-β2-glycoprotein I antibodies did not increase the risk of myocardial 




The lupus anticoagulant subpopulation of antiphospholipid antibodies is a heterogeneous 
pool of antibodies that have several antigenic targets. Insight into the mechanism behind 
the prothrombotic effects of antiphospholipid antibodies has increased steadily over the 
years. Antiphospholipid antibodies, particularly those with lupus anticoagulant activity, 
cause platelet activation and lead to a procoagulant endothelial phenotype.
28
 
Prothrombotic effects on the coagulation system, such as antiphospholipid antibody-
related acquired activated protein C resistance,
29
 are also seen in patients with the 
antiphospholipid syndrome. All of these prothrombotic effects of antiphospholipid 
antibodies might be responsible for the increased risk of myocardial infarction and 
ischaemic stroke described in this study. In view of the effects of antiphospholipid 
antibodies on the haemostatic system, it is not surprising that smoking, which causes 
endothelial dysfunction,
30
 and oral contraceptive use, which affects the anticoagulant 
protein C axis,
31
 increase the effect of lupus anticoagulants on the risk of ischaemic stroke 
or myocardial infarction. The reason why the effect of lupus anticoagulant on ischaemic 
stroke is more pronounced than its effect on myocardial infarction remains to be 
established, but might reflect a true difference in the aetiology of the two diseases. 
Although antiplatelet drugs are recommended over oral anticoagulants as secondary 
thromboprophylaxis for non-cardioembolic ischaemic stroke, the use of oral anticoagulants 
in patients with antiphospholipid syndrome, rather than treatment with antiplatelet drugs, 
is preferred by some experts.
32,33
 Therefore, screening for lupus anticoagulant in young 
women with ischaemic stroke might be warranted. 
Conclusions From the tested markers of the antiphospholipid syndrome, LAC proved to 
evoke the largest increase in risk for both myocardial infarction and ischaemic stroke. 
However, the was a striking difference between these two diseases in the magnitude of the 
effect. This,  together with the observation that anti-β2-glycoprotein I antibodies were 
associated with ischaemic stroke but not with myocardial infarction, shows that the role of 
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This thesis discusses the role of the coagulation system as a whole and its parts in the 
aetiology of both myocardial infarction and ischaemic stroke in young women. The 
underlying question of each chapter is whether ‘hypercoagulability’ has an equal effect on 
the occurrence of myocardial infarction and ischaemic stroke. 
To investigate this, several prothrombotic factors were analysed in the RATIO study. The 
study design of RATIO, a frequency-matched population-based case-control design, implies 
some limitations all of which have been discussed extensively in the different chapters of 
this thesis. For example, no absolute risks can be calculated which makes external data 
necessary to provide a context in which we have to put the relative results of the 
presented analyses. Also, the case-control design implies that blood samples can only be 
collected after the event, making it difficult to definitely establish temporality between the 
presumed cause and the effect. Furthermore, other sources of bias (e.g. confounding, 
recall bias, survivor bias) play a role in the over- or underestimation of the causal effects of 
interest.  
However, the mere presence of these threats to internal or external validity does not 
nullify the research done, but the effect as well as direction of the bias can. Therefore, 
these aspects should be discussed as is done in the discussion sections of each chapter. 
Only if it is unlikely that bias can explain the association, causal inferences can be made.
1
 
Knowledge derived from previous studies, both fundamental and clinical, should be taken 
into account during this process.
2
  The aim of this chapter is to summarise the research 
presented in this thesis and review to what extent causal inferences can be made from the 
results. Additionally, this chapter compares the results from the myocardial infarction 
analyses and the ischaemic stroke analyses to discuss whether the prothrombotic factors 
have a different role in mechanisms underlying these two diseases. 
Summary and discussion of causality 
Chapter 2 is the only chapter in this thesis that does not directly touch a question of 
causality. In this chapter the role of a positive family history in the risk prediction for 
ischaemic stroke and myocardial infarction is discussed. Although not a formal prediction 
study aimed at developing a validated prediction model, lessons on the predictive value of 
family history can be learned from these results.
3,4
 A positive family history of either 
myocardial infarction or stroke before the age of 60 in a first degree relative increases the 




remains virtually unchanged. But what can these data tell us from a causal point of view? 
Causal inference in the formal sense of the word is not possible since the exposure ‘family 
history’ cannot be regarded as a well defined intervention in a thought experiment. It does 
not adhere to both the positivity and the consistency conditions, even under conditional 
exchangeability, as formulated by Hernan and Robins.
5
 At most, family history can be a 
regarded as a marker for a plethora of risk factors that cluster in families either through 
genetics or household effects. If myocardial infarction and ischaemic stroke were two 
similar diseases with the same aetiology, it is likely that such a marker will have similar 
associations. So, although no formal causal statements can be made, these data at least 
provide a clue that these diseases do not share a common aetiologic mechanism. 
Chapters 3 through 6 focus on causality: they investigate the role of the intrinsic 
coagulation system and its effect on the risk of myocardial infarction and ischaemic stroke. 
This system includes coagulation FXI, FXII, prekallikreine and HMWK. People deficient in 
these proteins exhibit mild bleeding diatheses (FXI), or no increased bleeding at all (FXII, 
prekallikrein HMWK). Nonetheless, several studies suggest that the intrinsic coagulation 
system plays a pivotal role in pathologic thrombus formation.
6–15
 The intrinsic coagulation 
system is also linked to several other biological mechanisms relevant in cardiovascular 
diseases, such as fibrinolysis and inflammation.
14,16–20
 These proteins have several actions 
which complicates the unravelling of the causal mechanism, but does not have to 
complicate the analyses which determine whether these proteins are causal factors per se. 
The results as presented in this thesis suggest that activation of FXI, as well as FXI antigen 
levels, increases the risk of ischaemic stroke, whereas the risk of myocardial infarction is 
not affected. The results on FXII and kallikrein are less clear: a heightened state of 
activation of these proteins is only increased in ischaemic stroke patients, whereas the 
antigen level does not seem to affect the ischaemic stroke risk. Prekallikrein, the zymogen 
form of kallikrein, is only marginally associated with an increase in risk of myocardial 
infarction, although this effect might be explained by the homology between prekallikrein 
and FXI and the use of polyclonal antibodies in the used assays. HMWK, the only non-
enzymatic protein in the intrinsic coagulation cascade also only affects the risk of ischaemic 
stroke, albeit to a minor extent. In summary, these results in combination with other 
studies suggest a causal role for the intrinsic coagulation proteins especially for ischaemic 
stroke, although the mechanism is not known.  
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The differences between the protein-inhibitor analyses and the antigen analyses are not 
necessarily contradictory since the two measures, as intended by design, measure different 
protein characteristics. The discrepancy between FXII:C1-inh and FXII:ag data could for 
instance reflect difference in activation rate perhaps caused by a protein variant with 
altered functionality. More likely is that the levels of protein-inhibitor complexes reflect a 
more general notion of an activated coagulation system, either as a cause or a 
consequence of the disease. As said, the intrinsic coagulation proteins have several actions, 
which might also be the underlying reason for the differences between the results from the 
zymogen and activation analyses. Future studies, both laboratory and epidemiology, could 
help to further elucidate the underlying causal mechanism. The measurement of enzymatic 
active intrinsic coagulation proteins with specific antibodies can be useful for this purpose. 
Also, a genetic approach can be used to minimise the effect of confounding and reverse 
causation, could provide further insight in this matter.  
Chapters 7 through 9 use a genetic approach to investigate the role of coagulation in the 
aetiology of myocardial infarction and ischaemic stroke. Genetic variation in a gene could 
result directly in a difference in protein functionality, as is the case for example with the 
Factor VLeiden variation which causes the protein to be resistant to degradation by the 
natural anticoagulant activated protein C.
21–24
 Additionally, genetic variation can also be 
used as marker for a certain property of the protein of interest. This approach, better 
known as Mendelian randomisation, is discussed in chapter 7 and is a form of instrumental 
variable analysis where genetic variation is used as a proxy for a protein characteristic such 
as protein plasma level. When executed properly, this approach adheres to the three 
conditions of causal inference: ‘conditional exchangeability’ or even ‘unconditional 
exchangeability’ can be assumed from the second law of Mendel (i.e. the law of 
independent assortment). The ‘positivity’ condition also holds as a direct implication from 
this same idea that the genetic variation does not depend on the presence of other 
covariates. This way, the exposure is likely to vary in all strata of covariates and the 
‘positivity’ condition therefore holds. These two conditions do, however, not hold in rare 
but important situations where ‘population stratification’ introduces bias. ‘Consistency’ 
holds when the genetic variant only affects the protein property of interest; pleiotropy, 
where the genetic variant has multiple independent causal or associated effects violates 
this condition. Although potentially a strong causal inference instrument, Mendelian 




assumptions that in principle cannot be verified empirically because these assumptions are 
based on the absence of certain associations. At best, these assumptions can be checked 
against known possible sources of assumption violation. Although this adds to the 
credibility of a Mendelian randomisation study, the ‘absence of proof’ indeed does not 
imply ‘proof of absence’ and a critical attitude is necessary to prevent erroneous 
conlusions.
25
 Furthermore, a large number of observations are needed to provide sufficient 
power for formal instrumental variable analyses. Although the RATIO study is of reasonable 
size, especially when one considers the low incidence of myocardial infarction and 
ischaemic stroke in young women, it lacks the statistical power for formal Mendelian 
randomisation analyses.
26–29
 So, instrumental variable analyses such as the Mendelian 
randomisation approach can hardly be called an ‘epidemiologist dream’ in the quest to 
understanding the causal mechanism of a disease. But the line of reasoning still holds some 
of its value and can be used in causal inference.
28
 This is demonstrated in our study on 
genetic variation in the fibrinogen genes, fibrinogen levels and the risk of myocardial 
infarction and ischaemic stroke. An individual participant meta-analysis from the fibrinogen 
studies collaboration showed that high levels of fibrinogen are strongly associated with 
myocardial infarction and ischaemic stroke.
30
 However, reverse causation by subclinical 
disease, confounding and the acute phase properties of fibrinogen could in part explain 
these associations. The two SNPs used in chapter 8 were associated with a change in risk 
for ischaemic stroke, with the direction of the effects concordant with the effects of the 
SNPs on fibrinogen levels. Neither SNP affected the risk of myocardial infarction. However, 
these SNPs might also lead to pleiotropic effects so no strong conclusions can be drawn 
regarding the role of fibrinogen levels as causal factors of these two diseases. Several other 
studies, some with a Mendelian randomisation-like approach, drew similar conclusions: the 
role of fibrinogen levels on the risk of myocardial infarction is at best minimal, whereas the 
effect on ischaemic stroke risk is larger, although part of this role might be a qualitative 
rather than a quantitative effect.
31–37
   
The analysis of 4 SNPs in the F13 genes presented in chapter 9 showed no relationship with 
myocardial infarction, whereas results previously published by RATIO researchers show 
that these F13 SNPs are related to ischaemic stroke risk. However, the mechanism by 
which these SNPs affect the risk of ischaemic stroke is unclear. These SNPs might result in 
different forms of crosslinks, both quantitative and qualitative, in the fibrin mesh.
38
 These 
alterations  in clot structure are associated with thrombotic disease.
37,39–41
 Nonetheless, 
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our results indicate that the effect of the genetic variants in the F13 genes differ for 
myocardial infarction and ischaemic stroke, as is the case in our analyses of the genetic 
variation in the fibrinogen genes. This, irrespective of their exact mechanism, shows that 
the role of fibrinogen and FXIII is different for these two diseases. 
Chapter 10 through 12 do not focus on factors of the coagulation cascade, but rather 
investigate the role of other conditions related to an increased clotting propensity. VWF is 
not part of the coagulation cascade but is connected to prothrombotic processes in several 
ways. It is bound to FVIII in plasma, stored in platelets in α-granules and endothelial cells in 
Weibel Palade bodies and is released after activation which leads to platelet tethering, 
adhesion and activation.
42–44
  Therefore, VWF might also be just a marker of endothelial 
dysfunction. However, most evidence, including some genetic studies, suggest that VWF is 
also a cause of thrombotic disease.
45–50
 The results presented in chapter 10 corroborate 
this notion and suggest that VWF levels indeed are a risk factor for both myocardial 
infarction (VWF:ag & VWF:act) and ischaemic stroke (VWF:ag).
51
 Interestingly, low levels of 
ADAMTS13 antigen, a regulator of VWF size and therefore activity, also increased the risk 
of ischaemic stroke whereas the risk of myocardial infarction was only minimally affected. 
This difference might indicate that the relation of VWF and cardiac disease is be partly 
explained by endothelial dysfunction, but that the relation of VWF and ischaemic stroke 
indeed is a causal one. However, other studies that focus on the relation between 
ADAMTS13 and myocardial infarction are not conclusive on the size or even the direction 
of the association between the two, making it difficult to draw strong conclusions on the 
causal role of ADAMTS13 and its effect on VWF and the risk of myocardial infarction.
52–56
 
Nonetheless, observations on the role of  the VWF / ADAMTS13 system and its relation to 
platelet activation have resulted in the idea that VWF might be used as a target in 
ischaemic stroke therapy.
57,58
 Not surprisingly, recombinant ADAMTS13 is one of the new 
strategies that could prove to be useful in the treatment or prevention of ischaemic 
stroke.
59,60
 Recent studies identifying a link between activated platelets and coagulation 
activation through the excretion of platelet derived polyphosphates, further emphasize the 
possible key properties of VWF in the aetiology of thrombotic disease.
61
 
Another factor determining clotting propensity is fibrinolytic capacity. Chapter 11 discusses 
the relation between fibrinolytic capacity and the risk of myocardial infarction and 
ischaemic stroke. Since atrial fibrillation is a major source of cardiac emboli causing 




ischaemic stroke were excluded from the RATIO study. The risk of myocardial infarction is 
increased in women with a diminished fibrinolytic capacity, or hypofibrinolysis. 
Interestingly, the results for ischaemic stroke were reversed; an increased fibrinolytic 
capacity, or hyperfibrinolysis, was associated with an increase in risk. This counterintuitive 
finding might be explained by the different effects of plasminogen activator inhibitor-1 
additional to its effect on clot lysis, which has been shown to affect neurological cell death 
in mouse models.
62
 Other research is inconclusive on this topic, leaving it difficult to draw 
strong conclusion on the true implications of these results.
63
 This chapter also shows the 
difficulties in making causal inferences when the exposure of interest is a well defined, but 
composite measure. By definition, there are multiple ways to alter the value of a 
composite measure. Therefore, the use of composite measures violates the consistency 
assumption and causal inferences on the exact aetiologic mechanism cannot be made. 
Nonetheless, the results from our analysis do tell us something: although we cannot be 
sure on the underlying mechanisms, we can conclude that the proteins measured in this 
aggregate measure have a differential effect on myocardial infarction and ischaemic 
stroke.  
Markers of the antiphospholipid syndrome are subject of research in chapter 12. This 
autoimmune syndrome is characterised by thrombotic events and the presence of 
antiphospholipid antibodies and lupus anticoagulant. This latter trait is marked by a 
paradoxically elongated aPTT, an in vitro artefact probably caused by the antiphospholipid 
antibodies. The results of the RATIO study show that women with lupus anticoagulant have 
a approximate 40-fold increase in risk of ischaemic stroke, whereas the risk for myocardial 
infarction is 5-fold increased. Although this increase in myocardial infarction risk is stronger 
than almost any other effect studied in this thesis, there is an unequivocal difference in 
effect between the two diseases. Of the antiphospholipid antibodies, the most important 
class is targeted towards β₂-glycoprotein I (also incorrectly referred to as apolipoprotein-
H)
64
, which has been identified to interact with several proteins of the coagulation cascade, 
including the intrinsic coagulation proteins FXI and FXII.
65–67
 Anti β₂-glycoprotein I 
antibodies are associated with a doubling of ischaemic stroke risk, whereas no effect was 
observed for myocardial infarction. Although several functions of β₂-glycoprotein I, 
complexed with antibodies or not, have been identified that might explain the thrombotic 
events in the antiphospholipid syndrome, the exact mechanism still needs to be 
determined.
65,68–70
 As is the case for the intrinsic coagulation proteins, this complicates 
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causal inference, but it does not nullify the notion that markers of such a prothrombotic 
condition are stronger related to ischaemic stroke risk than to myocardial infarction. 
Similarities and differences: a direct comparison 
When a comparison between two diseases is made, there are some major sources of bias 
that could hamper a correct interpretation. Firstly, to do so one has to rely on different 
analyses often from separate cohort and case-control studies. Such a comparison is 
hampered by differences in study design, data acquisition, data analyses and the 
underlying research questions in the separate studies. However, these problems of 
comparability are not present, or at least minimised, when the results come from one 
single study. This is the case for the analyses and results presented in this thesis, all of 
which are embedded within the RATIO study. This ensures that study design, control group, 
questionnaires and sample measurement, analyses and research questions were similar for 
the two case groups.  
There might be an additional problem with such a direct comparison, even when the 
results for two diseases are compared within one single study: a difference in point 
estimates might be caused by a difference in background risk of the studied diseases. This 
could be interpreted as a real difference in causal effects of the exposure of interest, but is 
in fact a problem of interpretation of the point estimate used. This problem, which is in 
part similar to the mechanisms underlying so called paradoxes in recurrence research, is 
not present when the background risks of the different studies are similar.
71
 Since the 
incidences of myocardial infarction and ischaemic stroke in young women in the 
Netherlands are low and similar (i.e. both are approximately 14 per 100 000 women per 
year),
26,27
 this problem is not likely to affect a direct comparison of the myocardial 
infarction and ischaemic stroke results in the RATIO study. 
So, there are no major sources of bias when the results from the RATIO study are used to 
compare the role of prothrombotic factors in the aetiology of myocardial infarction and 
ischaemic stroke. However, such a comparison must be non-selective, interpreted 
cautiously and if possible quantitatively. Therefore, the comparison will be made with the 
relative odds ratio (ROR) for all prothrombotic factors studied in the RATIO study to assess 
the difference in effects between the two diseases. Also, to evaluate the impact of the 
different prothrombotic conditions on the incidence of the diseases the population 




allow not only a comparison between diseases but also a comparison between 
prothrombotic factors. 
ROR The results presented in this thesis, together with the publications from previous 
RATIO collaborators, yield a total of 30 prothrombotic factors that were studied for both 
myocardial infarction and ischaemic stroke.
21,24,72–84
 They are listed in table 1 together with 
the effects on the risk of myocardial infarction and ischaemic stroke. To compare these 













, where ORIS denote the adjusted odds ratio of the ischaemic stroke analyses and ORMI  
represents  the adjusted odds ratio of the myocardial infarction analyses. If the ROR >1 the 
effect of the prothrombotic factor is larger in the ischaemic stroke analyses, and 
conversely, if the ROR < 1 the effect is larger in the myocardial infarction analyses. If the 
ROR = 1 there is no difference in effect size. Normally, the variance of the natural logarithm 
of the ROR is the sum of the variances of the natural logarithm of the two separate odds 
ratios.
85
 However, this measure overestimates the variance in these analyses since it does 
not take the single control group of the RATIO study into account: now, the part of the 
variance introduced by the control group is counted twice. As a result, all confidence 
intervals are too wide (see appendix). Because all confidence intervals of the ROR are 
affected in a similar fashion, and probably only to minor extent, it is not likely this 
overestimation of the variance will lead to erroneous conclusions.  
Table 1 lists all 30 prothrombotic risk factors which were subject of research in the RATIO 
study, their effect estimates (i.e. ORMI  and ORIS), the ROR and corresponding 95% 
confidence interval, in ascending order of the ROR. Twenty-one of the 30 prothrombotic 
conditions have a ROR  >1, 13 >2, and 3 > 3. Is there a common mechanism to be found 
amongst the factors with the highest RORs? High levels of activated factor XII (ROR 2.8), PK 
(ROR 2.9) and factor XI (ROR 2.9) point towards a role of the intrinsic coagulation system. 
FXI can be activated by FXII, but also independent of FXII by thrombin in a positive 
feedback mechanism.
15,86
 The effect of factor V Leiden in combination with oral contraceptive 
use (ROR 5.89) points towards a role of the protein C system.
87
 Protein C is a natural 
anticoagulant which inhibits coagulation factor FVIIIa and factor Va,
88
 and thereby also  
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Table 1. Prothrombotic risk factors in the RATIO study, the effect on myocardial 
infarction and ischaemic stroke and their ROR 
# = number, ref = reference, ORMI = odds ratio from myocardial infarction analyses, ORIS = odds 
ratio from ischaemic stroke analyses, 95%CI = 95% confidence interval, :ag = antigen levels, C1-
INH = C1-inhibitor levels, AT-INH = antitrypsin-inhibitor levels, dominant = analyses based on 
dominant inheritance pattern 
# Thrombotic factor ref OR MI OR IS ROR 95%CI 
1 Anticardiolipin antibodies, p95 
72
 1.80 0.90 0.50 0.17 - 1.45 
2 hypofibrinolysis vs. normofibrinolysis 
78
 2.82 1.50 0.53 0.22 - 1.27 
3 Prekallikrein:ag p90 
79
 1.54 0.90 0.58 0.23 - 1.52 
4 F13A1 Pro564Leu, dominant 
73,74
 1.40 0.89 0.64 0.39 - 1.05 
5 F13A1 Val34Leu, dominant 
73,74
 1.07 0.77 0.72 0.44 - 1.17 
6 Factor XII:ag, p90 
79
 1.18 1.03 0.87 0.34 - 2.23 
7 Factor XII:ag ,p10 
79
 1.54 1.36 0.88 0.39 - 2.00 
8 Prothrombin G20210A, dominant 
24,75
 1.00 1.00 1.00 0.22 - 4.54 
9 High molecular weight kininogen:ag, p10 
81
 1.39 1.49 1.07 0.43 - 2.67 
10 Oral contraceptive use vs. non use 
21,84
 2.00 2.30 1.15 0.69 - 1.91 
11 MTHFR TT snp, recessive  
24,82
 1.30 1.50 1.15 0.57 - 2.33 
12 VWF:ag q4 vs q1 
80
 4.20 6.70 1.60 0.60 - 4.26 
13 Factor V Leiden, dominant 
24,75
 1.10 1.80 1.64 0.65 - 4.11 
14 Factor XI:ag, p90 
83
 1.61 2.65 1.65 0.79 - 3.44 
15 High molecular weight kininogen:ag, p90 
81
 1.05 1.82 1.73 0.74 - 4.08 
16 FGB -455 G/A, dominant 
77
 0.98 1.76 1.80 0.53 - 6.08 
17 FGA 312Ala, dominant 
77
 1.22 2.33 1.90 0.79 - 4.61 
18 F13B His95Arg, dominant 
73,74
 0.79 1.70 2.15 1.14 - 4.05 
19 ADAMTS13:ag, q1 vs q4 
80
 1.40 3.10 2.21 0.93 - 5.27 
20 prekallikrein:ag, 10 
79
 0.60 1.33 2.22 0.79 - 6.24 
21 anti prothrombin antibodies, p95 
72
 0.80 1.80 2.25 0.63 - 8.03 
22 anti-β2-glycoprotein antibodies, p95 
72
 1.20 2.80 2.33 0.92 - 5.93 
23 Factor XI AT-INH, p90 
76
 0.94 2.33 2.48 1.13 - 5.41 
24 Hyperfibrinolysis  vs. normofibrinolysis 
78
 1.60 4.07 2.54 1.03 - 6.27 
25 Factor XII C1-INH, p90 
76
 0.82 2.26 2.76 1.27 - 5.99 
26 Kallikreine C1 INH, p90 
76
 1.50 4.34 2.89 1.42 - 5.89 
27 Factor XI C1-INH, p90 
76
 0.96 2.76 2.89 1.31 - 6.34 
28 FVL + OC + vs FVL- OC - 
24,75
 1.90 11.2 5.89 1.32 - 26.4 
29 Lupus anticoagulant, ≥1.15 
72
 5.30 43.1 8.13 1.30 - 50.9 
30 F13A1 Tyr204phe, dominant 
73,74









affects the thrombin - factor XI feedback mechanism in which factor V is a co-factor.
89
 
Lupus anticoagulant (ROR 8.1) is a marker for the antiphospholipid syndrome. Some have 
proposed a link between the antiphospholipid syndrome and coagulation factor XI/the 
intrinsic coagulation system, whereby anti-β2-glycoprotein antibodies might play a role in 
disrupting the activation of FXII and FXI.
6,90–92
 The largest difference in effect was observed 
for a genetic variant of coagulation factor XIII (ROR 11.1), a protein which crosslinks fibrin 
monomers and thereby affects the clot structure. Although three of the four 
prothrombotic factors that have the largest difference in effect are linked to the intrinsic 
coagulation system, directly or indirectly, these links are not based on a full body of 
evidence. Nonetheless, from the numbers presented in table 1, a cautious conclusion can 
be drawn: the effect of prothrombotic factors on the risk of ischaemic stroke of non-
cardiac origin is larger than the effect on myocardial infarction.  
However, the use of the ROR as a measure of direct comparison entails a problem: being a 
single number denoting the ratio of two other numbers, the ROR is not dependent on the 
magnitude of its numerator and denominator. This way the ROR of two small effects could 
be similar to the ROR of two large effects. For example, exposure #12 (i.e. VWF with ORIS 
6.7 and ORMI 4.2) and exposure #13 (Factor V Leiden with ORIS 1.8 and ORMI 1.1) both have a 
ROR of approximately 1.6 whereas their effects and interpretation are quite different: high 
levels of VWF are a risk factor for both myocardial infarction and ischaemic stroke, whereas 
Factor V Leiden only imposes an increased risk of ischaemic stroke. Figure 1 circumvents 
this problem. Here, the left panel depicts the effects of the several prothrombotic factors 
plotted on a logit scale; the results from the ischaemic stroke analyses are plotted on the y-
axis and the myocardial infarction results are plotted on the x-axis. The numbers in this 
graph denote the exposure of interest and correspond with the numbers in table 1. Points 
alongside the horizontal line represent factors that increase the risk of myocardial 
infarction but have no effect on the risk of ischaemic stroke. Conversely, points next to the 
vertical line represent factors which increase the risk of ischaemic stroke, whereas the risk 
of myocardial infarction is not affected. When exposures #12 and #13 are plotted in this 
figure, the aforementioned differences between these two exposures are immediately 
visible; differences which cannot be grasped by the ROR alone. Nonetheless, the ROR can 
be deduced from this figure: the distance of a line drawn perpendicular from the diagonal 
towards a single point represents the ROR of this point on a logarithmic scale. If 
prothrombotic factors were to play a similar role in the aetiology of myocardial infarction  




Figure 1. Prothrombotic risk factors in the RATIO study and their effect on myocardial 



























































































MI = myocardial infarction, IS = ischaemic stroke, logit  = log of the odds ratio, PAF = population 
attributable fraction. Each point 1 depicts the logit as a measure of effect (left panel) or the population 
attributable fraction (right panel) of a particular risk factor on the risk of myocardial infarction (x-axis) as 
well as the effect on the risk of ischaemic stroke (y-axis). The red dashed lines indicate the null effect for 
either myocardial infarction (vertical line) or ischaemic stroke (horizontal line). The blue diagonal line 
represents the theoretical line along which all points would cluster when the role of thrombotic factors is 





and ischaemic stroke, all points, irrespective of the effect size, should cluster along a 
diagonal line. Since the incidences of myocardial infarction and ischaemic stroke in young 
women in the Netherlands are similar,
26,27
 this diagonal should be the x=y diagonal which is 
depicted in blue.  
With the use of table 1 and the left panel of figure 1 the difference in effect on myocardial 
infarction and ischaemic stroke can be established for each prothrombotic factor. This kind 
of comparison is only possible when the same definition of exposure is used for the 
myocardial infarction analyses and the ischaemic analyses. However, with a listing of all 
studied prothrombotic risk factors, it is tempting to compare the different risk factors with 
each other with regard to their impact on the incidences of the two diseases. Still, the odds 
ratios and the ROR only tell part of the story; the impact of a risk factor is determined by its 
effect size and prevalence. 
PAF For a proper quantitative comparison of the impact of these prothrombotic factors on 
myocardial infarction and ischaemic stroke the population attributable fraction can be 
used.
93
 This number, also known as the aetiologic fraction, represents the fraction of 
disease incidence that is prevented in a population when the cause of the disease is 










Pfractionleattributabpopulation cases  
, where Pcases  represents the proportion of exposed cases and OR represents the odds ratio 
of the risk factor of interest. Unlike other formulas that calculate the PAF, this formula 
yields valid estimates of the PAFs when confounding is present and therefore adjusted 
odds ratios are used.
94
 The presented 95% confidence intervals are based on the variance 
calculated as proposed by Greenland, although these again might be slightly conservative 
since this method does not account for the use of a single control group in the RATIO study 
and therefore overestimates the true variance.
93,95
 Since myocardial infarction and 
ischaemic stroke can be regarded as multicausal diseases, one has to keep in mind that the 
sum of this measure is not limited to 1.
93
 The right panel of figure 1 depicts the calculated 
PAFs for myocardial infarction (x-axis) and ischaemic stroke (y-axis) comparable to the 
graph in the left panel of figure 1. To facilitate a side by side comparison of several factors, 
the PAFs and corresponding confidence intervals for all 30 prothrombotic factors are also  
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Figure 2. Prothrombotic risk factors in the RATIO study and their population attributable 
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Population attributable fractions from the myocardial infarction analyses are represented by blue squares 
where the ischaemic stroke results are denoted by red dots. The corresponding lines represent the 
corresponding 95% confidence intervals. These intervals underestimate the variance of the point estimates 
since they do not take the single control group used in the RATIO study into account. Exposure # refers to 
the exposure number as denoted in table 1 in which the exposures are ranked according to their relative 





plotted in figure 2. The PAFs based on the odds ratios derived from the myocardial 
infarction analyses are depicted in blue squares whereas the ischaemic stroke results are 
depicted in red circles.  
Almost all points in the right panel of figure 1 show that the PAF derived from the 
ischaemic stroke analyses is higher than the PAF derived from the myocardial infarction 
results. Only 4 prothrombotic factors yield a PAF >0.1 in the myocardial infarction analyses, 
whereas 14 prothrombotic factors yield a PAF>0.1 in the ischaemic stroke analyses. Three 
points stand out, being exposure numbers 2, 4 and 5. Exposure 2, which represents the 
PAFs from the hypofibrinolysis vs normofibrinolysis analyses, points towards a large impact 
of this factor on the incidence of myocardial infarction with only a modest effect on 
ischaemic stroke incidence. As is discussed in chapter 10 and summarised above, the clot 
lysis time used to determine fibrinolytic capacity is mainly determined by PAI-1, which 
could be involved in other processes relevant for ischaemic stroke. However, it is also 
important to note that the RATIO study is focused on ischaemic stroke of non-cardiac 
origin, which might account for the modest impact of hypofibrinolysis. Exposure 4 and 5, 
i.e. two genetic variants in the F13A1 gene are the only two factors with a negative PAF for 
ischaemic stroke. However, the broad confidence intervals shown in figure 2 indicate that 
no strong conclusions may drawn from these PAFs; if anything the impact of these two 
genetic variants on both diseases is only modest. 
The measures used in this direct comparison are approximations of the true underlying 
effect and are likely to be biased. But the question at hand is whether the differences 
between myocardial infarction and ischaemic stroke can be explained by these biases. 
Given the same control group, questionnaires measurements and data analyses such a 
scenario is not likely. We believe that the impact of bias is similar for the myocardial 
infarction and ischaemic stroke analyses and therefore cannot explain the observed 
contrast between these two diseases. With regard to residual confounding, the conclusion 
can even go further: the presence of a differential effect of residual confounding - that is, 
part of the observed difference can be explained by confounding that is present in one 
analyses but not in the other - also provides a clue that the causal mechanism underlying 
these two diseases are in fact different. 
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In short, with the RORs as measures of direct comparison of effect size and the PAFs 
facilitating the comparison of the impact on the incidence of the two diseases, one single 
picture arises: prothrombotic factors do play an important role in the aetiology of 
ischaemic stroke of non-cardiac origin in young women. The role of these factors in the 
aetiology of myocardial infarction is minimal if not absent. 
Implications 
Coagulation vs hypercoagulability To investigate the implications of these findings, the 
overall conclusion has to be put into the right perspective. Although there is a minimal 
effect of prothrombotic factors in the aetiology of myocardial infarction, this does not 
imply that blood coagulation does not play a role at all in this disease. In the research 
presented in this thesis the exposure was often chosen to represent ‘hypercoagulability’, a 
state with an increased clotting potential. So, an increased clotting potential is a cause of 
ischaemic stroke but not of myocardial infarction. 
What can explain the involvement of coagulation processes in the mechanism underlying 
myocardial infarction while hypercoagulability does not play a role? Perhaps the answer to 
this question lies in the endothelial lining of the two vascular beds in relation to 
atherosclerotic lesions. The atherosclerotic burden of the women included in the RATIO is 
thought to be minimal: approximately 10% of the women included in both case groups 
were known with hypercholesterolaemia in the year prior to their event. Nonetheless, the 
subclinical atherosclerotic burden in the women suffering from myocardial infarction and 
ischaemic stroke women is higher than in other women and the related endothelial 
dysfunction could be part of the explanation of the observed differences between 
myocardial infarction and ischaemic stroke. 
The endothelial lining of the coronary vessels affected by myocardial infarction is quite 
homogeneous and often a myocardial infarction is preceded by endothelial dysfunction, 
atherosclerotic lesions and subsequent rupture of a atherosclerotic plaque. The content of 
atherosclerotic plaques is highly thrombogenic, possibly to such an extent that variations in 
clotting potential do not affect the outcome of such a plaque rupture: a thrombus will 
inevitably form after plaque rupture and downstream tissue will be deprived of oxygen rich 
blood, irrespective of variations in clot propensity. To put it differently, hypercoagulability 
is not a trigger of the coagulation cascade in the aetiology of myocardial infarction. Or to 




associated with irritation of the vessel and its vicinity’ better known as endothelial injury or 
dysfunction. 
Endothelial dysfunction, atherosclerotic lesions and plaque rupture can also be a cause of 
ischaemic stroke. For example, atherosclerotic plaques in the carotid arteries could rupture 
or erode resulting in coagulation initiation and embolising thrombi.
96
 Although this 
scenario is already somewhat different from the scenario for myocardial infarction (i.e. 
differences in flow patterns, endothelial composition, lumen diameter and embolisation) a 
hypercoagulable state might not play a role in these forms of ischaemic stroke. However, 
ischaemic stroke is a heterogeneous multicausal disease and a considerable proportion of 
ischaemic strokes are thought to have a different causal mechanisms which include 
vasoconstriction, dissection, patent foramen ovale, inflammatory conditions and other 
vasculopathies.
96–101
 The results from the RATIO study, as well as other studies, indicate 
that prothrombotic factors are likely to be also part of these different causal mechanisms: 
an increased clotting potential could in itself be a cause in the initiation of coagulation in 
the mechanism leading to of ischaemic stroke of non-cardiac origin. And in reference to 
Virchow’s triad: as a multicausal disease, ischaemic stroke of non-cardiac origin might be 
caused by both endothelial injury as well as ‘Phenomena of blood-coagulation’ or 
hypercoagulability. When we also consider cardiac embolic stroke we can see that 
ischaemic stroke, being a heterogeneous disease, covers all three components of Virchow’s 
triad. 
So what can be said about the heterogeneity of ischaemic strokes included in the RATIO 
study? Several ischaemic stroke classification system have been proposed to deal with the 
heterogeneous nature of this disease.
97,102,103
 Perhaps the most used system is the TOAST 
classification system, which categorises ischaemic stroke into 5 categories, each with their 
own causes and consequences: cardioembolism, large-artery atherosclerosis, small-vessel 
occlusion, stroke of other determined aetiology and stroke of undetermined 
aetiology.
97,103,104
 Results from other studies indicate that the role of certain risk factors 
could very well be different in different  categories.
35,39,46,105–111
 The most intriguing 
category must be the ‘stroke of undetermined origin’, which comprises about one third of 
all strokes, a proportion that might be higher in the young.
39,101,103,112
 This category 
comprises all stroke of which no overt cause is directly identified which makes it more 
difficult to directly target the underlying cause of the stroke to prevent recurrences of the 
disease.
110
 Unfortunately, the RATIO study cannot be used to determine possible 
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differences between subtypes of ischaemic stroke since the necessary data are not 
available. New studies will help to further elucidate the role of thrombotic factors in young 




Future research Within these new studies there is range of topics that is of interest in the 
elucidation of the causal mechanisms of ischaemic stroke. The importance of the intrinsic 
coagulation proteins is slowly emerging and more insight in their diverse interactions and 
effects could further increase the knowledge of ischaemic stroke. As said in this chapter 
and shown in this thesis, murine, biochemical and clinical studies show that the intrinsic 
coagulation proteins can play a pivotal role in pathologic thrombus formation.
10,12,13,114–116
 
Additionally, several mechanisms have been shown to activate and modulate the several 
actions of the intrinsic coagulation proteins, of which the link to inflammatory processes 
and the activation route through platelet derived polyphosphates might be the most 
significant.
16,19,89,92,117–121
 These new insights might even lead to new antithrombotic 
therapies: therapies targeting the intrinsic coagulation proteins, especially coagulation 
factor XI, could potentially be used in the secondary or even primary prevention of 
thrombotic disease.
58,120,122,123
 Why FXI and not FXII? This choice starts with the observation 
that FXI deficient humans have a reduced risk of ischaemic stroke and deep venous 
thrombosis.
124,125
 Also, FXII has a plethora of effects, also outside the realm of coagulation, 
whereas the role of FXI is more unambiguous and restricted to blood coagulation and the 
fibrinolytic system.
14,16,126–132
 And finally, promising animal studies in which FXI 
transcription was minimised, for example with antisense oligonucleotides, have shown that 
this diminishes clot formation without a large increase in bleeding risk.
133–135
 Inhibiting 
protein transcription lowers the antigen levels of the protein; compensatory mechanisms 
might increase protein activity by an increased activation rate nullifying this inhibition. In 
the RATIO study, FXI:ag levels were clearly and independently associated with ischaemic 
stroke whereas other antigen levels of the intrinsic coagulation proteins were not, leaving 
FXI as the most promising candidate to target. 
It is likely that such a new therapy is first used in a setting in which hypercoagulation plays 
an important role in the aetiology of the targeted thrombotic disease, as is done with the 
newer anticoagulants dabigatran and rivaroxaban as treatments in the prevention of 
ischaemic stroke in atrial fibrillation patients.
136,137
 Nonetheless, a FXI targeted drug might 




myocardial infarction. This is not in contrast with the main conclusion of this thesis: the 
contrast used in this thesis is variation in thrombotic potential within a normal population. 
Treatment with an anticoagulant is not the counterfactual of ‘hypercoagulability’ since it 
reduces the thrombotic potential drastically beyond normal variation. This concept is 
demonstrated by the studies which tested anticoagulation treatments in the prevention of 
coronary disease; anticoagulation therapy does reduce the risk of coronary outcomesbut is 
inferior to dual anti-platelet therapy in the cost-benefit analyses which takes bleeding risks 
into account.
138
 Therefore, if FXI targeted therapy indeed could reduce clotting potential 
with only minor increases in bleeding risks, such a therapy should be considered for the 
treatment of all thrombotic diseases, including those in which hypercoagulability is not a 
risk factor. 
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The variance of a relative odds ratio 
 
// Odds ratio 
An odds ratio is a measure of association between two dichotomous variables. 











lnvar +++=  
 
// Relative odds ratio 
A Relative Odds Ratio (ROR) can be used for example as a direct comparison of 






where the two compared studies are denoted with 1 and 2, respectively. The 
variance of such a ROR is equal to the sum of the variances corresponding to the 
two ORs reflected in the ROR.
1






ROR +++++++=  
 
// Relative odds ratio with a shared control group 
 A ROR can also be calculated in a single case-control study with multiple case-
groups and a single control group. In such a study the ROR of a particular 
exposure can be calculated to investigate whether there is a difference in effect 
of the exposure between the two diseases. The ROR from such a single study, or 
RORshared control, can be calculated from a 2x3 table 
 Exp+ Exp- 
Case A B 
Control C D 
Study 2 Exp+ Exp- 
Case A2 B2 
Control C2 D2 
Study 1 Exp+ Exp- 
Case A1 B1 














































This can also been seen from the formulas for the ROR derived from two studies, 
because with a single control group C1 = C2 and D1 = D2. This has also implications 



















Which implies that the variance of a RORshared control calculated as if it where the 
variance of a ROR from two different studies would result in an overestimation of 
the true variance. The number of control subjects in case-control studies usually 
equals or outnumbers the number of cases in the case group. Therefore, the 
overestimation will be relatively small and is not likely to nullify the results.  
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Cardiovasculaire ziekten hebben een grote invloed op de gezondheid in Nederland. Door 
de oorzaken van de verschillende presentaties van deze ziekten te onderzoeken is het 
mogelijk dat er aangrijpingspunten worden gevonden voor nieuwe preventie- en 
behandelingsstrategieën die de invloed van deze ziekten verminderen met een zo klein 
mogelijke kans op bijwerkingen. Hierbij is het van groot belang dat de verschillende 
cardiovasculaire ziekten een andere wijze van ontstaan kunnen hebben met directe 
gevolgen voor deze behandelingsstrategieën. Veel cardiovasculaire ziekten zijn het gevolg 
van trombose, waarbij een bloedstolsel ontstaat dat de bloeddoorstroming bemoeilijkt. Als 
zich een bloedstolsel vormt in een slagader spreekt men van arteriële trombose: 
zuurstofrijk bloed kan niet meer doorstromen naar de organen waardoor er een 
zuurstofcrisis ontstaat en het weefsel kan afsterven. Voorbeelden van arteriële trombose 
zijn het hart- en herseninfarct. Het is ook mogelijk dat een bloedstolsel ontstaat in een 
ader: zuurstofarm bloed kan dan niet meer ongehinderd terugstromen naar het hart en de 
longen, met stuwing ten gevolge. De meest voorkomende vorm van veneuze trombose, i.e. 
trombose van het been, heeft in de meeste gevallen niet een even sterk acuut en 
potentieel dodelijk effect als arteriële trombose. Echter, wanneer dit bloedstolsel in het 
been afbreekt, kan het in de longen of zelfs de hersenen terecht komen met mogelijk 
dodelijke afloop. 
Trombose  
Het is duidelijk dat het mechanisme dat leidt tot trombose een afwijking betreft: 
normaliter stolt het bloed alleen wanneer er sprake is van een beschadiging van een 
bloedvat, bijvoorbeeld bij een wondje opgelopen bij het scheren. Er zijn echter 
omstandigheden die de kans op een trombose vergroten. Al in 1865 heeft de Duitse 
patholoog Rudolph Virchow een drietal ‘Formen der Trombose’ geformuleerd. Dit heeft 
uiteindelijk geleid tot de ‘trias van Virchow’, een concept dat gebruikt wordt om de 
oorzaken van trombose in te delen in drie categorieën, te weten ı) veranderingen in de 
bloedstroom, ıı) verandering in de samenstelling van het bloed en ııı) veranderingen aan de 
vaatwand. Op het eerste gezicht lijken de verschillende manifestaties van trombose dan 
ook toe te schrijven aan één van de drie onderdelen van de trias van Virchow, zoals is 
weergegeven in figuur 1. Zo zijn veel, maar niet alle, bekende oorzaken van een 




tot een verhoogde stollingsneiging. Dit gebeurt bijvoorbeeld door een genetische variatie 
zoals Factor V Leiden die aanwezig is bij ongeveer 5% van de Nederlandse bevolking. Bij 
een herseninfarct met een cardio-embolische oorsprong ligt de oorzaak veelal in 
boezemfibrileren, een conditie waarbij het hart niet op de juiste manier pompt, wat leidt 
tot abnormale wervelingen en lokale stilstand van het bloed. Hierdoor ontstaat vaak een 
bloedstolsel dat kan afbreken, en vervolgens meegevoerd wordt naar de hersenen. Bij 
arteriële trombose is de algemene opvatting dat de oorzaak primair ligt in atherosclerose, 
ofwel slagaderverkalking, wat leidt tot beschadigingen van de vaatwand waardoor op die 
plek een bloedstolsel kan ontstaan.  
Trombotische ziekten zijn zogenaamde multi-causale ziekten, waarbij verschillende 
factoren samen leiden tot het ontstaan van een bloedstolsel: bijna geen enkele geïsoleerde 
risicofactor is een noodzakelijk voldoende oorzaak van trombose. Daarom is de voorstelling 
van verschillende typen van trombose met een eenduidig en makkelijk te classificeren 
ontstaansmechanisme, zoals weergegeven in figuur 1, een grove vereenvoudiging van de 
werkelijkheid. Toch heeft een dergelijke grafische weergave zin: het laat zien hoe in de 
klinische praktijk slechts op algemene kenmerken onderscheid gemaakt kan worden in 
diagnose en behandeling van trombose. 
Er wordt vaak, zowel expliciet als impliciet, gesproken over hart- en herseninfarcten alsof 
het één ziekte betreft, te weten een vorm van arteriële trombose ten gevolge van 
slagaderverkalking. De huidige standaard behandeling van deze twee ziekten is dan ook 
grotendeels gelijk, maar voor beide ziekten niet optimaal. Als bij nader inzien deze twee 
ziekten toch verschillende ontstaansmechanismen blijken te hebben, kan het zijn dat 
nieuwe gedifferentieerde behandeling- en preventiestrategieën meer ziekte en sterfte 
kunnen voorkomen dan momenteel het geval is. Hoewel wordt aangenomen dat arteriële 
trombose zijn oorsprong vooral vindt in slagaderverkalking en de bijkomende 
vaatwandbeschadigingen, is het nog onduidelijk in hoeverre een verhoogde 
stollingsneiging ook een rol speelt in het ontstaan van deze multicausale ziekten. De 
centrale vraag van verschillende deelonderzoeken verricht binnen het RATIO onderzoek is 
dan ook of er een verschil is in de rol van een verhoogde stollingsneiging bij het ontstaan 







Figuur 1.  Trias van Virchow 
De trias van Virchow beschrijft de drie categorieën waarin de verschillende 




Het RATIO onderzoek 
Het RATIO onderzoek is begonnen om de rol van orale anticonceptie, ook wel bekend als 
‘de pil’, bij het ontstaan van arteriële trombose te onderzoeken: er werd aan vrouwen die 
een hart- of herseninfarct hadden doorgemaakt gevraagd of zij de pil hadden geslikt. De 
frequentie hiervan kan dan worden vergeleken met de frequentie in een referentiegroep, 
bestaande uit vrouwen van dezelfde leeftijd die verder vergelijkbaar waren met de 
vrouwen uit de algemene bevolking. Verschil in deze frequenties kan duiden op een 
causale rol van pilgebruik in het ontstaan van deze ziekten. De resultaten lieten dan ook 
zien dat onder vrouwen met een hart- dan wel herseninfarct pilgebruik vaker voorkwam 
dan onder de vrouwen van de referentiegroep. Dit verschil in frequentie kwam overeen 
met ongeveer een verdubbeling van het risico op deze ziekten. In een later stadium werd 
hen verzocht om een bloedmonster af te staan zodat onderzocht kon worden of de 
samenstelling van het bloed ook een oorzaak kan zijn van deze ziekten. Deze bloedafname 
bood de mogelijkheid om te onderzoeken of een verhoogde stollingsneiging ook vaker 
voorkomt onder vrouwen met een hart- of herseninfarct dan onder de vrouwen uit de 
referentiegroep (zie ook figuur 2). Het RATIO onderzoek is uniek omdat het zich richt op 
vrouwen onder de 50 jaar. Omdat leeftijd een sterke risicofactor is voor deze ziekten, is het 
mogelijk dat in onderzoek dat zich richt op oudere vrouwen het effect van hun hogere 
leeftijd de effecten van de te onderzoeken factoren overschaduwt. Door relatief jonge 
patiënten te onderzoeken, zal het effect van leeftijd beperkt blijven en is het mogelijk om 
bijzondere oorzaken van deze ziekten makkelijker te onderscheiden. Daarnaast geeft dit 
onderzoek de mogelijkheid om na te gaan of een verhoogde stollingsneiging en het gebruik 
van de pil elkaar beïnvloeden wat betreft het risico op zoelte, een fenomeen bekend uit 
onderzoek naar oorzaken van trombosebenen. 
Het RATIO onderzoek is een zogenaamd observationeel onderzoek, een onderzoeksopzet 
waarbij, in tegenstelling tot bij een experiment, geen manipulatie van factoren die de 
ziekte kunnen beïnvloeden door de onderzoeker plaatsvindt. Een dergelijke 
onderzoeksopzet heeft enkele aspecten die, indien niet ondervangen, de conclusies 
kunnen invalideren: omdat de bloedmonsters worden verzameld na het hart- of 
herseninfarct is het mogelijk dat de bloedspiegels een gevolg zijn van de ziekte (zie ook 
figuur 2). Deze verwarring van oorzaak en gevolg, bekend als reverse causation, kan leiden 
tot foutieve conclusies over het ontstaansmechanisme. Tevens kan er in de studieopzet 




patiëntengroep en de referentiegroep, een fenomeen bekend als bias. Een voorbeeld 
hiervan is dat patiënten een vragenlijst anders invullen dan de controlepersonen of dat 
alleen gezondheidsbewuste mensen willen deelnemen aan de controlegroep. Daarnaast 
clusteren risicofactoren zich vaak binnen de patiëntengroep, waardoor het mogelijk is dat 
de effecten van twee risicofactoren met elkaar worden verward. Dit fenomeen staat 
bekend as confounding. De aanwezigheid van bias en confounding moet altijd overwogen 
worden bij observationeel onderzoek. Derhalve zijn er verschillende methoden ontwikkeld 
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Figuur 2. Stroomdiagram van RATIO deelnemers 
De deelnemers van het  RATIO onderzoek zijn in twee fasen benaderd: in de eerste fase 





Samenvatting van resultaten  
Hoofdstuk 2 begint met de bespreking van een positieve familieanamnese als indicator van 
een verhoogd risico op het krijgen van een hart- of herseninfarct bij jonge vrouwen: als 
vrouwen een zij eerstegraads familielid (i.e. ouders, broers of zusters) hadden die een 
hartinfarct of een beroerte hadden gekregen voor hun zestigste levensjaar, was het risico 
op een hartinfarct bij hen zelf 3.5 maal verhoogd, terwijl het risico op een herseninfarct 
niet anders was dan het risico van de vrouwen die geen aangedane familieleden hadden. In 
de formele zin van het woord is het niet mogelijk om hier te spreken van een causaal 
verband: louter een positieve familieanamnese is niet direct een oorzaak van het krijgen 
van een ziekte. Wel is het mogelijk een ‘familieanamnese’ te zien als een indicator van de 
aanwezigheid van risicofactoren. Als ziekten clusteren in families kan dat erop wijzen dat er 
sprake is van een erfelijke aanleg, dan wel een door de familieleden gedeelde ongezonde 
levensstijl die leidt tot een hogere incidentie van die ziekte. Toch valt er een voorzichtige 
causale conclusie te trekken uit deze resultaten: als hart- en herseninfarcten precies 
dezelfde oorzaken hebben, zou ook de relatie tussen een positieve familieanamnese en het 
risico op deze twee ziekten ongeveer gelijk moeten zijn. Onze resultaten geven een eerste 
indicatie dat deze twee ziekten, ondanks gedeelde eigenschappen, verschillende oorzaken 
hebben. 
Het onderzoek in hoofdstuk 3 tot 6 richt zich direct op een causaliteitsvraagstuk: zij 
beschrijven het onderzoek naar de eiwitten van het intrinsieke stollingssysteem als 
mogelijke oorzaken van zowel hart- als herseninfarcten bij jonge vrouwen. Deze eiwitten 
hebben de bijzondere eigenschap dat zij niet essentieel lijken te zijn voor een normale 
bloedstolling: mensen bij wie de functie van deze eiwitten drastisch verminderd is, 
vertonen slechts een milde neiging tot bloeden (in het geval van stollingsfactor XI) of 
hebben in het geheel geen verhoogde bloedingsneiging (in het geval van stollingsfactor XII, 
prekallikreine en co-factor hoog moleculair gewicht kininogeen, afgekort als HMWK). 
Daarnaast suggereren verschillende onderzoeken met diermodellen wel dat deze eiwitten 
een rol spelen in het ontstaan van een bloedstolsel.  
Van deze eiwitten zijn verschillende eigenschappen onderzocht, grofweg te beschrijven als 
de aanwezigheid, de activiteit en de activatie van een eiwit. De aanwezigheid van een 
eiwit wordt doorgaans gemeten door het antigeenniveau te bepalen. De meting van deze 




onderdelen van het immuunsysteem die andere eiwitten kunnen herkennen en binden. 
Door deze specifieke binding is het mogelijk om de hoeveelheid eiwit te kwantificeren, 
bijvoorbeeld uitgedrukt als percentage van een referentie plasma. De activiteit van een 
eiwit kan gemeten worden met behulp van een activiteitsmeting waarin het te 
onderzoeken plasma 1:1 wordt gemengd met een referentieplasma. De stollingstijd van dit 
mengsel na maximale activatie wordt uitgedrukt als percentage van de stollingstijd van het 
referentie plasma. De activatie van een eiwit kan op verschillende manieren worden 
gemeten. Hierbij wordt, omdat deze eiwitten in het bloed in het merendeel in inactieve 
vorm aanwezig zijn en pas werkbaar zijn na activatie, nagegaan of deze geactiveerde 
eiwitten, of sporen daarvan aanwezig zijn. De techniek die in dit proefschrift is gebruikt, is 
gebaseerd op antigeenniveaus, net als bij de bepaling van de aanwezigheid van een eiwit. 
Omdat de intrinsieke stollingseiwitten na activatie direct worden gekoppeld aan een 
remmer (inhibitor), kunnen antilichamen gericht tegen een dergelijk eiwit-inhibitor 
complex gemeten worden als mate van activatie. Normaliter wordt een stollingseiwit 
alleen geactiveerd in het geval van een bloeding. De eiwit-inhibitor complexen die gemeten 
zijn in dit proefschrift zijn geen maat voor deze tijdelijke eiwitactivatie, maar zijn indicatief 
voor een lage maar constante eiwitactivatie, hetgeen aangeeft dat er een proces op de 
achtergrond gaande is waarbij deze eiwitten worden geactiveerd. 
In hoofdstuk 3 wordt beschreven dat de activatie van de intrinsieke stollingseiwitten een 
verhoogd risico geeft op het krijgen van een herseninfarct. Dit effect was groter onder 
pilgebruikers dan onder niet-pilgebruiksters. Het risico op een hartinfarct blijft 
onveranderd bij een verhoogde maat van activatie. Hoofdstuk 4 richt zich specifiek op 
stollingsfactor XI: een verhoogde aanwezigheid van dit eiwit verhoogt het 
herseninfarctrisico, terwijl het hartinfarctrisico opnieuw niet verandert. Dit effect is 
onafhankelijk van de activatiegraad van het eiwit, zoals gemeten door de eiwit-
inhibitorcomplexen. Ook is dit effect onafhankelijk van de activiteit van stollingsfactor XI. 
Hoofdstuk 5 is gericht op stollingsfactor XII. Uit het RATIO deelonderzoek blijkt dat een 
verhoogde aanwezigheid van stollingsfactor XII en prekallikreine geen sterke invloed heeft 
op het risico van zowel hart- en herseninfarcten. In hoofdstuk 6 wordt beschreven dat 
vrouwen met een verhoogde aanwezigheid van HMWK wel een verhoogd risico hebben op 
het krijgen van een herseninfarct. Het hartinfarctrisico is echter vergelijkbaar met het risico 
van de vrouwen met niet verhoogde HMWK antigeenniveaus. Uit deze hoofdstukken valt in 




oorzakelijke rol spelen bij het ontwikkelen van herseninfarcten bij jonge vrouwen. Om het 
ontstaansmechanisme in meer detail te begrijpen is echter meer onderzoek nodig. 
In de volgende hoofdstukken wordt een genetische aanpak gebruikt om de rol van het 
stollingssysteem bij het ontstaan van hart- en herseninfarcten te onderzoeken. In 
hoofdstuk 7 wordt beschreven hoe genetische verschillen tussen mensen gebruikt kunnen 
worden om specifieke eigenschappen van een eiwit te onderzoeken teneinde problemen 
als confounding en het verwarren van oorzaak en gevolg te omzeilen. Bij deze methode 
wordt genetische variatie die geassocieerd is met bijvoorbeeld het antigeenniveau van een 
eiwit, en niet via een andere weg een effect heeft op het optreden van de ziekte, 
onderzocht op een relatie met ziekte. Deze methode wordt ook wel Mendeliaanse 
randomisatie genoemd, een naam die verwijst naar Gregor Mendel (1822-1884), één van 
de grondleggers van de moderne genetica, die stelde dat genetische variaties onafhankelijk 
van elkaar overerven. In het verlengde van deze waarneming ligt de basis van deze 
methode, namelijk dat genetische variatie in grote populaties niet samenhangt met 
mogelijk verstorende factoren zoals levensstijl, omgevingsfactoren en sociaal economische 
status. De gedachte is dat genetische variatie, analoog naar een gerandomiseerd 
geneesmiddelenonderzoek waarbij deelnemers willekeurig de nieuwe of de 
controlebehandeling krijgen toegewezen, gerandomiseerd zijn bij conceptie waardoor er 
geen confounding kan optreden. 
Hoewel in potentie een krachtige methode, dienen een aantal nadelen van Mendeliaanse 
randomisatie genoemd te worden: Mendeliaanse randomisatie steunt sterk op enkele 
aannames die per definitie niet empirisch te controleren zijn, omdat zij uitgaan van de 
afwezigheid van enkele associaties. Bovendien vereist het getrapte karakter van de formele 
analyses behorende bij deze methode (dat wil zeggen: genetische variatie  antigeen 
niveau  risico op ziekte) grote aantallen deelnemers om fout-negatieve resultaten te 
voorkomen. Helaas heeft het RATIO onderzoek niet voldoende deelnemers om formele 
Mendeliaanse randomisatie analyses uit te voeren. Desalniettemin, de gedachten 
onderliggend aan deze formele analyses kunnen wel gebruikt worden bij het wegen van 
bewijs over causale vraagstukken. Dit gebeurt dan ook in hoofdstuk 8. Hierin wordt de rol 
van fibrinogeen bij het ontstaan van hart- en herseninfarcten onderzocht. Fibrinogeen is de 
voorloper van fibrine, het belangrijkste bestanddeel van bloedstolsels. En hoog 
fibrinogeenniveau is in eerdere onderzoeken geassocieerd met een verhoogd risico op 




confounding en reverse causation. In het RATIO onderzoek zijn 2 kleine genetische 
variaties, zogenaamde Single Nucleotide Polymorphisms (SNP’s), in de fibrinogeengenen 
onderzocht op hun relatie met fibrinogeenniveaus alsmede het risico op hart- en 
herseninfarcten. Beide SNP’s waren geassocieerd met een verandering van het 
herseninfarctrisico, terwijl het risico op hartinfarcten onveranderd blijft. De richting van 
het effect op het herseninfarctrisico was overeenkomstig met het effect op fibrinogeen 
niveaus: de SNP geassocieerd met hogere fibrinogeen niveaus geeft een hoger 
herseninfarctrisico, terwijl de SNP geassocieerd met lagere fibrinogeen niveaus een 
verlaging van het herseninfarct risico geeft. Van de onderzochte SNP’s is bekend dat zij 
naast een kwantitatief effect mogelijk ook een kwalitatieve verandering van het 
fibrinogeen geven: de structuur van bloedstolsels is iets anders waardoor het risico op 
herseninfarcten ook verhoogd kan zijn. Het is dus niet mogelijk om het onderliggend 
mechanisme op grond van deze bevindingen precies te duiden. Desondanks is uit deze 
resultaten wel te concluderen, ondersteund door resultaten van andere onderzoeken, dat 
fibrinogeen een rol speelt bij het ontstaan van herseninfarcten maar niet van hartinfarcten. 
De resultaten uit hoofdstuk 9 hebben ook betrekking op de structuur van bloedstolsels. 
Nadat fibrinogeen wordt omgezet tot fibrine ontstaat er een netwerk van 
fibrinemoleculen. Stollingsfactor XIII speelt een belangrijke rol bij het ontstaan van dit 
netwerk, omdat dit eiwit de kruisverbindingen tussen fibrinemoleculen tot stand brengt. 
Een eerdere analyse van vier SNP’s in de genen van FXIII hebben laten zien dat FXIII een rol 
speelt bij het ontstaan van herseninfarcten, met het hoogste risico voor vrouwen die ook 
orale contraceptiva gebruikten.15 Deze SNP’s hebben mogelijk een effect op het ontstaan 
van de kruisverbindingen, zowel kwalitatief als kwantitatief, en verhogen daarmee het 
risico op trombose. Deze SNP’s bleken echter geen verhoging te geven van het 
hartinfarctrisico, waaruit geconcludeerd kan worden dat de rol van FXIII verschilt bij 
mechanismen onderliggend aan hart- en herseninfarcten. 
De volgende hoofdstukken richten zich niet zozeer op individuele factoren van het 
stollingsysteem, maar onderzoeken andere maten gerelateerd aan een verhoogde 
stollingsneiging. Zo wordt in hoofdstuk 10 de rol van Von Willibrand Factor (VWF) 
besproken. VWF is gebonden aan FVIII in bloedplasma, en wordt opgeslagen in 
bloedplaatjes en in de cellen van de vaatwand. Na activatie wordt VWF uitgescheiden en 
ontvouwt het zich als een lange draad in het bloedvat waarop bloedplaatjes afremmen, 




stollingsprocessen activeren of versnellen. Naast normale activatie kan VWF ook worden 
uitgescheiden door disfunctionerende cellen van de vaatwand, waarmee VWF naast een 
mogelijke oorzaak ook een gevolg kan zijn van vroege arteriosclerose. De lengte van VWF 
bepaalt in belangrijke mate de efficiëntie van zijn werking. Het eiwit ADAMTS13 reguleert 
de lengte, en daarmee de werkzaamheid van VWF: hoe minder ADAMTS13 hoe langer het 
VWF. Uit resultaten van het RATIO onderzoek blijkt dat hoge niveaus van VWF-antigeen 
het risico op zowel hart- als herseninfarcten verhoogt. Lage antigeenniveaus van 
ADAMTS13 verhogen echter alleen het herseninfarctrisico, waardoor de vraag opkomt of 
de associatie tussen VWF en hartinfarctrisico niet gedeeltelijk verklaard kan worden door 
beschadigingen van de vaatwand. 
Hoofdstuk 11 onderzoekt de rol van het fibrinolytische systeem. De eiwitten in dit systeem 
voorkomen dat bloedstolsels ongebreideld blijven groeien. Een verlaagde capaciteit van dit 
systeem is daarmee mogelijk debet aan een verhoogde stolselvorming, hetgeen kan leiden 
tot trombose. Een verlaagde fibrinolytische capaciteit bleek dan ook het hartinfarctrisico 
bij jonge vrouwen te verhogen. De resultaten voor de analyses van het herseninfarct risico 
lieten echter het tegenovergestelde zien: een verhoogde fibrinolytische activiteit, 
theoretisch leidend tot een verminderde stolselvorming, verhoogt het herseninfarctrisico 
bij jonge vrouwen. Wat kan een dergelijk contra-intuïtief resultaat verklaren? Mogelijk ligt 
het antwoord bij PAI-1, één van de belangrijkste eiwitten binnen het fibrinolytische 
systeem: naast een groot effect op de fibrinolytische capaciteit beïnvloedt PAI-1 mogelijk 
ook de overlevingskansen van hersencellen bij een infarct. Omdat het niet mogelijk is om 
met deze test voor fibrinolytische capaciteit alleen het effect van bijvoorbeeld PAI-1 te 
onderzoeken, is het niet mogelijk om vergaande conclusies te trekken uit de resultaten. 
Maar ook ander onderzoeken geven een onduidelijk beeld. Extra onderzoek is derhalve 
nodig om antwoord te krijgen de precieze rol van het fibrinolysesysteem bij het ontstaan 
van een herseninfarct. Overigens worden de tegenstrijdige resultaten misschien wel 
veroorzaakt doordat er verschillende subtypen herseninfarct werden onderzocht. Nieuw 
onderzoek moet dan ook zo worden opgezet dat deze verschillende typen zo goed mogelijk 
te onderscheiden zijn. Ondanks de onduidelijkheden over de precieze interpretatie van de 
gebruikte test om de fibrinolytische capaciteit te meten, suggereren de resultaten dat de 
rol van het fibrinolytische systeem en zijn componenten anders is bij het ontstaan van een 




In het volgende hoofdstuk wordt de relatie tussen het antifosfolipide syndroom en het 
risico op hart- en herseninfarcten onderzocht. Dit auto-immuunsyndroom wordt 
gekarakteriseerd door ziekten als gevolg van trombose, zoals hart en herseninfarcten maar 
ook zwangerschapscomplicaties en veneuze trombose. Er wordt echter alleen van het 
antifosfolipide  syndroom gesproken als er naast een dergelijke ziekte ook nog 
antifosfolipiden antilichamen of aanwijzingen daarvan (vastgesteld met een positieve lupus 
anticoagulans test) herhaaldelijk worden aangetoond in het bloed van de patiënt. Alhoewel 
deze ‘biomarkers’ onderdeel zijn van de definitie van het syndroom was het niet bekend 
welke risicoverhoging de aanwezigheid van deze markers met zich meebrengt. De 
resultaten in hoofdstuk 12 waren de eerste die een schatting gaven voor deze 
risicoverhoging: een positieve lupus anticoagulans test verhoogde het risico op een 
hartinfarct ongeveer 5 maal, terwijl het risico op een herseninfarct 40 maal werd verhoogd. 
Pilgebruik verhoogde deze risico’s nog verder. Ook al is deze 5-voudige verhoging van het 
hartinfarctrisico vele malen groter dan de die van andere risicofactoren beschreven in dit 
proefschrift, er is opnieuw een opmerkelijk verschil in grootte van de hart- en 
herseninfarctrisicoverhoging. Van de overige biomarkers die getest zijn lijken antilichamen 
gericht tegen β2-glycoproteine I een directe rol te hebben in de pathofysiologie van dit 
syndroom. De aanwezigheid van β2-glycoproteine I antilichamen verdubbelt het 
herseninfarctrisico, maar leidt niet tot een verandering van het hartinfarctrisico. Ook al is 
het onderliggende mechanisme nog niet bekend het is wel duidelijk dat deze biomarkers 
een maat zijn voor een verhoogde stollingsneiging. Derhalve is ook uit deze resultaten te 
concluderen dat een verhoogde stollingneiging een sterk verhoogd risico geeft op een 
herseninfarct, terwijl het hartinfarctrisico veel minder sterk is aangedaan.  
Verschillen en overeenkomsten  
Samen met resultaten uit eerdere RATIO-deelonderzoeken geven de resultaten beschreven 
in dit proefschrift  een overzicht van de rol van een verhoogde stollingsneiging in het 
ontstaan van hart- en herseninfarcten. Met een dergelijk overzicht valt dan ook makkelijker 
een antwoord te vinden op de vraag die eerder is gesteld: is er een verschil in de rol van 
een verhoogde stollingsneiging in het mechanisme dat leidt tot deze ziekten? 
Om dat overzicht te geven, kan men gebruik maken van de populatie attributieve fractie: 
dit is de fractie van het aantal zieken in een onderzochte populatie dat voorkomen had 




getal is een zuiver theoretisch getal en heeft geen directe implicaties voor het bepalen van 
de oorzakelijkheid van een bepaalde factor binnen één patiënt, maar dit getal is wel een 
goede maat voor het totale effect van een bepaalde factor op het vóórkomen van een 
bepaalde ziekte. 
In figuur 3 staan deze populaties attributieve fracties weergegeven voor zowel hartinfarct 
(op de x-as) en herseninfarct (op de y-as). Als het effect van een verhoogde stollingsneiging 
voor beide ziekten gelijk was, zouden alle punten op de blauwe diagonale lijn moeten 
liggen. Dit is echter niet het geval: vele factoren hebben geen noemenswaardige invloed op 
het hartinfarctrisico terwijl ze wel het herseninfarctrisico wel degelijk vergroten en liggen 
daarmee rond de verticale rode lijn, de nullijn van de x-as. Er zijn geen factoren die een 
uitgesproken effect hebben op het hartinfarctrisico terwijl zij dat niet hebben op het 
herseninfarctrisico. Er zijn wel factoren die het risico op beide ziekten lijken te verhogen, 
maar het herseninfarct risico is bij deze factoren bijna altijd groter dan het hartinfarctrisico. 
Kortom, figuur 3 geeft antwoord op onze oorspronkelijke vraag: een verhoogde 
stollingsneiging is een onderdeel van het ontstaansmechanisme van herseninfarcten, en 
heeft geen belangrijke rol bij het ontstaan van hartinfarcten. 
Implicaties 
Betekenen deze resultaten nu dat de bloedstolling geen rol speelt bij de 
ontstaansmechanismen van hartinfarcten, maar wel bij herseninfarcten? Nee, beide 
ziekten zijn immers acute vormen van arteriële trombose waarbij een bloedstolsel ervoor 
zorgt dat de toevoer van zuurstofrijk bloed naar achterliggend weefsel vermindert. Deze 
resultaten willen wel zeggen dat een verhoogde stollingsneiging alleen onderdeel is van 
het ontstaansmechanisme van herseninfarcten en niet bij hartinfarcten. Misschien is het 
wel zo dat het ontstaan van hartinfarcten primair ligt in een abrupte beschadiging van de 
vaatwand; als de vaatwand eenmaal beschadigd raakt is de activatie van het 
stollingssysteem zo sterk dat er altijd een bloedstolsel gevormd zal worden, ongeacht of de 
patiënt in kwestie een iets verhoogde stollingsneiging heeft. 
 Zijn zogenoemde antistollingsmedicijnen dan alleen geschikt voor het behandelen en 
voorkomen van herseninfarcten? Dit zou wellicht zo zijn als deze medicijnen een 
verhoogde stollingsneiging weer zouden normaliseren. Dit is echter niet het geval: 
antistollingsmedicatie verlaagt de stollingsneiging in zeer sterke mate, zo sterk dat er 

























Figuur 3 Impact van een verhoogde stollingsneiging op het 
vóórkomen van hart- en herseninfarcten onder jonge vrouwen 
Elke punt in deze grafiek geeft de impact van een bepaalde mate van 
verhoogde stollingsneiging op het vóórkomen van hart- en herseninfarcten 
onder jonge vrouwen. De blauwe diagonaal geeft de plaats aan waar de 
verschillende punten zouden staan als een verhoogde stollingsneiging een 
even grote impact op beide ziekten zou hebben; de grafiek laat echter zien 





ernstige bloedingscomplicaties. Door deze verlaagde stollingsneiging zal ook de 
stollingsreactie bij vaatwandbeschadigingen minder uitgesproken zijn: 
antistollingsmedicatie zal dus het risico op een hartinfarct verlagen, maar wel met 
bloedingscomplicaties tot mogelijk gevolg. De uitdaging bij het doseren van 
antistollingsmedicatie is dan ook om de stollingsneiging van een persoon wel te verlagen, 
zonder een al te grote kans op bloedingscomplicaties. Nieuwe vormen van 
antistollingsmedicatie zullen daarom gericht zijn op het normaliseren van de 
stollingsneiging om ziekte te voorkomen en ondertussen de kans op bloedingen niet of 
nauwelijks te verhogen. Het is daarmee mogelijk dat deze nieuwe antistollingsmedicatie de 
kans op een hartinfarct iets verlaagt, maar vanwege de verschillen in causaal mechanisme 
is het waarschijnlijk dat deze nieuwe medicatie een sterk effect zal hebben op het 
herseninfarctrisico. 
In verschillende hoofdstukken van dit proefschrift staat beschreven dat de gevonden 
risico’s sterker waren bij vrouwen die de orale anticonceptiva gebruikten. Dit is op zich 
geen nieuw verschijnsel: van pilgebruik is bekend dat het het risico op tromboseziekten 
ongeveer twee- tot driemaal verhoogt. Deze nadelige risicoverhoging weegt in de praktijk 
niet op tegen de tegen het voordeel van pilgebruik, vooral omdat het basisrisico van deze 
ziekten onder jonge vrouwen bijzonder laag is (zo treedt een herseninfarct op bij 14 per 
100.000 vrouwen per jaar). Maar verscheidene onderzoeken laten zien dat het effect van 
pilgebruik synergie vertoont met andere risicofactoren: de risicoverhoging bij vrouwen die 
zowel de pil gebruiken als zijn blootgesteld aan een bepaalde tromboserisicofactor is dan 
hoger dan verwacht mag worden op basis van de afzonderlijke effecten. Bijvoorbeeld, het 
herseninfarctrisico is bij vrouwen die alleen blootgesteld zijn aan pilgebruik ongeveer twee 
tot driemaal verhoogd, vrouwen blootgesteld aan hoge niveaus van geactiveerd kallikreine 
hebben een 5-voudige verhoging van het risico op een herseninfarct, terwijl vrouwen 
blootgesteld aan beide risicofactoren zijn bootgesteld aan een 23-keer verhoogd risico 
hebben. Met een dergelijke synergie rijst de vraag of het mogelijk is om met een nieuwe 
screeningsstrategie bij vrouwen die de pil willen gaan gebruiken die vrouwen te 
identificeren bij wie deze synergie kan gaan optreden. Echter, vanwege het lage 
vóórkomen van herseninfarcten bij jonge vrouwen leidt dit tot meer dan 15.000 te 
screenen vrouwen per jaar. Van deze vrouwen moet 10% vervolgens niet starten met het 
gebruiken van de pil om één herseninfarct te voorkomen. Kortom, de aanwezigheid van 




risico van hart- en vaatziekten zal niet snel klinische consequenties hebben in de vorm van 
een screeningsstrategie. Desalniettemin is dergelijke kennis nuttig: het kan inzicht geven in 
een specifiek mechanisme dat belangrijk is bij het ontstaan van de onderzochte ziekten. 
Samenvattend kan worden gesteld dat niet alle vormen van arteriële trombose eenzelfde 
ontstaansmechanisme hebben: bij jonge vrouwen blijkt een verhoogde stollingsneiging een 
oorzaak te zijn van herseninfarcten, maar geen effect te hebben op het hartinfarctrisico. 
Deze resultaten roepen direct een andere vraag op: hebben alle herseninfarcten wel 
eenzelfde ontstaansmechanisme? Het antwoord op deze vraag is waarschijnlijk nee. 
Herseninfarct is een zeer heterogeen ziektebeeld waarbij het zeer goed mogelijk is dat een 
verhoogde stollingsneiging vooral invloed heeft op het risico van bepaalde typen 
herseninfarcten. Dit kan dan, analoog aan de hartinfarct-herseninfarctdifferentiatie, gevolg 
hebben voor de effectiviteit van nieuw te ontwikkelen preventie- en 
behandelingsstrategieën. Nieuw onderzoek, met oog voor de verschillende typen 
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